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GLOSSARY 
 
This glossary is provided to help understanding the underlying concepts and notions of terminologies in 
this thesis. The definitions are adopted – fully or partially – or developed from literature and published 
references.  
Authority 
Government entities responsible for designing the regulatory framework and implementing policies (e.g. 
ministries, departments, public agencies) (Vogler and Zimmerman, 2013). 
Capitation 
A form of payment mechanism – paying provider a specific sum of money for the ongoing care of an 
individual or a person for a particular period of time (Vogler and Zimmerman, 2013). 
Community pharmacy 
Health care facility that provides pharmacy services including dispensing and other health-care related 
pharmaceutical/pharmacy services. It is subject to pharmacy legislation with pharmacist is appointed as 
the owner/person in-charge for the operational of the community pharmacy (Vogler and Zimmerman, 
2013). The term “pharmacy” is also frequently used in this thesis.  
Community Pharmacy Agreement(s) 
A series of five-year cooperative agreements since 1990 between the Australian government and the 
Pharmacy Guild of Australia that provides remuneration for dispensing Pharmaceutical Benefits Scheme 
medicines, regulation regarding the location of pharmacies and additional funding for delivery of 
professional pharmacy services and programs. The agreements also include funding for a Community 
Services Obligation (CSO) Funding Pool. The CSO Funding Pool ensures that all Australians have ongoing 
access to the full range of PBS medicines through community pharmacies. It provides financial support to 
pharmaceutical wholesalers, supplying the full range of PBS medicines regardless of pharmacy location 
and the relative cost of supply (Department of Health, 2015a).  
Cognitive pharmaceutical services 
Professional services provided by pharmacists, who use their skills and knowledge to take an active role 
in patient health, through effective interaction with both patients and other health professionals (Roberts 
et al., 2006). 
Culture-structure-agency approach 
An approach that views culture, structure and agency in a coherent relationship. Structure highlights 
regulations, legislative and policy frameworks constructing and controlling community pharmacy sector; 
Agency refers to pharmacists and community pharmacies; Culture reflects professional pharmacy practice 
(Hermansyah et al., 2018a). 
Dispensing 
To supply a clinically appropriate medicine to a patient or care giver, usually against a written prescription, 
for self-administration or administration by another professional, and to advise on a safe and effective 
use. In the Australian and Indonesian legislation, dispensing is the responsibility of a pharmacist. However, 
in realities in Indonesia, non-pharmacists may provide dispensing although it is against the law (Vogler 
and Zimmerman, 2013). 
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Diabetes Medication Assistance Services (DMAS) 
DMAS provides a service where a person with type 2 diabetes can have regular visits with the pharmacist 
and consists of an ongoing cycle of assessment, management and review. DMAS was developed from 
Pharmacy Diabetes Care Program funded under the 3rd CPA and was piloted throughout Australia as part 
of the 4th CPA. However, funding for DMAS was ceased after stage 2 of the national pilot program. The 
service subsequently refashioned into Diabetes Medscheck which has been funded and adopted in 
community pharmacy since the 5th CPA (Hermansyah et al., 2017b). 
Extended or expanded pharmacy services 
Services provided by pharmacists beyond the traditional pharmacists’ roles (e.g. compounding and 
dispensing medicines). These services can be considered as an expansion of pharmacists’ scope of practice 
and provided as an adjunct to the conventional pharmacy services. These services may include but not 
limited to vaccination, wound care management and weight management (Vogler and Zimmerman, 
2013). 
General Practitioner (GP) 
A physician (medical doctor) who does not limit his/her practice to certain disease categories and assumes 
the responsibility for the provision of continuing and comprehensive medical care or referring to another 
health professional (Vogler and Zimmerman, 2013). 
Healthcare provider 
A healthcare provider or health professional is a person who delivers proper health care in a systemic way 
professionally to any individual in need of health services. This term is interchangeably used with 
professional (Vogler and Zimmerman, 2013). 
Home Medicines Review 
Home Medicines Review (HMR) is a comprehensive clinical review of a patient’s medicines in their home 
by an accredited pharmacist on referral from the patient’s general practitioner (GP). The patient may 
choose to be referred to their usual community pharmacy or an accredited pharmacist who meets the 
patient’s needs (Department of Health, 2015b). 
Medicines 
Substance(s) which potentially heal or prevent disease. The term is often used interchangeably with 
“drugs” and “pharmaceuticals” in this thesis (Vogler and Zimmerman, 2013). 
Medscheck and Diabetes Medscheck 
Medscheck is an in-pharmacy, patient centred service that includes a review of a patient’s medicines, 
focusing on their education and self-management and aims to identify problems that the patient may be 
experiencing with their medicines, help patient learn more about their medicines, improve the effective 
use of medicines by patients and educate patients about how to best use and store their medicines. 
Diabetes Medscheck is a Medscheck with a focus on the patient’s type 2 diabetes medicines management, 
monitoring devices, education and self-management (Department of Health, 2015c). 
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PARIHS framework 
The PARIHS framework, developed by Kitson and colleagues is a conceptual framework for understanding 
and explaining the success or failure of implementation projects. The framework highlights that successful 
implementation (SI) of research is represented as a function (f) of the nature and type of evidence (E), the 
qualities of the context (C) in which the evidence is being introduced, and the way the process is facilitated 
(F); SI = f (E,C,F) (Kitson et al., 1998). 
Planes of analysis framework 
Developed from Rogoff’s planes of analysis, the framework explores three levels of practice in the 
community pharmacy sector namely micro level (individual pharmacists), meso level (community 
pharmacy as an institution or network of institution) and macro level (community pharmacy as part of 
healthcare system) as a holistic and integrated system. The three levels operate interdependently and 
dynamically with changes in one level affecting the operation of other levels (Hermansyah et al., 2017a). 
Pharmacy Asthma Management Services (PAMS) 
PAMS is an in-pharmacy service provision which includes series of patient (or carer) education sessions, 
medication review, assessment of asthma control and spirometry measurement for adults at risk of poor 
asthma control. Where appropriate, patients were referred to their GP for review. PAMS was developed 
from Pharmacy Asthma Care Program – a randomised controlled trial funded under the 3rd CPA. PAMS 
was funded as part of the 4th CPA and intended to be piloted in two stages. However, stage 2 did not 
eventuate and the pilot program was terminated (Armour et al., 2007). 
Physicians 
People who hold medical degree and who are practising medicine (Vogler and Zimmerman, 2013). 
Pharmacists 
A person who have completed studies in pharmacy at university level (granted by adequate diploma) and 
who are licensed to practise pharmacy. He/she may be either salaried or self-employed pharmacists 
delivering services irrespectively of the place of service provision (Vogler and Zimmerman, 2013).  
Pharmaceutical Benefits Scheme 
The Australian government program that provides provides universal access to subsidized medicines for 
all Australian residents and certain overseas visitors from countries which have reciprocal healthcare 
agreement with Australia (Department of Health, 2018a). 
Pharmaceutical Care 
Pharmaceutical care is the responsible provision of medicine therapy for the purpose of achieving definite 
outcome that improve a patient’s quality of life. These outcomes are: (1) cure of a disease, (2) elimination 
or reduction of a patient’s symptomatology, (3) arresting or slowing of a disease process, or (4) preventing 
a disease or symptomatology (Hepler and Strand, 1990). 
Practice change 
Changes in the practice of pharmacy as a result of a number of factors from both internal and external of 
the profession such as demand for expanded roles, changes in patient’s expectations, introduction of new 
pharmacy practice models and development of healthcare and pharmaceutical technology. 
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Price disclosure 
Price reduction policy introduced by the Australian government in 2007. The objective of the policy is to 
ensure that the prices of government-subsidised pharmaceuticals more closely reflect the prices charged 
in the market (Department of Health, 2018b). 
Professional pharmacy service 
An action or set of actions undertaken in or organised by a pharmacy, delivered by pharmacist, or other 
health practitioner, who applies their specialised health knowledge personally or via an intermediary, with 
a patient/client, population or other health professional, to optimise the process of care, with the aim to 
improve health outcomes and the value of healthcare (Moullin et al., 2013). 
Policy maker 
A person or institution that is involved in policy development and formulation (e.g. public agencies, 
regulatory bodies) (Vogler and Zimmerman, 2013). 
Primary care 
Basic or general healthcare focused on the point at which a patient ideally first seeks assistance from the 
medical care system (Vogler and Zimmerman, 2013). 
Pharmaceutical public health 
The application of pharmaceutical knowledge, skills and resources to the science and art of preventing 
disease, prolonging life, promoting, protecting and improving health for all through organised efforts of 
society (Walker, 2000). 
Stakeholder 
A person or organisation with a legitimate interest in a topic. Stakeholders related to community 
pharmacy system in this thesis includes regulatory bodies including government and parliamentarian, 
organisations representing healthcare professionals (e.g. doctors, pharmacists), patient organisations, 
insurance companies, school of pharmacy (including academics and researchers), other healthcare 
organisations (e.g. pharmacy owners group) (Vogler and Zimmerman, 2013). 
Universal healthcare coverage 
Universal healthcare coverage or sometime called universal coverage means that all people and 
communities can use the promotive, preventive, curative, rehabilitative and palliative health services they 
need, of sufficient quality to be effective, while also ensuring that the use of these services does not 
expose to financial hardship (World Health Organization, 2018). 
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ABSTRACT 
 
Background 
The past decades have witnessed significant changes in community pharmacy practice as widely 
documented in the literature. However, many of these studies have adopted a narrow approach 
in analysing the process of change by predominantly focusing on the individual practitioner 
without due consideration of the organisational factors in the community pharmacy itself and 
the wider system-related influences on practice change. Practice change is arguably a complex 
and dynamic process. Moreover, the context in which change has occurred plays an influential 
role in determining the pace of change. As practice change in community pharmacy is a global 
phenomenon, there is a need to investigate these changes in the context of both developed and 
developing countries. In fact, there is a strong argument that pursuing such research might be 
more critical in the context of developing countries where there is a paucity of research 
concerning practice in community pharmacy.  
Aims 
The overall aim of this thesis was to investigate changes in the contemporary practice in both 
Australian and Indonesian community pharmacy. This includes investigation of the factors 
influencing changes, policy implementation and the role of stakeholders in promoting changes in 
each country, with the goal of providing a framework for future policy development and 
implementation particularly for Indonesian pharmacy sector. 
Methods 
The research was conducted using two qualitative methods: in-depth semi-structured interviews 
in both countries and nominal group discussion in Indonesia. The Human Research Ethics 
Committee at the University of Sydney approved this research.  
A series of in-depth semi-structured interviews involving key stakeholders in pharmacy and the 
healthcare system was conducted in Australia and Indonesia. A maximum variation sampling 
approach was used to enable the selection of a wide range of participants representing practicing 
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pharmacists, pharmacy owners and managers, academics and researchers, peak pharmacy 
organisations, medical associations, insurance companies, consumer associations, policy makers, 
regulators and administrators including government. Potential participants were identified from 
the network of the researchers and key publications on the issues of practice change in 
community pharmacy. Participants were contacted via email and once they agreed to participate, 
time, place and the interview method (e.g. face to face, telephone call and video conference) 
were then confirmed based on the participant’s preference. The sample size was expanded using 
a snowball method by asking each participant at the end of the interview to nominate other 
potential candidates for this study.  
The interview guide was developed from the existing literature reviews on community pharmacy 
roles and practice change and discussion within the research team. Each interview was initiated 
with a broad question about the contemporary situation of the healthcare system and the 
practice of community pharmacy followed by specific questions to address each objective of this 
study. The interviews in Australia were conducted in English, while those in Indonesia were 
conducted in either English or Indonesian. The interviews were audio-recorded and subsequently 
transcribed verbatim. The transcripts of interviews conducted in Indonesian were translated to 
English and the translation was reviewed by an independent bilingual translator. Participants in 
both countries had the opportunity to review the transcripts. An inductive approach was used to 
derive the structure of analysis involving an iterative process of listening to audio-recordings, 
reading transcripts and interpreting the data. Several transcripts which were considered to have 
rich and unique information were thematically analysed by selecting initial coding, followed by 
sub-themes and themes formation and development of the coding framework. Each researcher 
created a coding framework which was then discussed to build the main coding framework. The 
interviews were continued until reaching “saturation”. 
A group discussion using the Nominal Group Technique (NGT) was conducted during a pre-
conference workshop in Indonesia with participants representing pharmacy stakeholders such as 
practicing pharmacists, academic and researchers, policy makers and government 
representatives. Participants were assigned into four small groups with each group discussing an 
area of action which was developed from the findings of the interviews in Indonesia and 
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Australia. The areas of action were: (1) Individual pharmacist empowerment, (2) Community 
pharmacy network recognition, (3) Education and scope of practice improvement and (4) Law 
and regulation enforcement. Each group was asked to provide recommendations based on their 
areas of action using the NGT format. Once the small group discussion concluded, participants 
were convened into a large group discussion to vote on the priority of all recommendations. The 
results were then tabulated to create a ranked list of priorities. The group discussion was 
conducted in Indonesian. It was audio-recorded and subsequently transcribed verbatim with the 
transcripts back translated to English. The data were subjected to thematic analysis. 
Results 
A total twenty-seven key stakeholders in Australia participated in the interviews which were 
conducted from December 2014 to August 2015. Fourteen participants were interviewed in 
person, seven over the telephone and the remainder via Skype© video conference. The duration 
of the interview on average was 71 min (range 43-93 min). Participants were from the Eastern 
part of Australia and represented both gender and urban-rural areas representativeness.  
In Indonesia, twenty-nine key stakeholders participated in the interviews which were conducted 
between February and August 2016. The majority of participants were interviewed in person 
(n=25) and the rest by telephone. On average, the duration of the interview was 77 min (range 
35-116 min). Participants were from several cities in Indonesia, reflecting both gender and urban-
rural areas representativeness.  
The nominal group discussion was conducted in July 2017 in Yogyakarta-Indonesia and attended 
by thirty-four pharmacy stakeholders. The duration of the group discussion was 90 minutes. 
Participants were from the main islands in Indonesia with the majority of participants from Java. 
Most of the participants were female (n=26). 
The Australian studies highlighted the complex and dynamic situation in community pharmacy 
sector with factors related to the social, economic and policy context influencing the practice at 
a micro (individual pharmacist), meso (community pharmacy as an institution or a network of 
institutions) and macro level (community pharmacy as part of healthcare system). These 
elements are interrelated and changing in the current climate and should be taken account of in 
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policy making. Participants perceived that community pharmacy has untapped potential to play 
a greater role in primary care, yet it has been slow to change to address the opportunities 
available in the current situation.  
The interviews in Indonesia revealed that the introduction of Universal Healthcare coverage (JKN) 
has changed the landscape of the Indonesian healthcare and affected the community pharmacy 
sector on the three levels of practice (micro, meso and macro level). Despite the good policy 
objectives of JKN to integrate community pharmacy within the primary care network, it has 
created some unintended and unpredictable consequences which may be detrimental to 
community pharmacy practice. Community pharmacy practice is still largely limited to dispensing 
and continues to be hampered by a number of ongoing issues, mainly pharmacists’ absence, lack 
of clinical competence and limited support from regulation change. 
The R&D programs funded under the consecutive Community Pharmacy Agreements (CPAs) have 
played an important role in the advent of Cognitive Pharmaceutical Services (CPS). The evidence 
generated by the R&D programs has been viewed as critical for influencing policy formulation, 
funding and implementation of CPS into practice. However, the overall impact of the programs 
appears to be minor as contemporary practice is still predominantly focused on dispensing. 
Notwithstanding the importance of evidence, policy decisions and subsequent implementation 
of CPS are influenced by other factors associated with context and facilitation. 
The key stakeholders in Australia acknowledged that the consecutive CPAs have been essential 
for business certainty for pharmacy and as a platform for some innovation in pharmacy services. 
However, the CPAs have been viewed as protecting the interests of the pharmacy owners. In 
addition, the pace of pharmacy role expansion has been slow since most CPA funding was 
allocated to the payment of dispensing, with remuneration processes for CPS being highly 
cumbersome and bureaucratic.  
The Indonesian studies identified seventeen policy documents aimed to promote community 
pharmacy practice in Indonesia. The presence of these policy initiatives within the past ten years 
highlights the enthusiasm for practice change. However, participants viewed that some of the 
initiatives were introduced in a piecemeal approach which created conflict and lack of 
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coordination with other policies. In addition, three notable barriers, namely poor policy 
enforcement, lack of trust of pharmacy stakeholders and scepticism towards the impact of the 
policy initiatives have hampered the effectiveness of such policy initiatives. Apart from national 
policy documents, participants mentioned several local initiatives claimed to improve pharmacy 
practice but were unable to demonstrate evidence showing their effectiveness. 
Four main recommendations targeting professional practice, education, policy enforcement and 
professional image of pharmacists were proposed by participants in the nominal group discussion 
to advance the practice of community pharmacy in Indonesia. The complex interplay between 
pharmacists as an agency, healthcare regulation/legislation as structure and the practice of 
pharmacy as a culture presents opportunities for pharmacists and pharmacies to develop 
professional practice and to communicate their competence and roles to different agencies 
within healthcare system. 
This study highlighted several key messages including lessons to be learned from the Australian 
context for developing pharmacy practice in Indonesia. Community pharmacies and pharmacists 
are well suited to respond to the healthcare needs of Indonesians. However, this will need some 
definitive strategies to achieve including creating a shared vision among pharmacy stakeholders, 
establishing a sense of urgency to change, building coalition, developing systematic plan to 
upgrade pharmacy graduates, encouraging both top down and bottom up initiatives 
simultaneously, ensuring good governance, and investing on research and resources. 
Conclusions 
In conclusion, this study provides evidence of practice change in community pharmacies in the 
context of developed and developing countries. Challenges occur as pharmacists’ professional 
practice evolves, and these challenges come from inside and outside the profession. The 
frameworks and approaches used in this study are helpful to navigate and explain changes in 
both countries’ contexts and to support pharmacists through the change process and offer 
promising avenues for further research. 
Keywords: practice change, role expansion, community pharmacy, Australia, Indonesia 
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THESIS OVERVIEW 
 
This thesis consists of seven chapters as follows (Table 1):  
Chapter 1 presents the literature review of practice change in community pharmacy. 
Chapter 2 sets the context of the study focusing on the community pharmacy landscape in 
Australia and Indonesia, two neighbouring countries which become the cases for this thesis. A 
systematic review of Southeast Asian (including Indonesia) community pharmacy development 
is provided to support the notion of practice change in the region in which both countries are 
located side by side. Chapter 3 emphasizes why this research is important and significant for 
community pharmacy practice. Furthermore, this chapter outlines several research objectives 
with which this thesis is structured. Chapter 4 outlines the research design of this study and 
provides the rationale for each stage of the research from the selection of research methods to 
interpretation of the findings. Chapter 5 explains the findings generated from twenty-seven 
interviews in Australia. Chapter 6 explains the results of the study in Indonesia generated from 
twenty-nine interviews and a nominal group discussion. Chapter 7 briefly discusses the main 
findings of this study, presents the main conclusion of this thesis and future directions for 
advancing community pharmacy practice in Australia and Indonesia. 
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CHAPTER 1. LITERATURE REVIEW 
This chapter reviews key factors that relate to practice change in community pharmacy. 
These include drivers, barriers and facilitators to practice change. 
1.1. Practice Change in Contemporary Situation 
The practice of pharmacists in the community has been changing within recent decades. 
Traditionally, pharmacists were known as dispensers of medicines based on prescription orders. 
Although this function still continues in contemporary practice, pharmacists have been 
increasingly involved in provision of clinical and primary care services. Pharmacists’ roles in 
providing support for management of chronic diseases, public health promotion and other 
professional pharmacy services related to the use of medicines and health devices has been 
widely reported in the literature (George et al., 2010, Agomo, 2012, Perraudin et al., 2016). The 
expansion of pharmacists’ scope of practice also covers new areas including limited prescribing, 
pharmacy immunization, and integration of non-dispensing pharmacists within general practice 
(Cooper et al., 2012, Bushell et al., 2013, Polasek et al., 2015). 
Role expansion in community pharmacy cannot be separated from its actual and potential 
benefits to healthcare. First, community pharmacies are located in the heart of communities 
making them the most accessible health setting of all health professionals. The accessibility has 
also been supported by the fact that consumers have more opportunities to interact with the 
pharmacists, often without prior appointment and with no fees for consultation. Second, 
pharmacists are trained and expert health professionals and in some countries are among the 
third largest healthcare workforce after physicians and nurses making them a relatively untapped 
resource within the health system (Mossialos et al., 2013). Third, evidence of the value of 
community pharmacists’ interventions is supported by a substantial body of research including 
their contribution in reducing drug related problems, preventing further hospitalisations and 
providing continuity of care to patients with chronic diseases (Bunting et al., 2008, White et al., 
2012, McMillan et al., 2014b). 
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The pace of practice change has varied between developed and developing countries. 
Community pharmacies in developed countries have been at the forefront of pharmacists’ role 
development and the practice change agenda. Several countries in particular USA, UK and 
Canada, have been working towards integrating community pharmacies within primary care 
networks (Mossialos et al., 2015). Other countries such as Australia and New Zealand introduced 
the community pharmacy agreements which have included remuneration for delivery of 
professional pharmacy services (Scahill et al., 2010, Singleton and Nissen, 2014). Such progress, 
however, is not without problems. 
While there has been a great deal of activity by government, pharmacy organisations and 
advocacy groups in developed countries in promoting practice change, the majority of 
community pharmacies still continue to focus primarily on dispensing-related activities (Moullin 
et al., 2013). In fact, dispensing is still the main income generator in most community pharmacies 
(Vogler et al., 2014). The over-reliance on dispensing has been partially driven by the fact that 
provision of professional pharmacy services has not been sustainable and profitable for 
community pharmacies (Houle et al., 2014, McMillan et al., 2015b). The provision of pharmacy 
public health services for example, remains small scale, sometimes free of charge and not widely 
available (Eades et al., 2011). Speedie and Anderson (2017) argued that community pharmacists 
often considered provision of clinical services as part of the prescription cost and therefore, have 
not charged additional payment for providing such services. This has made patient care services 
“episodic, undocumented and not well understood by health systems or payers” (Speedie and 
Anderson, 2017). In a nutshell, it is not yet the norm for community pharmacists to engage in 
extended patient care. 
Internationally, community pharmacy has been under great pressure to change, to 
reprofessionalise by expanding the scope of practice into more clinical roles, and to integrate 
within the primary care system. Despite many campaigns and much advocacy to 
reprofessionalise in developed countries, readiness to change is still a major barrier within the 
profession. The profession of (community) pharmacists has been relatively naïve to the agenda 
for change although policy makers have seen the benefits of expanding roles of pharmacists in 
healthcare as imperative. A number of studies conducted in the UK (Edmunds and Calnan, 2001, 
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Scott et al., 2007, Alsaleh et al., 2016), Canada (Paul et al., 2018), Australia (Hoti et al., 2013) and 
New Zealand (Bryant et al., 2017) highlighted positive views of pharmacists towards 
implementing enhanced services. However,  uptake and action to adopt  expanded roles has been 
slower than expected and often – if it is not largely – influenced by human factors such as poor 
confidence (Creurer, 2017), unwillingness to leave the comfort zone in the dispensary (Mak et 
al., 2012) and lack of professional culture (Jacobs et al., 2011). 
The situation in developing countries is even more critical. The pace of practice change 
has been very slow or minimal with community pharmacies struggling even in functioning as 
suppliers of medicines (Lowe and Montagu, 2009). The roles of pharmacists and community 
pharmacies have been unrecognized and under-represented in the healthcare system. Practice 
change can be difficult as a shortage of pharmacists is a major issue in many developing countries 
(Bates et al., 2018). Practice model in community pharmacy vary significantly between countries 
(Azhar and Ibrahim, 2018). For example, it is usual for pharmacies in some African and Asian 
countries to supply medicines without prescription (Miller and Goodman, 2016) or provide only 
part of the prescribed quantity  for patients who are unable to pay for their medicines (Wagner 
et al., 2014). Dispensing medicines may be conducted by non-pharmacists including physicians 
(Tiong et al., 2016), pharmacy qualified staff (Kheir et al., 2008, Hasan et al., 2012) or even 
untrained persons working at the pharmacy (Azhar et al., 2009, Puspitasari et al., 2011). The 
common perception of community pharmacy is a place to obtain medicines (Basak et al., 2009, 
Azhar et al., 2009). Sustainability of pharmacy operations has largely relied on the sales of 
pharmaceuticals. This situation has been intensified by competition among pharmacies leading 
to price wars (Hassali et al., 2013). The quality of pharmacy services has been deficient and far 
from acceptable (Smith, 2009b).  
The bottom-line of the situation in both developed and developing countries 
demonstrates that practice change is not an easy task (Elrod et al., 2012). Despite the imperative 
for community pharmacy to change, pharmacies have struggled to move beyond dispensaries. A 
number of barriers and facilitators affecting practice change have been identified in the 
literature, with some strategic solutions offered to aid the transformation of pharmacies 
(Gastelurrutia et al., 2009). But the current realities show that community pharmacies are still 
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struggling to continue to be an essential element within primary healthcare (Bryant et al., 2017). 
This has led to a question: what has actually changed in practice? 
Doucette and Koch noted that the underlying concept of practice change in pharmacy is 
the presence of dual opportunities facing the profession which are “to improve the use of 
medications in our society while at the same time developing new revenue streams for 
pharmacies” (Doucette and Koch, 2000). This underscores the need for community pharmacies 
to take into account both professional and financial aspects when aiming for practice change.  
However, practice change arguably is a complex and dynamic process. Community 
pharmacists are constantly pushed to meet professional standards, provide services and sell 
products to sustain pharmacy business while at the same time conforming to strict regulations 
and working within a large bureaucratic healthcare environment (Holiday-Goodman, 2012). It is 
fair to say that multiple “institutional logics” co-exist and simultaneously affect the community 
pharmacy operation reflecting the need for further investigation into the process of practice 
change in community pharmacy (Goodrick and Reay, 2011).   
Many studies have explored practice change but they have adopted a narrow approach 
in analysing the process of change, for example by predominantly focusing on the individual 
practitioner without due consideration of the organisational factors in the community pharmacy 
itself and the wider system-related influences on practice change (Rosenthal et al., 2015, Luetsch, 
2016). Similarly, some studies have focused on practice change at the community pharmacy level 
but failed to explain the impact of such changes for the individual and community pharmacy 
position within healthcare system (Feletto et al., 2011, Hall et al., 2011). Moreover, since context 
of the country has an influence on practice change, this factor must be considered when 
researching practice change (Walt et al., 2008). In essence, there is a paucity of research 
investigating practice change in community pharmacy that has taken consideration of the 
influences of such complexity, and the dynamic nature and contextual setting in which 
community pharmacy system has developed. 
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1.2. Drivers for Practice Change 
In general, the need and demand for practice change have been driven by factors from 
inside and outside the profession. Internally, demand for more patient care and clinical 
responsibility beyond the supply of medicines have become preeminent drivers to change 
practice in community pharmacy (Brown et al., 2014). As a result, during the past 60 years, there 
has been a major shift in how pharmacy students and pharmacists are educated and trained. For 
example, the curriculum of pharmacy schools has been shifting from pharmaceutical sciences 
and products/substances knowledge to more emphasis on clinical practice and individualized 
care (Toklu and Hussain, 2013). In addition, most professional development programs including 
continuing education for pharmacists have given more attention to clinical knowledge and skills 
(Foppe van Mil et al., 2004, Langley and Aheer, 2010) along with ongoing campaigns by pharmacy 
organisations and advocacy groups to change attitudes and values of pharmacists (Zellmer, 
2001). 
External influences affecting practice change in community pharmacy derived from 
changes in the social, economic and political context as well as changes in health care systems.  
Advances in health and pharmaceutical technology, the aging of populations, demand for 
individualized therapy and medical services, rising health expenditure and cost of 
pharmaceuticals, changing lifestyles, increased public awareness and education levels are some 
of the external forces driving transition in community pharmacy practice (Goodrick and Reay, 
2011). The progression of change indeed has been largely influenced by these external factors 
(Holland and Nimmo, 1999). 
One of the key external drivers of practice change is the changing landscape of the 
community pharmacy industry. Over the past decade, the industry has witnessed new 
competitive forces such as niche pharmacies (e.g. pharmacy in supermarkets, chain pharmacies 
and discount-style outlets) which in the main offer relatively cheaper prices on a wide variety of 
items, strong front shop appearance and massive promotion through advertising compared to 
independent pharmacies (Singleton and Nissen, 2014). This is not to mention supermarkets, 
retailers and department stores which have become open sellers of Over the Counter (OTC) 
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products and front-of-store items such beauty and health products (e.g. vitamins at very 
competitive prices) (Singleton and Nissen, 2014). The changing landscape has forced traditional 
pharmacy business models to adapt within a competitive environment. These pharmacies are 
under greater pressure to change and differentiate themselves from competitors (Mossialos et 
al., 2015). 
Ultimately, among the drivers of practice change, the rising cost of healthcare delivery 
continues to be the main force affecting contemporary pharmacy practice. With the healthcare 
industry under major turmoil, governments in many countries have re-examined and 
restructured the traditional roles of healthcare professions as an attempt to reduce costs, 
maintain quality of care and provide consumers with broader and appropriate access to care 
(Tootelian et al., 2007). One of the potential and realistic solutions rests on optimizing the roles 
of community pharmacists within the primary care system. 
Several policy documents supporting pharmacy role expansion have been enacted such 
as The Blueprint for Pharmacy: The Vision for Pharmacy in Canada (Canadian Pharmacists 
Association, 2008), Focus on the Future in New Zealand (Pharmaceutical Society of New Zealand, 
2004), The Right Medicine in Scotland (Scottish Executive, 2002), Pharmacy in England in England 
(Department of Health, 2008), Remedies for Success in Wales (Welsh Assembly Government, 
2002) and Project Destiny in the USA (American Pharmacists Association, 2008). While these 
documents may vary in specific contents, they share commonalities as follows: 
 Recognition that community pharmacy is an easily accessible health setting which is a 
strength of the health system. In addition, investing in community pharmacy is also making 
the best use of health funding 
 Leveraging pharmacy’s accessibility to play a greater role in health promotion, health 
prevention and medication management aligns with national health policy. 
 Recognition that pharmacists’ role expansion increases their responsibility and accountability 
in relation to patients’ health outcomes.  
 Recognition of the need to redefine the practice model of community pharmacy and 
therefore, the need for government to allocate funding to help realizing this agenda. 
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1.3. Barriers and Facilitators for Practice Change 
The presence of a myriad of barriers has made practice change very challenging. Most 
barriers to practice change can be classified under the broad headings of “skills, education, 
attitudes, resources and systems” (Roberts et al., 2005a). These barriers have been common in 
much of the published literature and their identification has led to similar conclusions by authors, 
thus it is necessary to overcome these barriers when addressing the issue of practice change.  
Researchers highlighted barriers that have been experienced or have potentially 
hampered the expansion of pharmacists’ roles (Berbatis et al., 2007b, Lounsbery et al., 2009, 
White et al., 2012, Jorgenson et al., 2014, Rosenthal et al., 2016). However, most reported 
research is based primarily on pharmacists’ perceptions and often no clear distinction is made 
between perceived and actual barriers influencing the failure or success of change. 
Lack of role definition, lack of support, lack of confidence, lack of orientation, lack of time, 
lack of reimbursement and other types of “lacking conditions” have been described in many 
studies as barriers (Berbatis et al., 2007b, Nunan and Duke, 2011, Carter et al., 2012a, Jorgenson 
et al., 2014, Hamrosi et al., 2014). However, since most studies involved pharmacists’ perceptions 
of current practice, it has been argued that these perceived barriers might have been overrated 
by the pharmacists. For example, although remuneration has frequently been described as a 
barrier, the allocation of money for professional services has not necessarily resulted in robust 
uptake of new services (Feletto et al., 2010a).  
At the same time, Rosenthal et al. (2010) have argued that the ultimate barrier for 
pharmacy practice change is the “pharmacist’s own psyche and culture”. They noted that 
pharmacists often lack confidence, fear new roles, are stuck when faced with ambiguity, always 
need approval and are risk averse. These internal characteristics of pharmacists hinder the 
progress of change. These “personality traits” also may influence the way pharmacists work with 
other health care providers, thus making it more difficult to integrate them into the health care 
team. In line with this research, several other studies (Rosenthal et al., 2011, Mak et al., 2012, 
Braund et al., 2012) found that a majority of pharmacists expressed a reluctance to change and 
move away from their comfort zones although they know that it is imperative for pharmacy and 
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pharmacists to change. Pharmacists appear to be supportive and interested when discussing 
potential future roles and expanding scope of practice. However, they were also satisfied with 
their current role as “dispenser of medication” and hesitated to undertake new roles if it involved 
giving away dispensing to a non-pharmacist (Mak et al., 2012).  
Surprisingly, pharmacy organizations as advocacy bodies that should play an essential role 
in facilitating change are not acting as agents of change. A Canadian survey found that the 
majority of pharmacy organizations (17 of 22 organizations surveyed) considered that Knowledge 
Translation (translating evidence based research into best pharmacy practices) is not part of their 
remit but rather the responsibility of faculties/universities or other advocacy bodies (Truong et 
al., 2010). Despite their prominent role in advocating the value of patient centred services with 
high evidence, their reluctance appears to reflect the problem of “pharmacist’s own psyche and 
culture” (Rosenthal et al., 2016). Perhaps, the unwillingness for pharmacists to change is the 
paramount barrier in community pharmacy practice (Rosenthal et al., 2010).  
Lack of recognition from the general public about provision of extended services by 
pharmacists in a community pharmacy setting is another common barrier in practice. For 
example, Krska and Morecroft (2010) reported that only 23% of consumer survey respondents 
(n=300) considered community pharmacy to be an appropriate setting to seek general health 
advice. Even for frequent users of pharmacy, they would not use pharmacy as a source to obtain 
public health advice. The public continue to view general practice as their preferred setting to 
obtain general health advice. Further the study mentioned that the lack of awareness of 
pharmacists’ capacity may be one reason for the public to hold this notion. Despite frequent use 
of services and contact with pharmacists, pharmacists have not been seen as health experts. In 
addition, there has been concern about privacy and confidentiality as there is often no private 
space available for consultation with pharmacists (Rapport et al., 2009, Thompson and Bidwell, 
2015).  
The expansion of the pharmacist’s role has also been variably received by other 
healthcare colleagues. For example, initiatives by pharmacy organizations to seek extension of 
pharmacists’ scope of practice to include prescribing rights have raised concern and objections 
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from Medical Associations in some countries (Emmerton et al., 2005, Hoti et al., 2011, Nissen, 
2011). This initiative is seen as a threat to the monopoly of doctors in the prescribing of 
medicines. Furthermore, it may represent a significant threat to the authority of the medical 
profession and the dominance of doctors as healthcare providers (Motulsky et al., 2011, Cooper 
et al., 2012).  
Pharmacists and community pharmacies in developing countries may face additional 
barriers to practice change compared to their counterparts in developed countries. There are a 
number of factors impeding practice change in developing countries. First, the combination of 
underdeveloped health systems, lack of professional regulations and lack of access to evidence 
has made it very difficult for pharmacists to provide even the most basic effective and evidence-
based pharmacy services (Babar and Scahill, 2014, Lowe and Montagu, 2009). The manifestation 
of these factors can be wide-ranging such as lack of remuneration, lack of universal healthcare 
coverage, accessibility and affordability of medicines and poor recognition of pharmacists’ role 
and position within the wider health system (Wagner et al., 2014, Miller and Goodman, 2016). 
Second, pharmacy practice in most developing countries is in a state of infancy. There are limited 
guidelines, standards and professional development strategies in pharmacy practice (Miller and 
Goodman, 2016). This has made delivery of pharmacy services sub-optimal, unclear and 
questionable (Smith, 2009b). Third, lack of investment in pharmacists’ education and 
professional training has limited the number of trained and competent pharmacists. While 
education and professional development are the key to improving pharmacists’ competence, 
they have not been adequately designed, directed and implemented to address health issues and 
population needs (Kheir et al., 2008, Ghani et al., 2010). As a result, a shortage of pharmacists is 
common, and many licensed pharmacists have limited skills and knowledge to perform clinical 
services. 
Despite the studies on barriers, there have been a number of attempts to identify the role 
of factors that can facilitate change (Roberts et al., 2006, Berbatis et al., 2007b, Roberts et al., 
2008, Gastelurrutia et al., 2009). The term “facilitator” describes the aspects or elements of 
practice that can assist pharmacy and pharmacists to overcome barriers to change.  
 37 
According to van Mil et al. (2004), professional experience and academic training of 
pharmacists are essential facilitators for change. Roberts et al. (2005a) identified two major types 
of facilitators: experiential facilitators and potential facilitators. Experiential facilitators refer to 
those elements that are actually experienced by pharmacists when changing their practice (e.g. 
environment of the pharmacy, remuneration, workforce and use of pharmacy technicians), while 
potential facilitators are those factors that may assist pharmacists to overcome barriers of 
change (e.g. advertising, proven benefits of services and legislation). Further in 2008, Roberts et 
al. (2008) described individual and organizational influences as facilitators of change. 
Pharmacists’ competence, training, skills, knowledge and autonomy have been the positive 
drivers for individual pharmacists to change, while organizational change relates to the physical 
environment of the pharmacy, work culture, manpower, delegation of tasks etc. that affect the 
operation of the pharmacy. Similar facilitators have been identified in Spanish studies of 
pharmacy practice change (Gastelurrutia et al., 2009). Remuneration for services has been 
consistently identified as one of the most crucial elements (Roberts et al., 2005b, Roberts et al., 
2008, Feletto et al., 2010b, McMillan et al., 2015b).  
Another facilitator that supports pharmacy practice change is acceptance by patients and 
healthcare professionals of an expanded health care role for pharmacy (Lea et al., 2012). 
Recognition has become the essential point to boost pharmacy services because being 
recognized means having greater opportunities to show the value of the pharmacist’s 
contribution. However, as White (2014) stated, recognition is not a gift, it is a process, and 
pharmacists must earn it. Public recognition will occur when the pharmacist’s role and 
contributions are both demonstrated by the profession as a whole and positively valued by other 
health professionals and the public. For example, the Australian Medical Association strongly 
favour locating pharmacists in general practice because “pharmacists working in general practice 
would assist in areas such as medication management, patient education, and by supporting GP 
prescribing with advice on medication interactions and newly available medications” (Australian 
Medical Association, 2015) but at the same time, they oppose the idea of pharmacists 
administering vaccinations mainly due to the perception that pharmacists do not have adequate 
skills and knowledge to administer vaccinations (Waterford, 2013).  
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1.4. Chapter Conclusion 
This chapter highlights that practice change in community pharmacy has been a global 
phenomenon. It has been an oft-repeated message that community pharmacy should shift the 
practice paradigm from a mere technical and conventional supply role towards professional 
practice attributing clinical, humanistic and economic benefits. While there has been an 
imperative for community pharmacy to change, the current realities demonstrate that changing 
practice is often challenging. The lack of resources and motivation are potential reasons for the 
slow pace of change, but this is not new and not unique to pharmacy. On the other hand, several 
factors facilitating practice transformation have been identified, however, it is not yet clear 
whether these factors – some of which were perceived factors – can provide significant impetus 
to advance practice. Given that pharmacy practice is evolving, perhaps a starting point for 
understanding the process and encouraging practice change would be to investigate the 
contemporary situation within and beyond community pharmacy system.  
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CHAPTER 2. SITUATING THE RESEARCH 
This chapter comprises three main sections. The first section describes the landscape of 
community pharmacy in Australia. The second section presents a systematic review of emerging 
public health pharmacy initiatives in developing Southeast Asian countries including Indonesia. 
This neighbouring region has been the strategic partner of Australia within the past few decades. 
The third section explains the community pharmacy situation in Indonesia, a country next door 
to Australia, representing the case of developing countries.    
2.1. The Australian Community Pharmacy Situation 
The structure of the community pharmacy sector in Australia previously has been 
dominated by pharmacist-owned pharmacies. Pharmacists who work in pharmacist-owned 
pharmacies will generally be responsible for the whole operation of the business, both as full-
time pharmacist and a business manager. In addition, the legislation has allowed pharmacist 
owners to have direct interest in building another pharmacy within any one jurisdiction. 
However, in recent years, there has been a major change in the industry with the increasing 
prominence of banner groups and a new retailer format such as larger super chemists and 
discount or warehouse style outlets (Richardson A, 2013). 
As of November 2016, there were 5,587 community pharmacies in Australia with a large 
majority (95.4%) operated in non-remote areas (Pharmacy Guild of Australia, 2016). It was 
estimated that there were more than 20,000 community pharmacists working in community 
pharmacy sector, assisted by approximately 43,000 pharmacy assistants (Pharmacy Guild of 
Australia, 2014a). Community pharmacy is the principal deliverer of Pharmaceutical Benefits 
Scheme (PBS) medicines and other health-related services including provision of a range of 
Cognitive Pharmaceutical Services (CPS). 
The PBS provides access to subsidized medicines for all Australian residents and certain 
overseas visitors from countries which have reciprocal healthcare agreements with Australia 
(Department of Health, 2018a). Expenses in the PBS are uncapped which leads to increases in 
costs when new pharmaceuticals are added or demand for pharmaceuticals increases. Therefore, 
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over the years, the government has made a series of changes to the PBS through PBS reform 
aiming to ensure that the PBS remains economically sustainable in the future (Sweeny, 2013). 
One change was the introduction of the Price Disclosure Policy which has had a considerable 
impact on community pharmacy income and practice such that there is concern that it may affect 
the long term survival of pharmacies (Watson, 2013). 
Community pharmacies in Australia are also encouraged to provide Cognitive 
Pharmaceutical Services (CPS). There are a number of remunerated CPS provided in community 
pharmacy namely Home Medicine Reviews (HMRs) and Residential Medication Management 
Reviews (RMMRs), Dose Administration Aids (DAAs), Staged Supply, Clinical Interventions, 
Medscheck and Diabetes Medscheck. In addition, some pharmacies also provide other 
professional pharmacy services alongside the remunerated CPS including vaccinations, smoking 
cessation services, weight management, wound care and opiate substitution treatment (Berbatis 
et al., 2007b, Benrimoj et al., 2010). 
The integration of CPS into daily practice has been endorsed by pharmacy organizations 
and the Australian government. In particular, two peak national pharmacy organizations, the 
Pharmacy Guild of Australia (PGA) and the Pharmaceutical Society of Australia (PSA) have each 
played a role in advancing pharmacy practice. The PGA is an employers’ organization with 
community pharmacy owners as members while PSA represents pharmacists in general, 
including community pharmacists with its the main agenda focused on pharmacists’ continuing 
education, development of professional pharmacy practice standards and advocacy. Figure 1 
illustrates the major stakeholders representing the profession of pharmacy.  
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Pharmacists of 
Australia
(SHPA)
Clinical and hospital 
pharmacists
Professional 
Pharmacists Australia
(Formerly APESMA)
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Ownership: 50% PSA, 
50% Guild
Pharmacy Guild of 
Australia
Retail pharmacy 
owners
Co-signatory of CPAs 
with the Health 
Minister
Pharmacy Board of Australia
Registers pharmacists and 
regulates profession
Australian Pharmacy Council
Independent accreditation agency 
for Australian pharmacy
Australian Friendly 
Societies Pharmacies 
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(PDL)
Liabilities and 
indemnity insurance 
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National Australian Pharmacy Students 
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(NAPSA)
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Council of Pharmacy Schools Australia 
and New Zealand*
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Australia
owns
owns
partner
 
*These organisations are not directly involved in the practice of pharmacists and pharmacy 
Figure 1. Stakeholders in Australian Community Pharmacy Sector 
 
The remuneration for community pharmacy to dispense PBS medicines and delivery of 
CPS has been formalized since 1990 under a series of five-year cooperative arrangements 
between the Australian government and the PGA, known as the Community Pharmacy 
Agreements (the CPAs). Despite the changes in objectives in each successive CPA, there are 
several elements of the agreement that are relatively unchanged as shown in Figure 2. 
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Figure 2. Elements of the Community Pharmacy Agreements 
 
The 1st CPA (1990-1995) secured the basis for regular funding whereby approved 
pharmacies were remunerated for dispensing prescriptions (Pharmacy Guild of Australia, 2012). 
A location rule was introduced to reduce the number of pharmacies and re-distribute them to 
achieve a more consistent population to pharmacy ratio. In tandem with ownership restriction, 
pharmacy location rules remain in place under the current 6th CPA, and are still the subject of 
debate regarding their effects (Kurti et al., 2010). The 2nd CPA (1995-2000) provided more space 
for the improvement of pharmaceutical services with the Residential Management Medication 
Reviews (RMMRs) as the first funded professional program. The 2nd CPA also marked the start of 
formal funding for Research and Development (R&D) in community pharmacy although the 
funding was largely reliant on residual funds of the agreement (see Table 6 for funding details). 
One of the funded research projects in this agreement was the Sugarcare project (Armour et al., 
2004). The research showed that individual specialised services by pharmacists (e.g. consultation 
and monthly follow up) resulted in significant improvement in glycaemic control in patients with 
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type 2 diabetes.  Funding for pharmacist services for type 2 diabetes have continued in 
subsequent CPAs. 
The transition in community pharmacy practice was expanded under the 3rd CPA (2000-
2005) with pharmacists involved in reviewing medication use in the domiciliary setting, known as 
Home Medicines Review (HMR). The 4th CPA (2005-2010) represented a significant increase in 
the scope of the professional role of community pharmacists. Professional programs funded 
under the 3rd CPA were continued including HMRs and RMMRs (Urbis Keys Young, 2005, 
Campbell Research, 2010). The Diabetes Pilot Program and the Asthma Pilot Program were two 
national trials under the 4th CPA. Unfortunately, at the conclusion of the 4th CPA, neither program 
was funded for further implementation. The 5th CPA (2010-2015) provided specific funding for 
medication review activities through payment for Medscheck and Diabetes Medscheck. The 5th 
CPA also provided incentives for delivering a range of services under the Pharmacy Practice 
Incentive (PPI) scheme such as Dose Administration Aids (DAAs), Clinical Interventions and Staged 
Supply services. There has been an increase in the total funding allocated under the 6th CPA 
(2015-2020). Total funding of $1.26 billion – double that of the 5th CPA – has been invested in 
continuing the successive CPS funded under the 5th CPA (Pharmacy Guild of Australia, 2015). 
Other significant changes in the 6th CPA were the removal of funding for Research and 
Development which then shifted to fund the Pharmacy Trial Program (PTP). The PTP will enable 
pharmacies to trial a range of new services to support involvement of pharmacists within primary 
care. In addition, there have been major changes in pharmacy remuneration with the 
Administrative, Handling and Infrastructure (AHI) fee introduced to replace the pharmacy mark-
up. Further details and information about the CPA can be viewed on the CPA website 
(www.6cpa.com.au). 
Until recently, research and investment under the CPAs have played a significant role in 
the development and introduction of new services in community pharmacies in Australia. There 
were a number of Research and Development (R&D) activities that contributed to the 
introduction of remunerated CPS under the CPAs. Such research in community pharmacy 
provides room for innovation and an impetus for practice transformation (Patwardhan et al., 
2014). However, notwithstanding evidence of both clinical and cost-effectiveness, there have 
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been questions about whether the research has been successfully translated into practice and 
ultimately changed the way community pharmacy practices (Crespo-Gonzalez et al., 2017). In 
fact, even following implementation with remuneration, some services have struggled for 
sustainability in the longer term (Pharmaceutical Society of Australia, 2014).  
For example, the importance of medication review which forms the rationale of the 
current HMR services has been highlighted in a number of studies (Gowan, 2006, Hilmer et al., 
2010, White et al., 2012, Carter, 2012, Brandt and Hahn, 2012). These studies demonstrated that 
HMR is a cost-effective way to resolve, manage, or reduce medicine related problems for a wide 
range of patients. While HMR was initially remunerated under the 3rd CPA and maintained 
uninterrupted funding under the CPAs ever since, there have been a number of problems 
following its implementation particularly prior to the conclusion of the 5th CPA. This includes the 
introduction of a capping policy of HMRs services in response to a budget blowout which was 
attributed to underfunding of the program and the “unscrupulous behaviour” of some 
pharmacists who used the services as a revenue stream driven by volume rather than need or 
quality (Pharmacy Guild of Australia, 2014b). The program continues to operate under a capping 
policy in the current 6th CPA. Similarly, other remunerated CPS such as Medscheck, Diabetes 
Medscheck and Clinical Interventions were capped at the end of the 5th CPA. Although these 
programs have continued under the 6th CPA, there has been concern regarding their effectiveness 
as there is no robust evidence for any clinical and cost benefits of the services to the health 
system (PricewaterhouseCoopers, 2015). Accordingly, these programs continue to be under a 
cost-effectiveness evaluation in the 6th CPA. The impact of the funded R&D program under the 
CPAs is further described in the chapter 5.2. 
Despite the environment in community pharmacy appearing ready for change, there is 
concern whether individual pharmacists are prepared to change. A study published in 2013 
investigated pharmacists’ readiness for change before and after implementation of PAMS 
(Pharmacy Asthma Management Services, a nationally funded trial under the 4th CPA) (Feletto et 
al., 2013). The study highlighted that pharmacists’ perception of readiness for change was high 
before implementing the PAMS service. However, the experience after implementation showed 
the opposite suggesting “a lack of in-depth understanding of managing a practice change”. This 
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study showed a gap between pharmacists’ willingness and readiness for change and actually 
implementing the change. A number of external, internal and individual factors affecting the 
process of change were identified reflecting the need to recognize and facilitate these factors 
during the implementation of new services. 
The results from the aforementioned study align closely with previous Australian research 
exploring practice change. For example, Roberts et al. (2006) outlined that awareness of the 
imperative for practice change was not necessarily the factor encouraging pharmacists to start 
implementing changes. The motivation, either driven by professional satisfaction or business 
pressure or both, is an important predictor of pharmacy’s success in implementing changes. Mak 
et al. (2012) added that pharmacists “very strongly and uniformly expressed” lack of awareness 
about their current and future roles. The study showed that a majority of pharmacists did not 
perceive any changes from their current supply roles, with no alternative model of practice on 
offer to replace retailing as the dominant business model in contemporary practice. Mak et al. 
(2012) concluded that Australian pharmacists were not well prepared to change. McMillan et al. 
(2013) suggested that despite the availability of funding for adopting CPS, support and policy 
guidelines were needed for community pharmacies to incorporate CPS into practice. The study 
suggested that this is perhaps the reason pharmacists were less clear about “the how to change” 
despite strong belief that they can change. It can be said that community pharmacies in Australia 
are under constant pressure to change as driven by multiple factors mainly from government 
policy, financial pressure, competitive business environment, and research and practice impetus.  
The presence of the CPAs has served as a platform for changes in Australian community 
pharmacies. The increased amount of investment and emphasis for provision of CPS since the 3rd 
CPA reflects a commitment particularly from the government to transform community pharmacy 
practice (Australian National Audit Office, 2015). At the same time, community pharmacies are 
experiencing declining profits largely as a result of PBS reform, specifically price disclosure 
(Quilty, 2014). The viability of pharmacy is further under jeopardy due to the emergence of the 
discount pharmacy model which has led to intense competition among pharmacies.  
 46 
It has been argued that the delivery of cognitive services by community pharmacists has 
not been effective in Australia given the fact that community pharmacists have never been fully 
integrated with other health disciplines in the wider health system (Gadiel, 2008). There are 
issues about the quality of services being delivered under the CPA, yet some services are still 
delivered as a “way of recouping losses from PBS reforms” (Lingam, 2013). The implementation 
of services such as HMR, RMMR and Medscheck does not essentially change the practice of 
community pharmacists; in reality pharmacists continue their “normal practice” and supplement 
it by documenting these activities and claiming the incentive payments. In addition, the audit on 
the administration of the 5th CPA revealed that there was “limited basis for assessing the extent 
to which the 5th CPA has met its key objectives including the achievement of $1 billion in expected 
savings” (Australian National Audit Office, 2015). 
The contribution of CPS to community pharmacy income in fact has been relatively small 
and not sustainable (Chapman and Braun, 2011, Moullin et al., 2016). Therefore, it is not 
surprising that the majority of pharmacies continue to rely on dispensing as their predominant 
activities. This situation to some extent has been preserved by the fact that a large proportion of 
CPA funding is allocated to remuneration for dispensing activities. Such a funding model has 
encouraged pharmacists to focus on delivering an efficient dispensing process and to treat it as 
a merely technical process of supplying medicines with minimum professional advice and 
interaction with patients (Pharmaceutical Society of Australia, 2014). The increased pressure for 
change, along with other issues such as low pharmacists’ wages (Fair Work Commission, 2017), 
have become the main reasons for pharmacists’ disillusionment and burnout leading to some 
pharmacists leaving the profession (Mak et al., 2013).  
The contemporary situation in Australia demonstrates two relevant lessons for this study. 
Firstly, Australia has an advanced system of community pharmacy practice within a unique 
healthcare system underpinned by universal access to health services and medicines. This 
provides an excellent opportunity for community pharmacy role expansion marked by delivery 
of remunerated professional services. In addition, government support, the use of technology, 
the quality of pharmacy education and graduates, and the educated and trained pharmacists’ 
workforce have been facilitators to meet existing and future demands of the practice. However, 
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secondly, a shift in practice has been hindered by strong reliance on a dispensing and retail 
business model. Notwithstanding the investment in research and development, robust evidence 
for the ongoing effectiveness of CPS is lacking and the funding of CPS has not been sustainable. 
Practice change towards patient care orientation has proven difficult although the supporting 
systems are available, and the environment is ready for change. This emphasizes that practice 
change is a complex and dynamic process which warrants further investigation to understand the 
process of change comprehensively based on the contemporary situation in community 
pharmacy.  
2.2 Community Pharmacy and Emerging Public Health Initiatives in Developing 
Southeast Asian Countries: A Systematic Review 
This section comprises the following publication: 
“Hermansyah, A., Sainsbury, E., & Krass, I. (2016). Community pharmacy and emerging public 
health initiatives in developing Southeast Asian countries: a systematic review. Health & Social 
Care in the Community, 24(5): e11-22. doi:10.1111/hsc.12289” 
This publication aimed to systematically review community pharmacy and public health 
initiatives in several developing Southeast Asian countries including Indonesia, and to assess the 
evidence associated with the services provided in the selected countries. This publication was 
submitted in March 2015, accepted for publication in July 2015 and available online in August 
2016. The published version of the paper is presented in appendix 6. 
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Community pharmacy and emerging public health initiatives in developing Southeast Asian 
countries: A Systematic Review 
Andi Hermansyah, Erica Sainsbury, Ines Krass 
 
What is known about this topic 
 Community pharmacies have both the opportunity and the potential to play a role in public 
health 
 Earlier research has shown that despite their potential, community pharmacies have been 
underutilized in the provision of public health care services 
What this paper adds 
 Community pharmacies in Southeast Asia have attempted to expand practice in public health 
 However, the pace of the expansion has been slow and lacking evidence for its sustainability 
in everyday practice 
 Fundamental policy change is needed to overcome the ongoing barriers which have limited 
progress 
Keywords: community pharmacy services, public health initiatives, Southeast Asia 
ABSTRACT 
The development of health and health care systems in Southeast Asia has influenced the practice 
of community pharmacy. Over the years, community pharmacy in the region has striven to 
expand services beyond dispensing to encompass more involvement in public health issues. 
Searches were conducted in Scopus, EMBASE, MEDLINE and PubMed for articles published 
between January 2000 and December 2014, with twenty-one studies in five countries meeting 
the inclusion criteria. The findings showed increasing interest in research into the delivery of 
pharmacy services and public health initiatives. Overall the review found that provision of some 
health services in pharmacies was common, however most public health initiatives appeared to 
be poorly implemented, had limited evidence and were not demonstrated to be sustainable 
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across the sector. This indicates that the practice of community pharmacy in the region has not 
significantly changed over the past fourteen years with respect to the scope and the quality of 
pharmacy services provided, and fundamental policy changes are necessary to improve this 
situation. 
INTRODUCTION 
Health care systems in Southeast Asia have dramatically changed over past decades as a 
result of rapid social and economic development and considerable population growth 
(Chongsuvivatwong et al., 2011). Health care in the region is at a crossroads, having to deal 
concurrently with both a rising tide of chronic conditions and ongoing issues with infectious 
diseases. Moreover, the diversity of cultures, languages and geographical landscapes continue to 
be daunting challenges to providing equitable access to health care services (Acuin et al., 2011). 
While lack of health care facilities and ongoing shortages of providers, especially doctors and 
nurses, have remained intractable problems over many years (Kanchanachitra et al., 2011), the 
increasing number of community pharmacies in the region creates unexplored opportunities for 
delivering public health services. In Vietnam, pharmacist numbers have nearly doubled from 
7,800 to 13,900 between 2000 and 2008 (Le et al., 2010). In Malaysia and Indonesia, pharmacist 
numbers have exponentially increased over the last decade as universities have graduated more 
pharmacists annually (Chee et al., 2009, Shafie et al., 2012).  
With strategic location in the heart of the community, extended opening hours and no 
appointment required for seeking health care advice, community pharmacy has great potential 
as a setting in public health. Moreover, pharmacy in the region has often become patients’ first 
point of health care contact (Chalker et al., 2005, Ngorsuraches et al., 2008, Chua et al., 2013). 
These benefits provide a platform for more proactive involvement of community pharmacy in 
addressing gaps in public health services and programs. 
As elsewhere, community pharmacy practice in Southeast Asia has evolved in response 
to the changing health care environment. Significantly, provision of a range of health care 
services beyond traditional dispensing has been trialled in community pharmacies across the 
region. Although relatively new, such services include blood pressure monitoring, chronic disease 
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screening, smoking cessation, and weight management programs (Chua et al., 2013, Dhippayom 
et al., 2012, Nimpitakpong et al., 2010, Phimarn et al., 2013). However, there is a dearth of 
evidence on the extent of implementation of these services in everyday practice and their impact 
on public health. 
In this paper we report the findings of a systematic review of the published literature on 
pharmacy services and public health initiatives in five Southeast Asian countries: Indonesia, 
Malaysia, The Philippines, Thailand and Vietnam. These countries were selected because they 
are the most populous countries of the region, they are representative of developing countries, 
and they have introduced privatization in health care which provides an avenue for community 
pharmacy partnership in public health (Ramesh and Wu, 2008, Lowe and Montagu, 2009). This 
review is guided by the research question: What is known about the role of community pharmacy 
of this region in public health services? To address this question, this paper briefly reviews the 
scope of practice and services provided in community pharmacy, then evaluates the evidence for 
the provision of community pharmacy public health care services, and finally identifies barriers 
to their provision. 
METHOD 
The literature search was conducted in Scopus, EMBASE, MEDLINE and PubMed. The 
database search was also supplemented with electronic searches in relevant journals and/or 
publications.  
Search terms included keywords such as community pharmacy§, pharmacy service§, 
pharmaceutical care, cognitive service§, pharmacy practice§ in combination with Southeast Asia 
or country name (Indonesia, Malaysia, Thailand, Vietnam, Philippines). The period covered 1 
January 2000 to 31 December 2014. This review was based upon full text original research articles 
written in English.  
The screening used three inclusion criteria: studies that (1) reported services provided 
including public health activities in community pharmacy, (2) were conducted in at least one of 
the five selected countries, and (3) involved community pharmacists and/or pharmacy workers. 
Studies were excluded if they: (1) were not conducted in a community pharmacy setting or (2) 
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were investigations of patient/student’s perceptions, attitude, knowledge, or satisfaction etc. 
conducted in community pharmacy. Details of literature search and screening process are shown 
in Figure 3. 
 
Figure 3. Flow diagram of paper selection process using PRISMA (Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses) 
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Community pharmacy in this paper was defined as a health care facility that operates 
under the full responsibility of a registered pharmacist and provides pharmacy services to the 
community. These services may include but are not limited to dispensing of prescribed 
medicines, self-medication advice and other roles providing consumer assistance in the use of 
pharmaceutical products. In relation to the public health role of pharmacy, this paper adopted 
Walker’s definition of pharmaceutical public health described as “the application of 
pharmaceutical knowledge, skills and resources to the science and art of preventing disease, 
prolonging life, promoting, protecting and improving health for all through organised efforts of 
society” (Walker, 2000). 
Selected studies were evaluated for the scope and quality of pharmacy services and public 
health initiatives. The evaluation also classified the level of evidence of each study using a grading 
system adapted from the public health literature (Anderson et al., 2004, Agomo, 2012, Neville et 
al., 2015): 
Level A : Evidence from meta-analysis or systematic reviews 
Level B : Evidence from randomised controlled trials (RCTs) 
Level C : Evidence from quasi-experimental studies 
Level D : Evidence from observational studies or quantitative surveys 
Level E : Expert opinion, case reports, focus groups, or qualitative studies 
RESULTS 
In the end, 796 articles were identified through the search process. After eliminating 
duplicates, titles and abstract screening and reviewing full text articles meeting the inclusion and 
exclusion criteria, twenty-one studies were included for analysis. Details of the twenty-one 
studies are presented in Table 2. 
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Table 2. Details of eligible studies 
Author and 
Country 
Level of 
Evidence 
Aims/Objective Study Design Primary findings/conclusions 
Management of minor ailments 
Chua et al. – 
Malaysia (Chua 
et al., 2006) 
Level D Assessment of 
community 
pharmacy 
response to 
patient with back 
pain symptoms 
Simulated patient; 
100 randomly 
selected 
pharmacies in 
Klang Valley, 
Malaysia 
Pharmacist’s assessment and 
counselling were considered 
suboptimal. Only 3 and 5 out of 13 
elements for assessment and 
counselling were addressed by 
pharmacists, respectively 
Saengcharoen 
and 
Lerkiatbundit – 
Thailand 
(Saengcharoen 
and 
Lerkiatbundit, 
2013) 
Level D Management of 
migraine in 
community 
pharmacy 
Simulated patient 
and interview; 142 
randomly selected 
pharmacies in 
South Thailand 
33% and 53% of pharmacy staff 
appropriately dispensed medication 
for patients presenting with mild and 
moderate migraine, respectively.  
Pharmacists showed higher knowledge 
than non-pharmacists in history taking, 
yet their level of knowledge was still 
not sufficient as on average they only 
achieved half of the full score. Fewer 
than 30% of pharmacists gave the 
appropriate advice to the “patients” 
Provision of smoking cessation services 
Thananithisak 
et al. – 
Thailand 
(Thananithisak 
et al., 2008) 
Level D Assessment of 
pharmacists' 
involvement, their 
perception and 
barriers in 
smoking cessation 
services 
Mail survey and 
interview; 83 
pharmacists 
participated in the 
survey, 13 early 
adopter 
pharmacists 
interviewed in 
Bangkok, Thailand 
51% of surveyed pharmacists provided 
smoking cessation services. Their 
perception of the services was positive 
yet barriers such as lack of demand, 
lack of educational materials, lack of 
smoking cessation products, lack of 
knowledge and skills and lack of follow 
up visits have hindered their services. 
Only 4 out of 13 early adopters still 
delivered the services by the third 
month due to these barriers 
Nimpitakpong 
et al. – 
Thailand 
(Nimpitakpong 
et al., 2010) 
Level D Evaluation of 
smoking cessation 
services and 
training in 
community 
pharmacy 
Mail survey; 1,001 
randomly selected 
pharmacies 
nationwide 
71% of pharmacists provided smoking 
cessation services but only 15% 
provided comprehensive services. 29% 
of pharmacists attended cessation 
training and they were more likely to 
provide comprehensive services than 
those who were not trained 
Provision of weight management program 
Phimarn et al. 
– Thailand 
(Phimarn et al., 
2013) 
Level B Involvement of 
community 
pharmacists in 
weight 
management 
program 
Randomized 
Controlled Trial; 
66 patients, 1 
selected pharmacy 
Although there is a potential role for 
pharmacist involvement in weight 
management programs, particularly in 
influencing eating behaviours and 
knowledge of obese patients, there 
was no significant improvement in 
clinical outcomes such as weight, waist 
circumference and Body Mass Index in 
the experimental group 
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Author and 
Country 
Level of 
Evidence 
Aims/Objective Study Design Primary findings/conclusions 
Prevention and management of infectious diseases 
Lönnroth et al. 
– Vietnam  
(Lönnroth et 
al., 2000) 
Level E Assessment of 
knowledge and 
dispensing 
practice of anti-
tuberculosis drugs 
Interview; 147 
randomly selected 
pharmacies in 
Hanoi, Vietnam 
The majority of the pharmacy staff 
members had adequate knowledge 
about Tuberculosis and National 
Tuberculosis Program. 58% of 
pharmacies dispensed anti-
tuberculosis drugs and 24% had sold 
them without prescription in the 
previous 4 weeks  
Chuc et al. – 
Vietnam (Chuc 
et al., 2001) 
Level D Management of 
childhood acute 
respiratory 
infections 
Interview and 
simulated 
patients; 60 
randomly selected 
pharmacies in 
Hanoi, Vietnam 
In actual practice, 83% of pharmacy 
dispensed antibiotics at the first 
encounter while only 20% of them 
stated in the interview that they would 
dispense antibiotics. Only 36% of 
pharmacy encounters were managed 
according to the guidelines 
Chuc et al. – 
Vietnam (Chuc 
et al., 2002) 
Level B Evaluation of 
multiple 
interventions in 
the case of acute 
respiratory 
infection, sexually 
transmitted 
disease, 
prednisolone and 
cephalexin 
request. 
Randomized 
Controlled Trial; 
68 randomly 
selected 
pharmacies in 
Hanoi, Vietnam 
Multiple interventions comprised of 
regulatory enforcement, education 
and peer influence significantly 
improved the practice of community 
pharmacy in terms of reducing 
dispensing of antibiotics and steroids 
without prescription, increasing history 
taking and advice to patients and 
increasing consultation with physicians 
Saengcharoen 
and 
Lerkiatbundit – 
Thailand 
(Saengcharoen 
and 
Lerkiatbundit, 
2010) 
Level D Management of 
childhood 
diarrhoea in 
pharmacy 
Simulated patient 
and questionnaire; 
115 randomly 
selected 
pharmacies in 
South Thailand 
Only 5% of pharmacies correctly 
dispensed ORS for “simulated 
patients” and 52% of pharmacies 
responded inappropriately by 
dispensing antibiotics as the first line 
therapy. In contrast, the majority of 
pharmacies stated they would 
dispense ORS as the first line therapy 
in the questionnaire 
Vu et al. – 
Vietnam (Vu et 
al., 2012) 
Level D Detection of 
suspected TB 
patients in 
pharmacy 
Simulated patient 
and interview; 138 
randomly selected 
pharmacies in 
Hanoi, Vietnam 
Almost half of the pharmacists were 
dispensing drugs for suspected TB 
patients and did not directly refer 
patients to healthcare facilities. No 
differences were found between 
accredited and non-accredited 
pharmacies in the case study 
Minh et al.  – 
Vietnam (Minh 
et al., 2013) 
Level D Evaluation of 
training and 
supervision in 
childhood 
diarrhoea and 
emergency 
Questionnaire and 
simulated patient; 
734 randomly 
selected 
pharmacies in five 
provinces in 
Vietnam 
Pharmacists’ knowledge and practice 
in terms of providing more information 
about drugs and offering ORS for 
diarrhoea were significantly increased 
after a sequence of training and 
supportive supervision 
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Author and 
Country 
Level of 
Evidence 
Aims/Objective Study Design Primary findings/conclusions 
contraceptive 
provision 
Screening for chronic diseases 
Pongwecharak 
and 
Treeranurat  - 
Thailand 
(Pongwecharak 
and 
Treeranurat, 
2010) 
Level C Screening for pre-
hypertension and 
cardiovascular risk 
Screening 
program; 350 
people in 1 
selected pharmacy 
in Songkla, 
Thailand 
Community pharmacy can play a role 
to identify people at risk of 
hypertension and cardiovascular 
disease 
Sookaneknun 
et al. – 
Thailand 
(Sookaneknun 
et al., 2010) 
Level C Comparison of 
screening 
programs for 
diabetes and 
hypertension 
Screening 
program; 457 
people in 2 
selected 
pharmacies in 
Maha Sarakham, 
Thailand 
Community pharmacy screening 
program resulted in a higher rate of 
detection of new patients and higher 
success rate for referral, with 
reasonable cost compared to same 
services provided by primary care unit. 
However, the study had high dropout 
rate (98%) as only 6 out of 457 clients 
came back for follow up meaning that 
only these 6 patients were actually 
referred to doctors. No particular 
reason was described for the low 
uptake 
Pongwecharak 
and 
Treeranurat  - 
Thailand 
(Pongwecharak 
and 
Treeranurat, 
2011) 
Level C Screening pre-
hypertension and 
cardiovascular risk 
Screening 
program: 400 
people in 1 
selected pharmacy 
in Hat Yai, 
Thailand 
Community pharmacy can detect 
patients at risk of hypertension, 
diabetes and/or dyslipidaemia 
Dhippayom et 
al. – Thailand 
(Dhippayom et 
al., 2012) 
Level C Opportunistic 
screening of 
diabetes in 
community 
pharmacy 
Screening 
program; 397 
people in 7 
selected 
pharmacies in 
Bangkok, Thailand 
The program was effective in detecting 
half of the participants who were at 
high risk of diabetes. However, 91% of 
participants (11 people) with 
suspected diabetes refused to see 
physicians despite frequent reminders. 
The main reason was that it was not 
convenient to visit a medical practice 
in a hospital setting 
Harm reduction activities 
Pankonin et al. 
– Vietnam 
(Pankonin et 
al., 2008) 
Level E Exploration of 
pharmacy harm 
reduction 
activities 
Interviews; 5 
conveniently 
selected 
pharmacies in 
Hanoi 
Community pharmacists could 
contribute to harm reduction 
programs and prevent the spread of 
HIV infections by providing sterile 
syringes and health education to 
injecting drug users 
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Author and 
Country 
Level of 
Evidence 
Aims/Objective Study Design Primary findings/conclusions 
Other identified studies 
Chalker et al. – 
Thailand and 
Vietnam 
(Chalker et al., 
2005) 
Level B Effectiveness of 
multi-component 
intervention on 
dispensing 
steroids and 
antibiotics 
Randomized 
Controlled Trial; 
68 randomly 
selected 
pharmacies in 
Hanoi, 78 
pharmacies in 
Bangkok 
Multi-faceted intervention improved 
dispensing behaviour of pharmacies in 
Hanoi but only improved it slightly in 
Bangkok 
Babar and 
Awaisu - 
Malaysia 
(Babar and 
Awaisu, 2008) 
Level E Investigation of 
generic drugs 
supply and 
substitution 
practice in 
pharmacy 
Interview; 40 
randomly selected 
pharmacies in 
West Malaysia 
Branded drugs were more widely 
available at community pharmacies 
and only 40-60% of pharmacy stock 
was generic drugs. 73% of pharmacists 
agreed with the concept of compulsory 
generic substitution. Generic 
substitution was more driven by 
consumer demand than pharmacist 
initiative 
Ping et al. – 
Malaysia (Ping 
et al., 2008) 
Level D Evaluation of 
generic 
substitution 
practice by 
community 
pharmacist 
Self-completed 
questionnaire; 34 
randomly selected 
pharmacies in 
Penang, Malaysia 
47% of pharmacies discussed the 
substitution with prescribers and a 
majority of doctors (84%) contacted 
agreed to substitution. 88% of 
consumers accepted the substitution 
and this could save 61% of their 
expenditure on drugs 
Chong et al. – 
Malaysia 
(Chong et al., 
2011) 
Level D Assessment of 
generic 
substitution 
practice among 
community 
pharmacists 
Mail survey; 157 
randomly selected 
pharmacies 
nationwide 
85% pharmacists recommended 
generic substitution, yet only 13% 
consulted about this practice with 
physicians. According to pharmacists, 
89% of patients accepted the 
recommendation for substitution, 
which could save 57% of patient’s 
expenditure on drugs 
Puspitasari et 
al. – Indonesia 
(Puspitasari et 
al., 2011) 
Level D Evaluation of 
community 
pharmacy 
workers' response 
to antibiotic 
request 
Simulated patient; 
88 randomly 
selected 
pharmacies in 
Surabaya, 
Indonesia 
Antibiotics were dispensed without 
prescription in the majority (91%) of 
pharmacies. Few (2-8%) pharmacies 
assessed patients’ suitability for 
antibiotics, and information about the 
medicines was mostly given when 
requested by the “patients”. The most 
frequent information provided were 
indication, dosing, duration and 
direction for use 
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Scope and quality of services 
The studies covered a range of topics related to public health services. 
Management of minor ailments 
Two studies examined the role of community pharmacy in managing minor ailments such 
as back pain (Chua et al., 2006) and migraine (Saengcharoen and Lerkiatbundit, 2013). Both 
employed simulated patient methods to investigate pharmacy responses when presented with a 
“patient” with specific symptoms. The Malaysian study (Chua et al., 2006) did not distinguish 
between responses given by pharmacists or other pharmacy staff, while the Thai study 
(Saengcharoen and Lerkiatbundit, 2013) compared the responses of pharmacists and non-
pharmacists. In general, the majority of “simulated patients” were actively asked by pharmacy 
staff members about their symptoms, especially in the Thai study where pharmacists asked more 
questions than non-pharmacists in relation to migraine. However, the services provided in both 
studies were considered suboptimal and inappropriate. The Malaysian study found that the 
pharmacist’s assessment and counselling activities only covered 3-5 elements of a total of 13 
elements which constituted appropriate service. Likewise, only 30% of 142 pharmacists in the 
Thai study had given appropriate advice to the migraine “patients”. 
Provision of smoking cessation services 
Two Thai studies highlighted the role of pharmacy in smoking cessation programs. A mail 
survey was employed in both studies to assess pharmacists’ perceptions and practice in providing 
smoking cessation services. The first study (Thananithisak et al., 2008) also included an interview 
to gather the opinion of early adopter pharmacists about smoking cessation services, while the 
second study (Nimpitakpong et al., 2010) was more focused on a nationwide survey to evaluate 
the program and the effectiveness of cessation training. 
The studies found that more than half (51% and 71% respectively) of pharmacies surveyed 
were actively providing smoking cessation services. However, in the first study only four of 
thirteen early adopters consistently provided the services after the third month. Barriers to 
 58 
continuation included insufficient demand, educational materials, smoking cessation products, 
knowledge and skills and follow up visits.  
Although the provision of the services was higher in the second study, only 15% of 1,001 
participating pharmacies provided comprehensive services which covered the standard 5As (ask, 
advise, assess, assist and arrange follow up). Almost half of pharmacists only provided brief 
interactions such as advice about the risks of smoking, giving leaflets or suggesting smoking 
cessation products. This finding was associated with the fact that only 29% of surveyed 
pharmacists had received smoking cessation training, and it was this group which was more likely 
to provide comprehensive services. 
Provision of weight management program 
One study from Thailand (Phimarn et al., 2013) examined pharmacists’ role in weight 
management. A randomized controlled trial with 66 obese patients investigated clinical 
outcomes such as weight loss, waist circumference and Body Mass Index between a control 
group (attended one-hour advisory session every four weeks) and experimental group (received 
comprehensive treatment including routine monitoring) for 16 weeks after the initial advisory 
session. Even though pharmacist interventions were observed to improve patients’ healthy 
eating behaviours and knowledge, the findings showed no significant improvement in clinical 
outcomes in the experimental group. 
Prevention and management of infectious diseases 
The region has long struggled with communicable diseases, prevention and management 
of infectious diseases, and this was reflected in six studies, five from Vietnam and one from 
Thailand, which addressed different types of infectious diseases including tuberculosis (TB) 
(Lönnroth et al., 2000, Vu et al., 2012), acute respiratory infections (Chuc et al., 2001, Chuc et al., 
2002) and diarrhoea (Saengcharoen and Lerkiatbundit, 2010, Minh et al., 2013). Four studies 
(Lönnroth et al., 2000, Chuc et al., 2001, Saengcharoen and Lerkiatbundit, 2010, Vu et al., 2012) 
explored services provided in pharmacy associated with the diseases, while two studies (Chuc et 
al., 2002, Minh et al., 2013) were aimed at improving practice by introducing multiple 
interventions. 
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Overall, the four studies which explored pharmacy services targeted to management of 
infectious diseases showed negative outcomes. In the case of TB, both studies conducted in 
Hanoi (Vietnam) showed that pharmacists dispensed drugs for suspected TB patients without a 
prescription. In the earlier study (Lönnroth et al., 2000), 58% of 147 pharmacies had dispensed 
anti TB drugs in the last 4-week period, and 24% of this number without prescription. In the more 
recent study (Vu et al., 2012), almost half of 138 pharmacists dispensed anti TB drugs without 
prescription and did not refer patients to doctors or healthcare facilities, thus delaying 
appropriate diagnosis and treatment. In the management of childhood diarrhoea, only 5% of 115 
pharmacies correctly responded to symptom presentations by simulated patients (Saengcharoen 
and Lerkiatbundit, 2010). A “mystery shopper study” using an acute respiratory infection scenario 
revealed that community pharmacies in Vietnam commonly dispensed antibiotics without 
prescription, and only 36% of 60 pharmacies managed the case appropriately according to the 
guidelines (Chuc et al., 2001).  
Two Vietnamese studies reported attempts to improve practice in pharmacy by 
introducing multiple interventions such as regulatory enforcement-education-peer influence 
(Chuc et al., 2002) and training-supportive supervision (Minh et al., 2013). Both studies concluded 
that multiple interventions significantly improved the practice of community pharmacy in 
managing infectious diseases. Chuc et al. (2002) demonstrated that these interventions could 
reduce the frequency of dispensing of antibiotics and steroids without prescription in the 
management of acute respiratory infection and sexually transmitted diseases, while Minh et al. 
(2013) concluded that training and supportive supervision improved pharmacists’ knowledge, 
and their dispensing patterns became more appropriate according to the guidelines for 
presentation of “patients” with diarrhea. 
Screening for chronic diseases 
The escalating rates of chronic disease have focused attention on the need for early 
detection of those at risk. Four studies in Thailand investigated screening programs conducted in 
community pharmacy. Two focused on hypertension and the risk of other cardiovascular diseases 
(Pongwecharak and Treeranurat, 2010, Pongwecharak and Treeranurat, 2011), one investigated 
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diabetes screening (Dhippayom et al., 2012), and one compared a screening program conducted 
by pharmacy and a primary care unit (Sookaneknun et al., 2010).  
All studies demonstrated a potential role for community pharmacy in the detection of 
people at risk of hypertension, diabetes and predisposing factors such as dyslipidaemia. In 
addition, community pharmacy screening programs generated higher detection and referral 
rates compared to similar services provided by the primary care unit (Sookaneknun et al., 2010). 
However, two studies reported a poor uptake of referral by customers detected as at high risk of 
chronic disease (Sookaneknun et al., 2010, Dhippayom et al., 2012). Reasons for the poor uptake 
were that customers felt healthy (Sookaneknun et al., 2010), and that it was not convenient to 
visit a hospital for follow-up (Dhippayom et al., 2012) 
Harm reduction activities 
One Vietnamese study (Pankonin et al., 2008) investigated the role of  community 
pharmacy in the supply of sterile syringes for Injecting Drug Users (IDU). The five pharmacies in 
the study sold on average 93 syringes per pharmacy to IDU in a one-week period. The study 
demonstrated that the participating pharmacists had a solid understanding and strong 
commitment to taking part in HIV prevention activities through selling sterile syringes and 
providing educational materials for IDU. Therefore, the authors suggested that pharmacists 
might potentially play a role in the provision of harm reduction services. 
Other identified studies 
Five studies related to the safe supply and distribution of medicine, namely the role of 
pharmacists in dispensing antibiotics and steroids, and the practice of generic substitution in 
pharmacy. Three studies carried out in Malaysia (Babar and Awaisu, 2008, Ping et al., 2008, Chong 
et al., 2011) focused on generic substitution practice and drew similar conclusions that the 
majority of pharmacies were engaged in generic substitution, however fewer than half of 
pharmacists discussed this practice with prescribers. Interestingly, these studies revealed that 
generic substitution was driven more by patients than by pharmacists. Since doctors in Malaysia 
have dispensing rights, however, the number of prescriptions actually dispensed in pharmacy 
represented only a fraction of the total. In the other two studies, in Indonesia (Puspitasari et al., 
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2011) and in both Thailand and Vietnam (Chalker et al., 2005), dispensing antibiotics and steroids 
without prescription was commonly found. In Indonesia, inappropriate dispensing was 
compounded by a lack of adequate patient assessment and counselling. Chalker et al. (2005) 
found that a multi-faceted intervention which comprised regulatory enforcement, education and 
peer review was able to improve dispensing practice significantly in Hanoi but only slightly in 
Bangkok.  
The strength and level of evidence 
The level of evidence demonstrated by the twenty-one studies ranged from B to E (see 
table 2). Three studies generated level B evidence, four with level C evidence, the majority (11) 
produced level D evidence, and three generated level E evidence. The level B studies involved 
randomized controlled trials evaluating the effectiveness of multiple interventions to improve 
dispensing practice in the management of diseases, and the role of pharmacists in weight 
management programs. Level C evidence focused on opportunistic screening and early detection 
of chronic diseases in pharmacy. The majority of studies producing level D evidence employed 
simulated patient methodology to assess the actual practice of pharmacy service provision, while 
a minority used surveys. Studies with level E evidence employed interviews as a means to explore 
the knowledge and perception of pharmacists about current services, in particular dispensing 
anti TB drugs, harm reduction services and generic substitution practice. 
Across the range of research undertaken in the region, the overarching limitation was a 
lack of broad generalizability, since most studies were preliminary or pilot studies employing 
small sample sizes, were conducted in a narrow area of research and employed non-random 
sampling techniques. In addition, only two studies were carried out nationwide (Nimpitakpong 
et al., 2010, Chong et al., 2011). As a consequence, it is not possible to extrapolate any of the 
reported findings to the wider community pharmacy setting even within the same country. In 
addition, most studies reported poor quality and low success rates for public health services 
provided in pharmacy which may indicate structural and systemic barriers for provision of these 
services.  
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Given the variability in context within Southeast Asia, it is also not possible to extrapolate 
evidence from one country to another. Despite finding that an intervention is successful in one 
country, it may not work in another. A good example is the study conducted both in Thailand and 
Vietnam (Chalker et al., 2005). While there was strong improvement in practice in Hanoi, the 
same was not the case in Bangkok. This suggests that while much can be learned from other 
countries in designing pharmacy public health interventions, they must be replicated and 
evaluated in different settings in order to build and strengthen the evidence base. This paper 
argues that cross-country learning is critical in implementing the best strategies for improving 
pharmacy public health services in developing countries. 
Barriers to provision of services 
A number of barriers that have hindered the provision of public health services are 
highlighted in this review. Lack of knowledge and skills have been reported as contributing to 
inappropriate response in some chronic diseases (Chuc et al., 2001, Thananithisak et al., 2008, 
Saengcharoen and Lerkiatbundit, 2010, Puspitasari et al., 2011, Saengcharoen and Lerkiatbundit, 
2013). Lack of confidence (Chong et al., 2011) and adequate training (Nimpitakpong et al., 2010) 
have been documented as barriers in the case of generic substitution and smoking cessation 
services. External to the pharmacy environment, barriers that have impeded the uptake of 
pharmacy services and public health initiatives include lack of policies (Babar and Awaisu, 2008, 
Chong et al., 2011), low patient demand (Pongwecharak and Treeranurat, 2011), poor 
recognition within the health care system (Ping et al., 2008, Dhippayom et al., 2012) and patients’ 
reluctance to use pharmacy services (Sookaneknun et al., 2010). 
DISCUSSION 
To the best of our knowledge, this is the first systematic review of community pharmacy 
practice and public health initiatives in developing Southeast Asian countries. This review is 
important because a move into public health services is reflective of the expanding potential of 
community pharmacy as a service provider. Identification and evaluation of current pharmacy 
services in public health highlight opportunities that exist at the present time, as well as 
suggesting areas for future growth. The findings have also documented a range of barriers to 
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implementation and have outlined key reasons why they have not been introduced more 
appropriately, adequately and widely in the community.  
The core finding of this study was that provision of a range of pharmacy public health 
services has been researched in the region, and these services can be clustered into seven topics 
as presented in the results. On the positive side, it is apparent that Southeast Asian pharmacy 
practice is moving in similar directions to the international context and following the patterns of 
developed countries (Anderson et al., 2004, Agomo, 2012). However, the review has also 
revealed limited evidence of the efficacy, effectiveness, generalisability and sustainability of such 
services at the current time.  
The majority of the reviewed studies were not designed to produce a high level of 
evidence, thus suggesting that the majority of the research was still proof of concept rather than 
knowledge translation. Where randomized controlled trials were undertaken, interventions to 
improve practice generally showed only limited success. The agenda for public health practice in 
pharmacy has remained at the level of vision rather than actively directed by sound evidence-
based health policy. 
This review has furthered and strengthened the findings of previous reviews of pharmacy 
services in developing countries by Smith (2009a) and Smith (2009b), who reported that private 
pharmacies in African, Central and South American and Asian countries (including Thailand, 
Vietnam and Indonesia), played an important role in the supply of pharmaceuticals and had the 
potential to contribute more in primary care and public health. They also highlighted that the 
quality of services in pharmacies was far from acceptable.  
Despite the differences between the geographical scope and year of publication, common 
and consistent themes are evident in this review and the two previous reviews in that community 
pharmacy generally provided similar types of services. Despite the rapid growth in the region, 
the evidence reveals that community pharmacy services in Southeast Asia have not changed 
significantly in the last 5 years, suggesting that barriers identified earlier continue to limit their 
uptake in day-to-day community pharmacy practice. 
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Unlike the earlier reviews which focused only on scope and quality of pharmacy services, 
in this review we also explored the level of evidence for pharmacy public health initiatives in the 
targeted countries. The use of level of evidence allows a more fine-grained analysis of the findings 
and informs their interpretation. Research with higher levels of evidence is more likely to provide 
an explanation of why the services were effective or ineffective (Rychetnik et al., 2002), and thus 
guide strategies for improvement. Few of the reviewed studies employed RCTs, thus highlighting 
the need for more robust research to strengthen the evidence base. However, it should also be 
recognized that public health interventions are complex and context dependent and not always 
amenable to RCTs. Observational (level D) or qualitative studies (level E) may also provide 
important and relevant information about the services. In the search for effective pharmacy 
public health services, stakeholders in the region must decide on an acceptable level of evidence 
on which to base broad implementation. 
It is apparent that barriers associated with service provision, many outside the 
pharmacist’s control, have constrained successful introduction of high quality programs. If 
community pharmacists in these countries aspire to expand their role and contribute more 
effectively in the health care system, then resolving the barriers at all levels is critical. The 
approach must be multi-faceted and include both a willingness on the part of pharmacists to 
become more involved, as well as policies which recognise and utilise the potential of community 
pharmacy to provide expanded services. This review has identified the need for fundamental 
structural and policy change to encourage and facilitate delivery of high quality services by 
pharmacy. Furthermore, it has highlighted fundamental anomalies within the health system: 
demand for public health services is increasing but there is limited capacity of the health system 
to meet this demand; the number of pharmacies has increased but they are underutilized. This 
is exacerbated by the fact that community pharmacy in this region is effectively independent of 
the mainstream health care system and is not defined as a health care provider in some 
jurisdictions. Significant policy reform founded on a fundamental rethinking of the role and value 
of community pharmacy is needed.  
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Countries in the Southeast Asia region might reflect on how developed countries have re-
established their roles in the public health system over recent years. Regardless of the context, a 
common thread through the experience of these countries is the need to engage with the 
government  in order to be recognised as a legitimate public health provider (Mossialos et al., 
2013), and to be recognised by the public as a useful and accessible source of public health 
services. The process of achieving this is not an easy task and requires sustained efforts over a 
period of years.  
Aside from policy change, attention must be directed to increasing public awareness of 
both service provision and pharmacists’ roles in public health. Lessons from the UK and Australia 
show that public understanding is critical to enhancing the uptake of novel services. Although 
there is evidence of increasing recognition of the expanded services among the general public in 
both the UK (Taylor et al., 2012, Saramunee et al., 2014) and Australia (White et al., 2012), it 
takes many years to change entrenched community perceptions.  Studies in both countries 
illustrate that the key barriers to uptake have mostly been related to lack of consumer awareness 
of the services and of pharmacists’ skills to deliver them. Lack of demand and poor perceptions 
of pharmacists have been consistently reported (Krska and Morecroft, 2010, Eades et al., 2011). 
When consumers (and health care providers) are not aware of the breadth of the pharmacist’s 
role and expertise in delivery of services other than dispensing medications, they will not seek 
those services in pharmacy and will remain unaware. As a result, despite significant uptake by 
pharmacists, the services are still underutilized. Addressing these barriers is therefore likely to 
increase utilization of the services. 
The presence of these barriers is exacerbated by the perception of pharmacy as a retail 
business (Babar and Scahill, 2014). In order for pharmacy to be regarded as a key player in the 
provision of public health, patients must come to view the pharmacist as someone who can assist 
them to remain healthy, rather than purely as someone to be consulted in the context of illness. 
Pharmacists have a key role to play in promoting themselves and their profession directly to the 
patients with whom they come in contact, and this will in turn help to promote credibility with 
governments which is necessary to stimulate regulatory change.   
 66 
There are some signs of progress, albeit relatively small, in some Southeast Asian 
countries. In Malaysia, although pharmacies still lack support for a monopoly over dispensing, 
the Community Pharmacy Benchmarking Guideline has facilitated the initiation of health 
promotion services in pharmacy, in particular for smoking cessation and weight management 
(Ministry of Health Malaysia Pharmaceutical Services Division, 2011). In 2003 the Thai Pharmacy 
Council introduced an accreditation program for service quality, and since 2005 has trained 
pharmacy to provide smoking cessation services in collaboration with the Thai Pharmacy 
Network for Tobacco Control (Thananithisak et al., 2008, Nimpitakpong et al., 2010). Vietnam has 
implemented an accreditation system to improve practice in pharmacy (Vu et al., 2012). 
Indonesia is moving forward to a policy of re-certification and licensure that is aimed at improving 
pharmacists’ presence and capacity to work in pharmacy (Ikatan Apoteker Indonesia, 2014b). 
These initiatives highlight the growing opportunity for community pharmacy to play a more 
prominent role in public health in the region.  
Almost half of studies reviewed in this paper were published more than five years ago. 
Although they do provide the framework for understanding overarching public health practice, 
they also highlight the dearth of research on current practice. As public health achieves greater 
focus in pharmacy services, research is increasingly critical as a vehicle for understanding the 
process of change. Studies in the delivery of pharmacy public health should continue to 
investigate this process and its outcomes.  
This review thus has important implications for future research and policy in community 
pharmacy practice. To date there is insufficient high-level evidence to support a role for 
pharmacy in public health practice in Southeast Asia. Future research is needed to improve the 
quality of evidence, which will in turn provide a basis for rational health policy change to foster 
the significant potential contributions of community pharmacy to public health initiatives in the 
region. 
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Despite the significant contribution of this review, the decision to include only articles 
published in English may have limited the findings as some potentially relevant non-English 
language articles may not have been identified. Furthermore, only original published research 
articles were evaluated, and additional information available from the grey literature may need 
to be considered in order to provide a broader perspective. 
CONCLUSION 
Over the past fourteen years, attempts have been made to expand the scope of 
community pharmacy practice in Southeast Asia through piloting the introduction of new services 
in both pharmacy and public health practice. However, the pace of such expansion has been 
relatively slow and is not supported by a strong evidence base for pharmacist involvement in 
public health. Several notable barriers internally and externally to the pharmacy environment 
such as lack of knowledge, lack of confidence, poor recognition from the general public and lack 
of supportive policies have constrained progress. There remains considerable scope for 
community pharmacy to extend their practice into public health care initiatives, but this will 
require clear and planned efforts to address the barriers identified in this review. These efforts 
should focus on a coordinated approach to change in both public perceptions and the regulatory 
environment in order to realise the significant potential of community pharmacy as a legitimate 
resource for the delivery of public health services. 
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2.3. The Indonesian Community Pharmacy Situation 
Community pharmacy in Indonesia is mostly situated in the private sector and ranges 
from small independent pharmacies to networks of large chain pharmacies. In 2017, Indonesia 
had 25,339 community pharmacies of which around 60% were located in Java (Ministry of Health 
Indonesia, 2017b). Ownership of pharmacy is not restricted to pharmacists however non-
pharmacist owners must employ pharmacists prior to opening a pharmacy.  
As in many other countries, pharmacists hold the main authority and sole responsibility 
for the operation of community pharmacy such that the pharmacy requires the presence of 
pharmacists at all times. However, in practice, pharmacists’ absence is common. The majority of 
operating pharmacies only utilize pharmacists on a token basis. Studies have indicated only 14-
23% pharmacists work on a full-time basis with pharmacy services being delivered particularly by 
pharmacy assistants (Purwanti et al., 2004, Kartinah et al., 2015, Dominica et al., 2016). This has 
been an ongoing issue and a concern of the Indonesian Pharmacists Association (IAI) and other 
pharmacy stakeholders (Figure 4). Initiatives to attract pharmacists to practice have been 
introduced including by government and advocacy groups, yet there has been no evaluation to 
determine whether these efforts have been effective in implementation. Further details about 
contemporary situation, multiple policy initiatives in the current practice and role of stakeholders 
in the Indonesian community pharmacy sector are presented in Chapter 6.1, Chapter 6.2 and 
Chapter 6.3, respectively. 
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Figure 4. Stakeholders in Indonesian Community Pharmacy Sector 
 
Community pharmacies derive their income from general pharmacy business and sales 
such as dispensing prescribed medicines, providing pharmacy and over-the counter medicines, 
and other healthcare and retail products (Hermansyah et al., 2012, Tri Murti Andayani and Satibi 
Satibi, 2016). However, under JKN (Universal Healthcare Coverage program) which was launched 
in 2014, community pharmacies have the opportunity to be involved in two schemes: 1) as a 
pharmacy affiliated with the primary care network (Apotek Jejaring) and 2) as a pharmacy 
contracted by BPJS Health (Apotek Rujuk Balik). These two schemes provide different scopes of 
service under different contractors, yet an individual community pharmacy can apply to become 
either or both (see Figure 9).  
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Limited interaction between pharmacists and patients has been reported in several 
studies (Hermansyah et al., 2011, Hermansyah et al., 2012, Wiryanto et al., 2014). Some authors 
argue the reason may be that pharmacists are often absent making it impossible to build rapport 
with patients. However, the presence of pharmacists in a pharmacy does not always translate 
into improved care since they are occupied by other activities associated with running the 
business (Hermansyah et al., 2012) such as management of inventory, accountancy, marketing 
and sales. This has been worsened by public perception about community pharmacy and 
pharmacists. Community pharmacists have been portrayed as drug sellers by the general public 
with the pharmacy perceived as a grocery store which sells pharmaceuticals and health products 
(Hermansyah et al., 2012). Patients often do not recognize the person who served them. In fact, 
they do not really care whether the person who dispenses drugs may have lower qualifications 
than a pharmacist or no formal training. Interestingly, it has been documented that patients feel 
confident about seeking medical advice from pharmacy and they are satisfied with the services 
given by pharmacy staff regardless of the qualifications of the personnel (Setiawan et al., 2010, 
Wathoni and Rahayu, 2014).  
In recent years, community pharmacy development in Indonesia has been largely driven 
by the enactment of regulation in the community pharmacy sector. Among these regulations, the 
Pharmacy Practice Act 2009 and the Community Pharmacy Decree 2017 have been pivotal in 
supporting community pharmacy practice in Indonesia. 
The first and currently the highest order of legislation governing pharmacy practice in 
Indonesia is the Pharmacy Practice Act 2009 (Government of Indonesia, 2009). The Act, which 
can be considered the main policy framework, defines the scope of pharmacy practice regardless 
of the setting, with the pharmacist appointed as the sole authorised professional for pharmacy 
practice. On the other hand, the Community Pharmacy Decree 2017 is specific legislation 
regulating community pharmacy operation and services including ownership (article 3), “location 
rules” (article 5), workforce (article 11) and provision of a range of pharmacy services (e.g. drug 
education and counselling, home care services, and drug surveillance and monitoring) (article 16) 
(Ministry of Health Indonesia, 2017a). Specific to the latter point, while the decree requires 
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community pharmacy to provide these services, no remuneration is allocated for pharmacists 
and pharmacies. 
There is no specific and formal funding provided by the government or other sponsors for 
R&D in the community pharmacy sector. Research in community pharmacy has been 
predominantly conducted by academics and researchers from universities funded under 
competitive grants allocated for higher education research. Although there has been increasing 
interest in pharmacy practice research, the number of publications is still very low reflecting 
limited evidence in community pharmacy (Tri Murti Andayani and Satibi Satibi, 2016).  
There are some examples of research activities designed to improve the way community 
pharmacy practices. However, there is a paucity of information reporting the impact of this 
research on practice change and policy-making in the Indonesian community pharmacy sector. 
For example, a 2015 study on smoking cessation training revealed that the majority of 
pharmacists were able to perform smoking cessation counselling (Kristina et al., 2015). However, 
there was no further information about whether such initiatives have been adopted into 
everyday practice in pharmacy. Similarly, several other studies highlighted the positive impact of 
pharmacists’ counselling for patients with chronic diseases (e.g. hypertension, asthma and 
diabetes) such as increased patient compliance and improvement in the clinical outcomes (Wati 
et al., 2015, Widayati et al., 2018, Wibowo et al., 2016). Although the research findings suggested 
a potential for pharmacists’ involvement in primary care, the studies were mainly conducted in 
a single area and involved small sample sizes (e.g. up to ten pharmacies) which limits their 
generalizability. More importantly, the quality of evidence and strength of the recommendations 
generated by these studies has been limited as they were designed as observational studies, not 
RCTs. Ultimately, there have been no reports or publications confirming that such pharmacy 
services have been widely and sustainably implemented in community pharmacies. In essence, 
it is not yet the norm in Indonesia for research to inform public policy making. 
Apart from regulation and research, the attempt to change practice was also initiated 
through improvements in the education system. Subjects related to delivery of cognitive services 
have been incorporated in the curriculum of pharmacy education. In addition, since 2017 
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pharmacy graduates must undertake a national competency test prior obtaining a license to 
practice (Ikatan Apoteker Indonesia, 2016). The test has been standardized across the nation to 
ensure that graduates have met the minimum standard to become a pharmacist. The IAI has also 
encouraged pharmacists to undertake Continuing Professional Development (CPD) as a 
requirement to renew their license (Ikatan Apoteker Indonesia, 2014d). However, there are a 
number of problems hampering pharmacy education in Indonesia such as a lack of practical 
experience, the focus of education has been on pharmaceutical science rather than pharmacy 
practice and the lack of proper facilities to educate students (Kristina et al., 2014, Herman and 
Handayani, 2015, Ristiono et al., 2015). One of the contemporary issues that has drawn attention 
from pharmacy stakeholders is the explosion of the number of schools of pharmacy within the 
past ten years and particularly after the introduction of JKN. Unfortunately, the majority of these 
new pharmacy schools were poorly accredited which in turn may affect the quality of the 
graduates (Langley and Aheer, 2010, BAN-PT, 2017). Further details about multiple approaches 
to improve community pharmacy practice in Indonesia are presented in Chapter 6.2. 
2.4. Chapter Conclusion 
In summary, there are two contrasting situations which structure this thesis. One context 
is Australia which is among the frontrunners in the development of community pharmacy 
practice. The Australian situation reflects a mature context where community pharmacy practice 
has moved towards role expansion of pharmacy marked by the nationwide implementation of 
remunerated CPS and other pharmacy services as well as an established culture of professional 
pharmacist practice. The experience with practice change, however, has been challenging. 
Despite the high adoption rate of CPS, there is a lack of evidence confirming their effectiveness 
on the health of communities. The over-reliance on the dispensing funding model has continued 
although there have been ongoing threats to pharmacy profitability due to multiple factors 
affecting community pharmacy operation. The provision of CPS as an alternative funding stream 
for pharmacies is not reliable and sustainable.  
In contrast, Indonesia has a pharmacy practice landscape undergoing major changes. If 
we observe the regional situation, Indonesia is located in Southeast Asia in which community 
pharmacy practice is in a state of infancy. The findings in chapter 2.2 showed that despite a body 
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of research over the past fourteen years designed to expand pharmacy scope of practice in the 
region by piloting new services in community pharmacies, there is limited evidence this has led 
to widespread implementation in practice.  This highlights the fact that most of the research was 
proof of concept. In fact, some of the countries within the region have encountered serious 
problems related to delivery of pharmacy services such as the absence of separation between 
dispensing and prescribing (Tiong et al., 2016, Saleem and Hassali, 2016), lack of guidelines and 
indicators with respect to quality use of medicines (Nguyen et al., 2012) and shortage of 
pharmacists’ workforce in almost all countries, leading to the provision of pharmacy services 
unsupervised by pharmacists (Kanchanachitra et al., 2011, Bates et al., 2018). This situation, to 
some extent, may have an influence on practice change in Indonesia. 
Despite lagging behind Australia in its development of community pharmacy service, 
Indonesia has a strong structure of regulations and supportive pharmacy stakeholders, two 
essential factors for facilitating practice change. In fact, there are some experiences and values 
with respect to pharmacy practice that are common to both countries. This is particularly related 
to the involvement of community pharmacy in primary care as a provider of medicines. In 
addition, more recently there have been moves to develop community pharmacies’ role in 
Indonesia such as contracting pharmacies under the JKN scheme and making CPD mandatory for 
pharmacists. Despite these initiatives, progress in advancing practice has been slow. Whether 
pharmacy is up to the challenge remains to be seen. 
Therefore, the investigation of practice change in contemporary pharmacy situation may 
offer benefits for the two countries. It offers insight for Australia on how to maximise the 
opportunities that exist to improve pharmacy practice and how this might be achieved within the 
complex and dynamic situation in community pharmacy. On the other hand, Indonesia can draw 
lessons from the Australian experience to assist further development, scale up of current 
pharmacy practice and more importantly to reinvent ways to overcome the perpetual barriers in 
practice.  
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CHAPTER 3. RATIONALE, AIMS AND SIGNIFICANCE 
This chapter addresses the rationale for conducting this research, the aims and objectives 
of the studies and their significance. 
3.1. Rationale of the research 
As outlined in chapter 1 and 2, the changing nature of community pharmacy has been 
investigated and described in a growing body of literature. The focus of changes has been 
directed towards pharmacists’ involvement beyond a dispensing service to a broader and more 
strategic role in primary care and community health particularly through provision of professional 
pharmacy services and health related services. The provision of such services in the current 
community pharmacy sector has been limited and generally free for patients. Provision of 
expanded pharmacy services however has not been considered to be sustainable in daily practice 
due to barriers which are both internal and external to the pharmacy profession. 
Many of the studies in pharmacy practice change have focused on one particular level of 
practice either at individual pharmacist, community pharmacy setting or community pharmacy 
position within the healthcare system. An examination of each level individually does not provide 
a holistic view of the potential barriers and facilitators to change and their interaction. The factors 
affecting practice change cannot be confined to a particular level as they occur and influence all 
levels simultaneously. In addition, the contextual situations (from local, regional to country 
context) in which community pharmacy operates vary between level and change over time. This 
plays an influential role in shaping the process of change which has been underrepresented in 
the current literature.  
The introduction of the Community Pharmacy Agreements (CPAs) since 1990 in Australia 
has provided a platform for practice change in community pharmacy. Within the agreements, 
there has been a quantum of money invested to support practice change including payment for 
dispensing PBS medicines and remuneration for several professional pharmacy services (Sclavos, 
2010). Despite the fundamental contributions of the consecutive CPAs to pharmacy practice, 
there is a paucity of research investigating practice change in contemporary Australian 
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community pharmacies and the extent to which remunerated professional pharmacy services 
have been effectively adopted in daily practice. This has raised a question whether community 
pharmacies have really changed their practice under the era of CPAs (Gilbert, 2009). 
At the same time, the situation of the healthcare and pharmacy system in Indonesia has 
also changed. The introduction of Universal Healthcare Coverage (JKN) in 2014 has changed 
Indonesian healthcare (Mboi, 2015). The implementation of JKN has provided opportunities for 
community pharmacy to be integrated with primary healthcare networks. However, there is a 
dearth of information reporting the roles of community pharmacy under the JKN era leading to 
a question as to whether the new system has been beneficial in supporting practice change.  
Practice change is a complex and dynamic process. The lack of information about practice 
change in current community pharmacy highlights the need for more in-depth research on this 
topic and provides the rationale for this PhD thesis. As practice change in community pharmacy 
is a global phenomenon, there is a need to investigate these changes in the context of both 
developed and developing countries. In fact, there is a strong argument that pursuing such 
research might be more critical in the context of developing countries where there is a paucity 
of research concerning practice in community pharmacy.  
3.2. Aims and significance 
The overall aim of this thesis is to investigate changes in the contemporary practice in 
both Australian and Indonesian community pharmacy. This includes investigation of the factors 
influencing changes, policy implementation and the role of stakeholders in promoting changes in 
each country, with the goal of providing a framework for future policy development and 
implementation particularly for Indonesian pharmacy sector. 
The specific objectives were to: 
1. Investigate the perceptions, awareness and experiences of stakeholders regarding changes 
in contemporary practice of community pharmacy in Australia and Indonesia; 
2. Explore the role of Research and Development (R&D) program in community pharmacy and 
its impact on practice change in community pharmacy in Australia; 
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3. Evaluate the role of key policy initiatives and stakeholders in the community pharmacy sector 
in promoting practice change in Australia and Indonesia and; 
4. Develop recommendations to advance community pharmacy practice in Australia and 
Indonesia. 
The significance of this study is twofold. First, this study is intended to provide a better 
understanding of the process of change including the related factors – whether they constrain or 
facilitate changes – and the role of pharmacy stakeholders as agents of change in contemporary 
practice. Second, the information generated in this study will be critical in assisting future 
planning and development of community pharmacy practice particularly in Indonesia. The 
intended audience for this thesis is academics, researchers, practitioners and policy makers who 
are interested in the topic of pharmacy practice, social and administrative pharmacy and those 
who are concerned with the evolution and role development of pharmacists as a profession and 
community pharmacy. This thesis was created to explore the process of change particularly in 
Australia and Indonesia based on the contemporary situation in community pharmacy and more 
importantly this thesis presents suggestions about how to navigate changes in community 
pharmacy especially in Indonesian setting. 
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CHAPTER 4. RESEARCH METHODS 
This chapter discusses the overall research methods utilized in this study. As presented in 
Figure 5, two main qualitative approaches were used to address the aims of the thesis. This 
chapter is organized into two sections. The first section describes an overview of qualitative 
methods used in this study (section 4.1). The second section highlights the theoretical 
frameworks which underpin the analysis of findings in this study (section 4.2). 
Literature review
Changes and gap analysis of the contemporary pharmacy 
practice
Qualitative research
INDONESIAAUSTRALIA
Community pharmacy and emerging public health initiatives in 
developing Southeast Asian countries: A systematic review
In-depth semi-
structured interviews
In-depth semi-structured 
interviews
Nominal group discussion
 
Figure 5. Research Design of the Thesis 
4.1. Qualitative methods 
This research employed two types of qualitative research methods; semi-structured 
interviews and nominal group discussion. The Australian studies used a series of in-depth semi-
structured interviews to explore practice change in Australian community pharmacy. The 
Indonesian studies used two qualitative research methods to investigate changes in community 
pharmacy practice. First, a number of semi-structured interviews were conducted to obtain 
information about practice change in Indonesian community pharmacy. Second, a nominal group 
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discussion was used to select and prioritise several recommendations which were developed 
from the findings of the interviews. A summary of the research design is presented in Table 3.  
Table 3. Summary of research design 
Description of 
methods 
Qualitative study 
AUSTRALIA 
Semi-structured interviews 
INDONESIA 
Semi-structured interviews 
INDONESIA 
Nominal group discussion 
Literature 
review 
 Reviewing the contemporary situation, drivers, barriers and facilitators for practice 
change in community pharmacy from a global perspective 
 Reviewing the contemporary situation and practice of pharmacy focusing on the context 
in Australia and Indonesia 
 Developing systematic review of community pharmacy role expansion in regional 
context: Chapter 2.2 – Community pharmacy and emerging public health initiatives in 
developing Southeast Asian countries (see appendix 6) 
Objectives Preliminary findings to investigate state of change in the 
contemporary community pharmacy practice 
Proposing 
recommendations to 
advance community 
pharmacy practice 
Preparation of 
guide 
The interview guide was developed from reading the 
literature, understanding the contemporary situation in the 
community pharmacy sector and discussion among 
researchers (see appendix 3 and appendix 4) 
The guide was developed 
from findings of the 
interviews 
Ethical 
consideration 
The studies were approved by the Human Research Ethics Committee of the University of 
Sydney (2014/820). Participants were required to provide consent prior to data collection 
(see appendix 1 and appendix 2) 
Sampling 
Sampling design Purposive sampling with maximum variation of participants 
and expanded using snowball method; 
Participants representing key stakeholders in community 
pharmacy and healthcare system. 
Purposive sampling; 
Participants representing 
community pharmacy 
stakeholders. 
Participants’ 
background 
 Practicing pharmacists 
and managers; 
 Other healthcare 
professionals; 
 Academics and 
researchers; 
 Policy makers and 
administrators; 
 Consumer 
representatives; 
 Insurance providers. 
 Practicing pharmacists; 
 Pharmacy managers; 
 Other healthcare 
professionals; 
 Academics and 
researchers; 
 Policy makers and 
administrators; 
 Consumer 
representatives; 
 Insurance providers. 
 Practicing 
pharmacists; 
 Peak pharmacy 
organisations 
representatives; 
 Academics and 
researchers; 
 Policy makers and 
administrators. 
 
Data Collection 
Time period 2015 2016 2017 
Methods of 
delivery 
 Face to face; 
 Over the phone; 
 Skype video call. 
 Face to face; 
 Over the phone. 
Face to face 
Number of 
participants 
27 individuals 29 individuals 34 individuals 
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Description of 
methods 
Qualitative study 
AUSTRALIA 
Semi-structured interviews 
INDONESIA 
Semi-structured interviews 
INDONESIA 
Nominal group discussion 
Recording and 
transcription 
Audio recorded and subsequently transcribed verbatim. Interviews conducted in Indonesian 
were back-translated to English and reviewed by a proof-reader for the quality of 
translation (see appendix 5 for translation certificate) 
 
Data Analysis 
Method for 
analysis 
Inductive approach involving thematic analysis 
Software for 
management of 
data 
NVivo 10 
Results (and 
theoretical 
frameworks 
used to explain 
the results 
Chapter 5.1 – Investigating 
influences on current practice 
at micro, meso and macro 
levels (The planes of analysis 
theory) 
See appendix 7 
Chapter 6.1 – Investigating 
the impact of the universal 
healthcare coverage 
program on community 
pharmacy practice (The 
planes of analysis theory) 
See appendix 9 
Chapter 6.3 – Prioritising 
recommendations to 
advance community 
pharmacy practice 
(Culture-structure-agency 
approach) 
See appendix 11 
Chapter 5.2 – The operation 
of the Research and 
Development (R&D) program 
and its significance for 
practice change in community 
pharmacy (The PARIHS 
framework) 
See appendix 8 
Chapter 6.2 – Multiple policy 
approaches in improving 
community pharmacy 
practice: the case in 
Indonesia (The planes of 
analysis theory) 
See appendix 10 
 
4.1.1. Rationale for the use of qualitative methods 
In general, there are two research paradigms used by researchers to answer a question(s). 
A quantitative method seeks to answer a research question by collecting data related to the size, 
commonness and frequency of a problem. Qualitative methods seek to explore a phenomenon 
in-depth by focusing on “why” and “how” a problem can happen (Pope and Mays, 2006). For 
example, if a researcher wants to investigate barriers experienced by pharmacists when 
delivering professional pharmacy services, using the quantitative approach, the researcher can 
discover the type of barriers and quantify how commonly the barriers occur in practice. On the 
other hand, using a qualitative approach, the research not only explores “what are the barriers?” 
but also addresses “why and how do the barriers occur?” which provides more opportunities to 
delve into the nature of the barriers from the perspective of participants. 
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Although quantitative methods have been widely used in pharmacy practice research, 
there has been an increasing trend towards the use of qualitative methods within recent decades 
(Varela Dupotey and Ramalho de Oliveira, 2009). This has been fuelled by the desire of 
researchers to explore social interactions within community pharmacy settings and gain an 
understanding of the human experience and behaviour of the actors including pharmacists, 
pharmacy staff and patients as well as the underlying factors influencing their behaviour 
(Almarsdóttir et al., 2014).  
The strength of qualitative studies lies in their ability to elucidate an in-depth 
understanding of a problem. By using participants’ perspectives as a lens to explore a 
phenomenon it generates greater richness of data in real life settings as experienced by 
participants especially when the participants are experts or have experience of a particular topic.  
It can also be a very efficient yet effective method to address the objectives of a study. In contrast 
to quantitative studies, the qualitative approach typically involves small numbers of participants. 
Qualitative methods are not designed to represent the voices of a population as generalisability 
is not the primary objective. However, qualitative methods can be used to obtain the full 
spectrum of experiences across a population. A qualitative study can apply maximum variation 
sampling to include a wide range of respondents – sometimes the extreme opposites such as the 
oldest vs the youngest respondents, the most experienced vs least, or the richest vs the poorest 
– rather than seeking the views of average respondents (Palinkas et al., 2015). In addition, the 
exhaustion of a population’s perspectives can be achieved through the concept of “data 
saturation” whereby the researcher continues data collection until no new information is being 
generated from participants (Fusch and Ness, 2015). 
However, there are a number of methodological limitations (Ercikan and Roth, 2016). 
First, the usability of qualitative methods relies on the sampling procedure. As the nature of a 
qualitative study is rooted in a phenomenological paradigm, the opinions collected from the 
participants construct the reality and define the situation of those studied. This means selection 
of participants is crucial as it determines the overall conclusions generated by the study. Second, 
as qualitative research is more concerned with understanding social phenomenon from the 
participants’ perspective, the process of collecting information (e.g. interviews and focus group 
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discussion) relies heavily on the ability of interviewer or group facilitator to draw out details from 
the participants. Third and relatedly, qualitative research requires researchers to become 
immersed in the participants’ situation which may contribute to bias as a consequence of the 
researchers’ interest. Fourth and accordingly, the process of analysing data and drawing 
conclusions from the findings requires researchers to be neutral and disengage their interest in 
order to avoid bias while also interpreting participants’ perceptions. Researcher bias may be 
minimized by planning and pretesting the phases of the studies and analysing the findings 
together with other research members. 
Practice change is complex and dynamic and cannot be quantified based only on what has 
occurred. Uncovering explanations and causes of the current state of changes is better explored 
using qualitative methods. The presence of multi-level decision making associated with pharmacy 
stakeholders’ behaviour and experiences of practice change is another reason for using 
qualitative methods as multiple meanings about practice change might be anticipated from the 
participants’ perspectives.  
There are several ways to collect data using qualitative approaches including 
observations, interviews and focus group discussions. The next section will only focus on in-depth 
interviews and focus group discussions as these methods were used in this research.  
4.1.2. Interviews 
Interviews are the most commonly used qualitative technique in pharmacy practice 
research. Through interviews, researchers can investigate subjective understandings, feelings, 
ideas, and experiences of participants relevant to the areas of research. In principle, interviews 
involve a conversation between researchers with one or more interviewees in a manner which is 
designed to obtain as much information as possible from the interviewee(s) (Smith, 2010a).  
Interviews are commonly classified into three types: structured, unstructured and semi-
structured interviews. The major difference among the three types is the technique for delivery 
of interview questions and whether the researcher has control over the direction of conversation. 
A structured interview is characterized by researchers asking questions based on interview guides 
with no deviation, often with categories of answers, which allows the researcher to steer the 
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direction of the conversation (Smith, 2010a). In contrast, unstructured interviews avoid full 
control of researchers in a certain direction which allows participants to talk freely, in-depth and 
to determine the flow of the interview. The most commonly used interview form which was also 
used in this study is the semi-structured interview. Semi-structured interviews allow researchers 
to ask questions according the interview guide which may comprise both, structured and open 
questions, relatively few but specific. However, the order and the weight of the questions depend 
on the responses of the participants with researchers able to probe participants’ answers to get 
a better understanding of the issue. In this way, researchers can more deeply explore the 
perspective of the participants without losing control of the interview. 
A limitation of the interview is that the respondent may not give a true account of actual 
behaviours and events. If researchers wish to investigate actual behaviour of the participants, 
other approaches such as observation are more suitable. 
Development of an interview guide 
The interview guide is a list of questions which structures the conversation within the 
interview process and is crucial in the semi-structured interview. A combination of open-ended 
questions to stimulate rich responses from participants and closed questions to emphasize 
specific issues or perspectives is recommended. The questions in the guide can be developed 
from a variety of sources. This includes literature reviews, expert knowledge and theories.  
Sampling  
Selecting sampling units from the population is crucial for any study. In general, there are 
two classifications of sampling design: Probability and non-probability sampling. Probability 
sampling highlights that each sample has an equal chance of being selected. Probability sampling 
involves random selection of samples to minimise researchers’ bias in selecting samples or 
observation units. Probability sampling allows researchers to extrapolate the findings based on 
the sample to the population (Aparasu, 2011).  
In qualitative research non-probability sampling is the norm. Therefore, researchers need 
to put much effort into understanding the characteristics of the population prior to sampling. 
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There are four common types of non-probability sampling: purposive sampling, convenience 
sampling, quota sampling and snowball sampling (Suri, 2011). This section will only focus on 
purposive sampling and snowball sampling which were used in this study.  
Purposive sampling is a nonprobability sampling strategy which requires researchers to 
have a strong understanding of the target population and develop selection criteria to determine 
the characteristics of the sample. Subjectivity plays an important role in purposive sampling as 
the decision to select a sample lies with the researchers. Another form of purposive sampling is 
maximum variation sampling which is characterized by researchers selecting a diverse 
representation of participants. The logic of using maximum variation sampling is to include a 
broad range of subjects from which this study can obtain rich information across variations. 
Maximum variation sampling is not aimed to select “average participants” but rather recruit a 
number of different groups of participants representing a high proportion of the population 
(Kaae and Traulsen, 2015).  
However, it may be the case that one participant has multiple roles. For example, a 
government officer working in a regulatory body in Indonesia such as the Ministry of Health can 
practice as a community pharmacist, own a community pharmacy, teach in college as an 
academic and be the official of the Indonesian Pharmacists Association which is the peak 
pharmacy organization in Indonesia. Similarly, Australian participants may be pharmacy owners, 
practicing pharmacists and an office bearer in a peak pharmacy organization such as the 
Pharmacy Guild of Australia. While it is not always possible or indeed necessary to ask 
participants to wear a particular hat during the interview, it is important to distinguish the 
perspective adopted when responding to questions during the interview.  
Snowball sampling is an effective method used to identify a sufficient sample of 
participants who are difficult to recruit for a study (Noy, 2008). The principle is that the sampling 
starts with a small number of initial participants who are relevant to the research topic and the 
researcher asks these participants to identify other potential candidates to be recruited for the 
study. In this way, researchers can recruit more respondents whose perspectives are critical for 
the study, and access participants beyond their own networks. 
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Another issue is the sample size. As mentioned before, “saturation” occurs when no new 
themes, information or explanations emerge from the interviews (Mason, 2010). Theoretically, 
the sample size can be predicted from other previous studies. For instance, Creswell proposed 
that interviews using a grounded theory approach would require 20-30 participants (Creswell, 
2013), while Morse suggested 30-50 participants to meet saturation (Morse, 1995). However, 
this might be different in practice. Ideally speaking, the research team must discuss when it is the 
right time to conclude recruitment.  
Conducting interviews 
Conducting an interview requires considerable skills on the part of the interviewer to be 
interactive and sensitive to the verbal and non-verbal expression of the interviewee, allowing 
participants to express their ideas while at the same time managing the conversation fit to the 
agenda of the interview. It is vital for an interviewer to respond to changing circumstances during 
the interview, control flow and pace of the interview and be flexible within the discussion. This 
is particularly important as there is potential for misunderstanding of terminology, questions 
posed and participants’ responses (Britten, 2006).  
Both interviewer and interviewee should engage in a mutual discussion and therefore first 
impressions are crucial to start this engagement process. The interviewer can start with open-
ended, simple yet encouraging questions at the beginning of the interview. The process continues 
with other types of questions (e.g. closed questions) and combined with probing (or prompting) 
to elicit more information from the interviewees. It is also likely that the interviewer is asked 
questions by the interviewee during this process. In these circumstances, researchers should take 
care not impose their own opinions during the interview. As an interview is an active mutual 
process, the interviewer may respond to such questions with a refusal to answer, tactfully answer 
the questions or provide the answer after the interview is concluded (Britten, 2006). Each option 
has its consequence which must be acknowledged by both parties. 
 Field and Morse (1996) identified some common pitfalls during the interview process such 
as “outside interruptions, competing distractions, stage fright, awkward questions, jumping from 
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one subject to another and temptation to counsel interviewees”. A researcher must be aware of 
these pitfalls and develop ways to manage when encountering such situations. 
 
Once a candidate has consented to participate in the study, a preferred time, place and 
technique for the interview should be arranged to ensure that the interview is convenient and 
comfortable. Three interview formats may be offered to participants: face to face, telephone or 
video conference, with face to face interview the most preferred format. Each format has 
advantages and disadvantages (Rosenthal, 2016). A face to face interview offers the benefits of 
building rapport and direct contact with the interviewee. It allows researchers to conduct the 
interview in a private environment with minimum distractions. In addition, the interview can also 
take place in a natural setting allowing researchers to understand contextual information 
relevant to the participant. However, distance, travel time and costs as well as limited coverage 
of participants due to geographical area are drawbacks of face to face interviews. To overcome 
these shortcomings, researchers can use telephone interviews and video conferencing. However, 
these are not without drawbacks. The primary issue with these formats is they limit the verbal 
and non-verbal interaction between interviewer and interviewee. Other issues are related to the 
use and setting of the equipment (e.g. telephone, computer availability and internet 
connections). For example, video conferencing was not an option in the Indonesian studies given 
the lack of internet coverage and poor quality of internet connections in this country.  
There are various ways for recording interviews. This includes taking notes (at the time 
and/or after the interview), audio recording and video recording. The recording files are stored 
and subsequently transcribed verbatim.  
Analysing interview data 
The process of analysing interviews generally involves three steps: data management, 
description and explanation (Liz et al., 2014). This process is flexible and non-linear, such that the 
researcher can go forwards or backwards between data and emerging interpretations. The 
analysis is started whilst the data are being collected. This means researchers do not wait until 
all interviews have been completed but commence analysis once they have completed each 
 86 
interview. The use of transcripts and field notes are important to provide descriptions, but 
researchers still need to interpret them as these sources do not provide explanations. Constant 
comparison between transcripts, audio-recording and researchers’ field notes is conducted to 
explore and interpret data. Non-verbal expressions such as laughter, crying, lengthy pauses can 
affect the interpretation of the data (Lapadat and Lindsay, 1999).  
Interpretation of interview data can be conducted deductively – by incorporating a 
framework or theory at the beginning or part way through the analysis – or inductively, where 
the researcher gradually derives the interpretation from the data (Kaae and Traulsen, 2015). 
Deductive analysis is less common in analysing interviews but it can be used as a way of 
approaching data for example using a framework approach. Therefore, the focus of this section 
is to explore the inductive approach used in this study. 
A qualitative study is often conducted when there is a lack of existing theory to adequately 
explain a phenomenon of research interest. Therefore, analysis of a qualitative study generally 
involves an inductive process. The inductive process requires researchers to build concepts, 
hypothesis or theories from the findings of the study rather than deductively testing theories 
with the data (Ritchie et al., 2014). The process typically starts with researchers collecting data, 
building data toward concept, theory or hypothesis and continues to derive the structure of 
analysis by forming, combining and ordering data into themes or categories about a particular 
aspect of practice (Figure 6). Constant comparison plays a vital role in exploring across existing 
data. However, the inductive process does not mean researchers have a blank mind or absence 
of any thoughts regarding the phenomenon under study. Researchers still need to have a concept 
in mind to derive the structure of analysis (Pope et al., 2006). 
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Figure 6. Typical Process of Analysing Interview Data 
While there is variety of analytical approaches in the inductive process, this study 
described three general approaches: grounded theory, thematic analysis and discourse analysis 
(Liz et al., 2014). Each has a different style which may influence the interpretation of the findings.  
Grounded theory, first developed by Glaser and Strauss (1967), relies on the analysis of 
the text. This approach focuses on developing theory which emerges or is “grounded” in the data. 
In practice, the process of analysing interviews using grounded theory is usually a mixture of 
induction and some deduction involving the shifting between data and the theory. The analysis 
begins with open coding, that is examining data to create as many relevant codes as possible. The 
coding is then developed into categories. Within this process, researchers constantly and 
critically examine categories, their importance and how the data would be generated into a 
theory. Axial coding is used to identify the relationship between codes and selective coding to 
develop the existing codes into an analytical category. The categories are then organized to 
create the central elements of the analysis. Grounded theory is a useful method to integrate 
relevant theories about the data while at the same time testing the emerging ideas of the 
Trancription of data
•Familiarisation to the issues
Coding the data
•Focusing on specific and unique expression
•Constant comparison across data sources
Developing primary coding framework
Developing more detailed coding frames
•Refining data and eliminating duplications
Ensuring validity, reliability and trustworthiness
•Involving consensus among research team
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interviews. However, the flexibility of the analysis often requires a process of re-analysing the 
data which can take a long time (Starks and Brown Trinidad, 2007). 
Thematic analysis is the most common analytic technique in qualitative studies perhaps 
because it is much simpler than other forms of analysis. The process of analysing interview data 
using thematic analysis can be very similar to grounded theory with the researchers grouping and 
building the data into codes, developing codes into specific themes and identifying the 
relationship between themes to structure the central themes of the interview (Braun and Clarke, 
2006). Unlike grounded theory, thematic analysis does not involve the process of testing the 
emerging theories from data. However, it is possible to anticipate a particular central theme as 
sometimes the connection between themes is obvious.  
As a method of analysing interview data, discourse analysis emphasizes the role of 
language to convey the meaning and experiences and authentic intention of participants (Starks 
and Brown Trinidad, 2007). Discourse analysis examines how language and words can shape and 
reflect social reality. The general method for analysing data using discourse analysis is fairly 
similar to other approaches, however, researchers must understand the use of language in a 
given situation and remain cognizant that the interviewee’s selection of words may have 
different meanings. Therefore, the coding and analysis should include for example the 
comparison of technical language or professional jargon. 
Software for analysis 
The use of software has become common in facilitating the management of interview 
data. Several software programs are available in the market such as NVivo, Atlas Ti, 
HyperResearch and CAQDAS (Computer Assisted Qualitative Data Analysis Software) (Pope et al., 
2006). Computer-assisted analysis software can help researchers in analysing especially large 
datasets which include audio, video and photographs that make preparation of data as a written 
text unnecessary. Computer software also offers several analytical functions such as gather, sort 
and retrieval functions, indexing terms and codes, identifying and combining common codes 
which may reduce laborious analysis of data (Pope et al., 2006). However, computer software is 
not designed to do the analysis. These software programs do not provide researchers with an 
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analytical framework or particular methodologies. They only help researchers with analytical 
processes, primarily organizing, accessing and displaying data. It is the researchers themselves 
who analyse and interpret the data.  
4.1.3. Nominal Group Technique 
Another form of qualitative method which is commonly used is the Focus Group 
Discussion (FGD). FGD provides opportunities for researchers to obtain opinions from a number 
of participants in a single forum. Within the FGD, there is interaction between researchers as 
facilitators – or in some cases other persons on behalf of researchers to minimise researchers’ 
bias – and participants and among participants. FGD enables researchers to collect more 
information and ideas in a more efficient fashion than in a single interview. However, dominant 
personalities can influence the discussion such that the findings might not cover all participants’ 
voices. In addition, prioritization of ideas may not be achieved due to the influence of dominant 
participants (Harvey and Holmes, 2012). Researchers can apply consensus methods in order to 
reduce the limitations of FGD while trying to achieve a general agreement around a particular 
topic. One of the more widely used consensus methods is the Nominal Group Technique. 
The Nominal Group Technique (NGT) is a group discussion aimed to elicit participants’ 
opinions and generate consensus or convergence of opinion over a number of issues. NGT 
provides equal opportunities for participants to express their ideas and be involved in the 
problem solving or decision making around the topic of the discussion. NGT is characterized by 
three features. First, it is a group process in which each participant has the opportunity to work 
individually but in the presence of other participants. Second, it allows interaction and 
brainstorming between participants. Third, it involves a ranking and ordering process to prioritise 
ideas (McMillan et al., 2016). 
Despite its potential for obtaining group consensus, the NGT has a number of issues. For 
example, van Teijlingen et al. (2006) expressed concern with the role of the facilitator as there is 
a high potential for bias in leading or directing the group discussion. They recommended that the 
facilitator should be someone who is “a topic expert or non-expert who has credibility with the 
participants” that facilitates and does not lead or direct the group. As a group discussion, the NGT 
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may generate a wealth of information and recommendations to address the topic or the 
question. However, Potter et al. (2004) warn that the fact consensus is achieved among members 
does not always mean “the correct answer has been found”. They suggest that the nature of the 
recommendations might be exploratory, lead to other solutions or perhaps requires further 
testing and validation. Although NGT is a more time-efficient method to achieve consensus than 
FGD or a Delphi study, conducting NGT and reaching consensus may also be time-consuming as 
there are several stages in the protocol and diversity of opinions (Hugé et al., 2018). Lack of time 
to reach consensus was reported in some studies (Andrew and Delbecq, 1974, Hutchings et al., 
2010, Fakih et al., 2016). Again, the role of facilitator is important to keep the NGT manageable 
within the time limit. 
Development of a data tool 
Similar to interviews, the central questions for the NGT can be developed from a number 
of sources. However, as a consensus development method, NGT aims to “raise a potential 
solution or answer to a question which then can be prioritized or agreed upon” (McMillan et al., 
2016). Therefore, only a few questions – generally one or two questions – are discussed within 
the group. This also means NGT is often conducted as a follow up of former studies from which 
prior information and findings were employed to develop the central question of the NGT. 
Recruitment strategy 
As NGT aims to seek consensus from the members over a problem, participants must be 
familiar with the problem. Black (2006) stated “the key issue when selecting participants is that 
they represent the target audience for the output”. Therefore, purposive sampling is the 
appropriate sampling strategy for conducting NGT. Unlike a Delphi study which only comprises 
“experts” in the discussion process, NGT can be attended by heterogeneous groups from lay 
people to specialists or experts. The selection of individual experts in a Delphi study may be 
pragmatic as the panellists can be individuals who have interest and involvement in the topic 
being explored. This may tend to “centralise opinion” about the objectives of the study (van 
Teijlingen et al., 2006). In contrast, NGT may produce more diversity of opinion and ideas which 
can be useful for prioritisation. However, a researcher must be aware of the gradient of expertise 
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and experiences between participants as it influences the quality of the discussion (McMillan et 
al., 2016). The NGT can be conducted in a single data collection event through a highly structured 
meeting (face to face is preferable), but a Delphi study is better organised in several stages with 
participants not needing to meet up (van Teijlingen et al., 2006). 
Apart from other important stakeholders such as researchers, educators, users (patients 
and clients) and payers, practitioners and policy makers are often central to the change process. 
This is perhaps due to their ability to initiate and implement changes. Studies observing practice 
change in community pharmacy have often included practitioner and policy makers highlighting 
the importance of these two actors as agents of change (Roberts et al., 2008, Gastelurrutia et al., 
2009, Elrod et al., 2012). Since the central aim of the NGT used in this study was to propose 
recommendations for advancing community pharmacy practice in Indonesia, practitioners and 
policy makers were selected as the main participants with additional participants representing 
other backgrounds. 
Although the sample size is variable, generally an NGT session involves five to fifteen 
participants (Gastelurrutia et al., 2009, McMillan et al., 2014c, Fakih et al., 2016). Fewer than five 
or more than fifteen participants might reduce the effectiveness of NGT. A smaller sample size 
might be inadequate to represent consensual agreement and also limit the range of ideas 
generated from the group. In contrast, a larger sample size may complicate the process of NGT 
which can be frustrating for participants and facilitator(s).  
Conducting nominal group discussion 
The process of NGT normally involves four stages (McMillan et al., 2014a). Stage one is 
silent generation of ideas, during which the facilitator asks individual participants to write their 
ideas to a defined question with no discussion permitted until all ideas have been listed. Stage 
two is round robin, during which each participant shares their ideas in turn within the group. The 
ideas are recorded, and the process is continued until no new ideas are generated from the 
group. During this process, no discussion is allowed. Stage three is clarification and discussion. 
The facilitator allows group members to ask questions to clarify the ideas on the list and to discuss 
their merits and deficits. Ideas or items which have similar meanings can be combined and 
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duplication of ideas is removed. The last stage is ranking or voting, in which participants are asked 
to select their top preferences from the listed ideas. The number of items selected by the 
participants is dependent on the topic, but commonly consists of the ranking of five ideas with 
the idea/item with the highest priority assigned the highest score. The score for each item/idea 
is tabulated and presented to the group. The step-by-step process of conducting the NGT in this 
study can be viewed on Chapter 6.3 
The time to conduct an NGT depends on the number of participants, number of questions 
asked, and the type of participants involved. It can vary from 2 hours for one question to half a 
day for two questions and may even be followed up with another day for discussion of results 
(McMillan et al., 2016). While it is common that one group can be led by one facilitator, it is also 
possible to employ more than one facilitator depending on the function of each facilitator. For 
example, a group session can involve three or four facilitators with primary facilitators controlling 
the discussion and the others being responsible for recording or taking notes, tabulating the 
results and helping participants to familiarize themselves with the NGT process. 
Analysing group discussion data 
NGT can generate both quantitative and qualitative data. The quantitative data can be in 
the form of Likert scale scoring or rating and therefore it is necessary to translate this data into a 
qualitative judgement. A critical factor of analysing NGT data is “how strict a definition of 
consensus is used” (Black, 2006). For example, a consensus is achieved when there are top five 
ideas or recommendations generated from the tabulation of quantitative results. However, the 
situation may not be clear if in practice there are more than five ideas which have similar scores. 
Therefore, it is important for the facilitator to explain and address such practical issues 
beforehand. The qualitative data of the NGT mainly revolves around the discussion between 
participants. Researchers can apply a number of approaches similar to analysing interview data.  
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As the aim of NGT in this study was to generate recommendations for advancing practice 
in Indonesian community pharmacy, the ranking system was used to achieve the consensus. This 
means that the recommendations which generated the highest scores were assigned the top 
priority from the group discussion. A thematic analysis was used to describe major patterns of 
conversation between participants. 
4.1.4. Validity, Reliability and Trustworthiness of the Qualitative Research Findings 
Validity and reliability of data are important whatever methods are used. Potential 
threats to validity and reliability occur in all stages of research from the design to interpretation 
and presentation of the findings.  
Validity refers to “the extent to which the findings of a study are a true reflection of 
phenomena under study. Do the instruments (e.g. question in an interview) actually measure 
what they are designed to measure?” (Smith, 2010b). Potential problems in validity are often 
concerned with the development of instruments and during data collection, yet ensuring validity 
includes every step of the research. As a qualitative study deals with phenomena, there is always 
a question of how the instruments can identify the phenomena and serve to generate valid 
reflection of the actual conditions experienced by the interviewees. To ensure validity of 
qualitative works, researchers can employ several approaches (Morse, 2015, Noble and Smith, 
2015, Leung, 2015): (1) during data collection, researchers may use data to argue with 
respondents’ viewpoint (e.g. acting as devil’s advocate), (2) after data analysis, researchers can 
collect additional data to verify a hypothesis or ask the respondents to clarify whether the 
findings have accurately represented the experiences and perspectives of the respondents, (3) 
researchers can also compare their findings with relevant theories or other studies to assess the 
validity of the findings. However, researchers must be aware that their assumptions, experiences 
and ideas about the respondents and respondents’ perspectives may affect the credibility of the 
findings and be a source of researcher bias. As a result, researchers need to keep a “distance” 
from the data and the interviewee and avoid influencing the response of the interviewee.  
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Reliability refers to “the extent to which procedures, measures and data are reproducible 
or internally consistent” (Smith, 2010b). Reliability in qualitative studies has been associated with 
the analysis of data and considered of little relevance with data collection due to the uniqueness 
and richness of each interview. During data analysis, researchers must ensure that they employ 
similar concepts and explanations in the coding of an interviewee’s responses. This can be 
conducted in several ways. For example, each researcher independently develops their own 
coding framework from the raw data which is then compared with other researchers’ coding 
framework (Noble and Smith, 2015, Leung, 2015). This is close to the concept of inter-rater 
reliability which is similar in quantitative research. Another way is that the researchers can 
conduct the coding together and generate consensus about the potential problems arising from 
the data. However, the concept of involving other researchers for verification and validation is 
also contested as the nature of qualitative research is subjective (Morse, 2015). 
Another important element in ensuring the quality of qualitative research findings is rigor 
and trustworthiness. Qualitative research has been criticized for lacking rigor, transparency and 
justification of data collection and methods of analysing being used. This has implications for the 
integrity of the findings. Guba (1981) constructed four criteria in the pursuit of a trustworthy 
study. These are credibility (related to internal validity, the “truth” of the findings), transferability 
(related to external validity/generalizability, the findings can be applicable in other contexts), 
dependability (related to reliability, the findings are consistent and could be repeated) and 
confirmability (related to objectivity, the findings show a degree of neutrality and not researcher 
bias, motivation or interest). Of the several possible provisions to address Guba’s criteria, peer 
scrutiny of the project and provision of background data to explain the context of the study were 
adopted in this thesis (Shenton, 2004). 
The last essential task with a qualitative study is interpreting and building explanations 
from the findings. After researchers have generated the coding, refined the concepts of data and 
recognized the central theme of the findings, it is time to explain the meaning of the findings. 
Building explanations is a difficult process. Researchers must be familiar and knowledgeable 
about the data and able to think laterally about relevant theories or other important studies. 
There are two main approaches to writing up the findings of qualitative research (Rosenthal, 
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2016). First, researchers can report key findings under each theme or category by displaying some 
quotes to illustrate the findings. This is then followed by separate discussion in relation to the 
findings. Second, the discussion can be incorporated into the findings. This means findings and 
discussions are combined into one narrative. 
4.1.5. Reflexivity: Researcher’s Position towards the Research 
Reflexivity is increasingly used in qualitative research and accepted as a methodological 
tool to define the researcher’s position including views, beliefs and experiences and his/her 
influence towards the research and potential bias which may arise from researcher’s attitude 
(Patnaik, 2013). While reflexivity can span from “how researchers shaped and how they were 
shaped by the research process” (Palaganas et al., 2017), there is avenue to value reflexivity 
based on “the individual researcher’s ability to construct an overall sense of congruence in their 
research practice” (Attia and Edge, 2017). The term congruence entails “the expression of 
personal values, along with the use of personal skills in professional lives and vice versa” (Attia 
and Edge, 2017). This is the concept which is used in this section. 
This thesis (and the PhD journey) draws on my long-vested interest in community 
pharmacy practice. Therefore, this section is particularly important to represent my position and 
views about the research. 
I graduated from the Bachelor of Pharmacy program and gained certification as 
pharmacist in 2006. I started my career as community pharmacist in a pharmacy which is located 
next to a main city road. Our pharmacy was very famous within the neighbourhood. The 
customers were not only the surrounding people but also employees from several companies 
since the pharmacy was contracted by these companies to supply pharmaceuticals for their 
workers. The good thing about working in this pharmacy was that we had a pharmacist on duty 
at all times, which might not be the case in many other pharmacies. However, my role as a 
community pharmacist was mostly confined to compounding and dispensing of medicines with 
minimal interaction with patients due to the considerable volume of the prescriptions and 
customers. In addition, there was little opportunity (and time) to evaluate and improve the 
services as we were really tied up with activities in the dispensary. 
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In 2008, I started a new career as academic and researcher in a university. I was assigned in 
the Department of Pharmacy Practice which covers the area of research in community pharmacy 
policy and practice. The experience of practicing in community pharmacy was really useful in the 
process of teaching and research in the department. However, over years in researching 
community pharmacy practice, I started to realise and accept the fact that progress of community 
pharmacy practice in Indonesia has been slow with no significant change in the way pharmacists 
practice in the community. The lack of pharmacist’s presence is a chronic problem for the 
profession. Additionally, community pharmacy operates under uncertain conditions in terms of 
regulation support and enforcement, despite the fact that pharmacy is often considered a highly 
regulated health institution. For example, community pharmacy was scrutinised by the 
authorities for their actual and lawful roles in dispensing and providing medicines, yet there were 
no measures or penalties were given against those distributing medicines illegally or beyond their 
scope of practice (e.g. drug stalls, drug distributors and non-pharmacist professional). Literally, 
anyone can supply medicines. My first international publication (Hermansyah et al., 2012) 
underlined my huge concern about contemporary practice in pharmacy. 
I was aware that the poor practice was also influenced by the problems from inside the 
profession. I also understood that such a situation cannot be resolved unless there is recognition 
and real demand from policy makers, patients and other health professionals for professional 
pharmacy services. But what might be interesting and thought provoking at that time was the 
fact that Indonesia is going to implement universal healthcare coverage, an era which reflected 
a “point of no return”. It remained to be seen whether pharmacy would join the band or be kicked 
out of the wagon. This left me wondering about what can be offered to move the profession 
forward and to integrate with the rest of primary care sector. 
When I embarked on this PhD, there was scant research investigating practice change in 
developing countries and the lessons these countries can learn from their counterparts in 
developed countries. Literature from developed countries are almost one-way direction by 
imitating, comparing and benchmarking studies from countries such as UK, USA, Canada and 
Australia as if there are limited shared lessons (or lessons learned) from developing countries. 
During the PhD life, I started to realise and accept that the context of each country is decisive for 
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pharmacy development. Nevertheless, I still have faith that there are insights that can be shared 
between these “two different worlds” in which developing countries can learn from developed 
countries and developed countries can avoid the “classic” pitfalls occurring in developing 
countries. 
This is how I came to design the thesis and the study. I cannot ignore my interest to learn 
more about Australian pharmacy practice and I cannot entirely remove my thoughts and ideas of 
improving the system in Indonesia which perhaps have influenced the way I asked questions 
during the interviews and directed the group discussion. However, I completely understand that 
objectivity, credibility and truthfulness are the keys for successful qualitative studies. Therefore, 
within the research team, I was often reminded of wearing the researcher’s hat to reduce 
potential for bias. We worked together to resolve issues and looked for the best strategy to 
improve the quality of the study. In essence, I strove to adhere to the scientific and ethical 
requirements for conducting the research and presenting this thesis. 
4.1. Theoretical frameworks 
This section describes the theoretical frameworks which were used in this study. The use 
of a theoretical framework is helpful in the interpretation of studies. A theoretical framework 
also provides focus and boundaries for research studies. Equally this can serve as a limitation 
because it excludes other potential variables beyond the boundaries. Therefore, the use of a 
theoretical framework must be “conceptually appropriate and practically useful” (Scahill, 2013). 
A summary of the theoretical frameworks used in this study is provided in Table 4. 
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Table 4. Summary of theoretical frameworks 
Description Rogoff’s planes of analysis The PARIHS framework Culture-Structure-
Agency approach 
Key concept The modified theory 
explores three levels of 
practice (micro, meso, 
macro level) in the 
community pharmacy 
sector as a holistic and 
integrated system. The 
three levels operate 
interdependently and 
dynamically with changes in 
one level affecting the 
operation of other levels.  
Successful 
implementation of 
research into practice is 
a function of evidence, 
the context in which 
evidence is taking place, 
and facilitation 
Practice change is 
influenced by the 
structure in which 
pharmacies are 
operated, the culture 
supporting professional 
practice and ultimately 
the roles of agency to 
drive changes and 
maintain interaction 
between culture and 
structure 
Unit of analysis Individual pharmacists 
(micro level), community 
pharmacy (meso level) and 
healthcare system (macro 
level) 
Research and 
development in 
community pharmacy 
Structure highlights 
regulations, legislative 
and policy frameworks 
constructing and 
controlling community 
pharmacy sector; Agency 
refers to pharmacists and 
community pharmacies; 
Culture reflects 
professional pharmacy 
practice 
Features for analysis Foregrounding and 
backgrounding approach 
Guide and matrix for 
evaluation 
Coherent relationship 
between the three 
elements 
Strengths The holistic view offers the 
possibility to understand 
change by focusing on each 
particular level without 
losing attention on the 
operation and the impact in 
other levels 
Simple, clear and easy to 
use. It can fit with other 
theories and useful for 
both ongoing and 
retrospective projects 
The interplay between 
the three elements can 
help in the identification 
of conditions and factors 
supporting or impeding 
the implementation of 
change 
Limitations Deeper understanding of 
each level and the whole 
system is necessary to 
analyse changes. It is 
difficult to consistently 
determine micro, meso and 
macro levels in a complex 
system such as healthcare 
The concept may be too 
broad and diffuse. It 
may lack clarity in 
defining the 
operationalisation of the 
elements and sub-
elements. It may also 
lack validated 
measurement tools 
It is sometimes difficult 
to define culture and 
structure in the real case 
experience since the two 
elements are co-existent 
and may influence 
agency in similar ways 
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4.2.1. Rogoff’s planes of analysis 
The broad scope of change operating at the micro, meso and macro levels of the 
community pharmacy system presents challenges in selecting the appropriate unit of analysis as 
“the smallest object of analysis in a study” (Matusov, 2007). Previous studies have considered 
each of these three levels separately, with each level considered to operate independently from 
the others (Vygotsky, 1978, Dopfer et al., 2004, Kapiriri et al., 2007, Ong et al., 2014). Analysing 
changes in community pharmacy requires comprehensive understanding of the operation of 
these three levels as one cohesive system rather than treating each level separately. In doing so, 
this study used and modified Rogoff’s planes of analysis.  
The theory developed by Barbara Rogoff was originally designed to understand the 
developmental process of learning using a sociocultural approach. Rogoff proposed the 
observation of development in three planes of analysis corresponding to personal, interpersonal 
and community processes (Rogoff, 1995). These three levels are “inseparable, mutually 
constituting planes comprising activities that can become the focus of analysis at different times 
but with others necessarily remaining in the background of analysis” (Rogoff, 1995). Rogoff 
illustrated her theory “By analogy, the organs in an organism work together with an inherent 
interdependence, but if we are interested in foregrounding the functioning of the heart or the 
skin, we can describe their structure and functioning, remembering that by themselves the 
organs would not have such structure or functioning. Similarly, we may consider a single person 
thinking or the functioning of a whole community in the foreground without assuming that they 
are actually separate elements” (Rogoff, 1995). 
Rogoff’s planes of analysis was modified in this study by substituting the context of human 
development for the community pharmacy sector, namely micro level (individual pharmacists), 
meso level (community pharmacy as an institution or network of institution) and macro level 
(community pharmacy as part of healthcare system). Details of information about the 
modification of Rogoff’s theory to this study are provided in chapters 5.1 and 6.1. 
The strength of the framework is in its ability to include three different levels of operation 
as the unit of analysis. Although the framework only focuses on one particular level as the centre 
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of attention, the “foregrounding and backgrounding” concept allows researchers to consider the 
operation and the impact of other planes. In addition, the framework offers the option to remove 
boundaries between levels as it views the three levels as interrelated and working together. This 
view asserts that the existence of one level cannot be excluded from the context of other levels. 
In other words, the operation of one level cannot be understood without understanding the 
holistic nature of the system. This has become the key concept of the framework to understand 
change in community pharmacy: that practice change is a comprehensive process involving 
activities within three levels by which a change in one level can lead to change in all levels. Such 
concept offers that the actors or stakeholders within the system do not only engage in the 
activities within three levels but are also shaped by the three planes. This provides direction for 
pharmacists and pharmacies to lead change by engaging and contributing in each plane. The 
holistic view, however, is also the weakness of the framework. The approach relies on a deeper 
understanding of not only one plane but all planes which makes the discourse of understanding 
transformation more complicated. In addition, it is difficult to consistently apply the metaphor of 
micro, meso and macro level given that the nature of the healthcare and pharmacy system is 
heterogeneous and non-linear. 
4.2.2. The PARIHS Framework 
One of the issues with practice change and pharmacy role expansion is the extent to 
which research and development in community pharmacy can be effectively and sustainably 
translated into everyday practice. Knowledge obtained from the research program may be of 
little value unless it is successfully adopted into practice. Knowledge Translation (KT) has 
emerged as a paradigm to increase the use of research evidence and accelerate the process for 
research adoption into practice. KT involves a complex process and therefore, it implies the need 
for a tool to understand such a process (Glasgow and Emmons, 2007). This study utilized the 
PARIHS framework as a tool to understand KT in community pharmacy sector. 
The PARIHS (Promoting Action on Research Implementation in Health Services) 
Framework, developed by Kitson and colleagues (Kitson et al., 1998), is one of the more widely 
used conceptual frameworks for understanding and explaining the success or failure of 
implementation projects. The framework highlights that successful implementation (SI) of 
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research is represented as “a function (f) of the nature and type of evidence (E), the qualities of 
the context (C) in which the evidence is being introduced, and the way the process is facilitated 
(F); SI = f (E,C,F) (Kitson et al., 1998). In essence, a successful implementation of research is likely 
to occur when (a) the research generates solid scientific evidence aligned with professional 
consensus and patients’ preferences, (b) the context is receptive to change which includes a 
sympathetic culture for change, strong leadership and presence of a system for monitoring and 
evaluation, and (c) there is an appropriate mechanism to facilitate change from both internal and 
external facilitators. The application of the PARIHS framework to this research is explored in 
chapter 5.2. 
 Ullrich et al. (2014) noted that the use of three elements in the PARIHS framework has 
become the primary rationale for researchers to select the framework. The three elements have 
been considered “accurate in describing factors important to implementation”. For example, the 
facilitation element has been seen as crucial in encouraging an action-oriented approach to 
implementation and it is often the focus in implementation science. The second rationale for 
using the PARIHS framework is its ease of use. The framework often conceptually fits with and 
thereby supplements/complements other theories that make it useful for both ongoing and 
retrospective projects. Overall, the framework has been described as “simple, sensible, clear and 
easy to use and apply” (Ullrich et al., 2014). The simplicity of the PARIHS framework, however, 
has become a weakness as it can be too broad and diffuse. The PARIHS elements and sub-
elements are poorly defined which limits the use and operationalization of the framework for 
specific projects such as designing and measuring interventions. In fact, the lack of validated 
measurement tools is the major weakness of the framework (Helfrich et al., 2010).  
4.2.3. Culture-Structure-Agency Approach 
An empirical key to understand the process of change can be identified from the presence 
of structure that supports the shift of (social) culture within a society which has clear definition 
and mission towards a change (Rubinstein, 2001). In the field of social science, these three 
elements have been portrayed to have strategic importance in the construction of social change. 
This study, therefore, utilized the culture-structure-agency as a theoretical framework to explain 
the process of change in community pharmacy. 
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The term “structure” has often been posited as “structuring” the aspect of social 
existence or a power that determines, strives and constitutes social life (Hays, 1994). This implies 
“structure” as a rigid, hierarchical form that constrains nature by ruling or regulating a society 
(Archer, 2005). On the other hand, apart from different usage of the word in the academic 
discourse, the concept of “culture” can resemble an “aspect of social life that must be abstracted 
out from the complex reality of human existence” (Sewell, 2005). Culture in this sense has been 
perceived as flexible and concerns beliefs, values and ideologies. The interaction between 
“structure” and “culture” is sometimes perceived as contradictory in some papers, but they can 
be equally compatible and coherent with a possibility to influence each other as described in 
other research (Dutta, 2011). The key to this interaction is the role of “agency” which may include 
individuals, group of individuals, and group of organisations or government (Walt and Gilson, 
1994). “Agency” is the force behind social action as they are the ones who have capacity to plan 
and initiate action (Onyx and Bullen, 2000). Such capacity may include power, access to 
information, diverse intellectual capital and wisdom which makes possible to respond and 
transcend crisis and produce a desired effect (Newman and Dale, 2005).  
There is a dearth of research in pharmacy practice that contextualizes the relationship 
between structure, culture and agency. However, in the literature each element has been 
individually used in in reference to the philosophy and vision of practice change. Under this 
notion, this study adopts the framework by viewing pharmacists and community pharmacy as a 
group agency within the structure of the healthcare system. The culture of practice which is 
developed during the interaction between pharmacists, community pharmacy and the health 
system structure reflects the opportunity for change. Further application of this framework is 
presented in chapter 6.3. 
The strength of the framework lies on its views about structural, cultural and agential 
conditions being developed or intended to develop to support changes. The interplay between 
these three elements has been critical to explain “what was experienced and observed at the 
levels of the empirical and the actual” (Boughey, 2013). Since each “agency(ies)” would 
experience change in different and unique ways, these experiences would be important to 
determine for example which structural mechanism has been developed by the agencies to 
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trigger social change or what cultural conditions have emerged as a result of particular 
individuals/groups exercising agency. The elusive terms of the elements, however, has made the 
discursive complex and tends to be “unstable”. This is an important drawback as the three 
elements co-exist in many cases, with some elements being more or less dominant at any one 
time. The distortion of interpretation for example of structure as rules or culture as rules may 
lead to failure to identify important areas in the endeavour of change. This may lead to inaccurate 
understanding of what is defined as successful or effective change. 
4.3. Chapter Conclusion  
 
This chapter outlines the preferred method to address the aims of the study as presented 
in Chapter 3. Qualitative study design in the form of in-depth semi structured interviews was 
selected to explore key stakeholders’ opinion and perspectives regarding practice change in 
community pharmacy in both countries. The interviews were conducted with purposively 
selected participants representing stakeholders in community pharmacy and the healthcare 
system in Australia and Indonesia. A nominal group discussion was chosen as a method for 
obtaining consensus among Indonesian participants. Three theoretical frameworks – the planes 
of analysis, the PARIHS framework and the culture-structure-agency approach – were employed 
to provide a particular theoretical perspective in explaining or examining the findings of the 
study. 
The findings of this study were presented in two separated chapters as seen in the 
subsequent sections following the rationale that the study was conducted in two different 
countries. Such separation, however, does not mean that there is no connection between the 
results in each country. The chapter separation reflects the notion that each country case is 
unique despite the possibility that there might be some lessons that can be learned among the 
two countries. 
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CHAPTER 5. THE AUSTRALIAN STUDIES 
This chapter comprises two publications which report the findings of Australian studies. 
A number of in-depth semi structured interviews were conducted involving twenty-seven a wide 
range key stakeholder across Australia. The interview guide can be viewed in appendix 3. The 
results were discussed in these two publications, each with specific topic regarding practice 
change in Australian community pharmacy sector. 
The first publication (chapter 5.1) focuses on analysing the contemporary situation in 
Australian community pharmacy and the second publication (chapter 5.2) was designed to 
evaluate the impact of the Research and Development program in supporting practice of 
community pharmacy. 
5.1. Investigating influences on current community pharmacy practice at micro, meso 
and macro levels 
This section comprises the following publication: 
“Hermansyah A, Sainsbury E, Krass I (2017) Investigating influences on current community 
pharmacy practice at micro, meso, and macro levels. Research in Social & Administrative 
Pharmacy 13(4) pp. 727-737. https://doi.org/10.1016/j.sapharm.2016.06.007” 
The publication reports on the investigation of the nature of contemporary practice in 
Australian community pharmacy and the potential for community pharmacy to play a greater 
role in the healthcare system. This article was submitted in March 2016, accepted without further 
review and available online in July 2017. The published version of the paper is presented in 
appendix 7. 
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Investigating influences on current community pharmacy practice at micro, meso and macro 
levels 
Andi Hermansyah, Erica Sainsbury, Ines Krass 
 
Abstract 
Background The nature of Australian community pharmacy is continually evolving, raising the 
need to explore the current situation in order to understand the potential impact of any changes. 
Although community pharmacy has the potential to play a greater role in healthcare, it is 
currently not meeting this potential.  
Objective To investigate the nature of the contemporary practice of community pharmacy in 
Australia and examine the potential missed opportunities for role expansion in health care. 
Methods In-depth semi-structured interviews with a wide-range of key stakeholders within and 
beyond community pharmacy circles were conducted. Interviews were audio-recorded, 
transcribed verbatim and analysed for emerging themes. 
Results Twenty-seven key informants across Eastern half of Australia were interviewed between 
December 2014 and August 2015. Several key elements of the current situation representing the 
social, economic and policy context of community pharmacy have been identified. These 
elements operate interdependently, influence micro, meso and macro levels of community 
pharmacy operation and are changing in the current climate. Community pharmacy has 
untapped potential in primary health care, but it has been slow to change to meet opportunities 
available in the current situation. 
Conclusions As the current situation is complex, interrelated and dynamic with often unintended 
and unpredictable consequences, this paper suggested policy makers to consider the micro, 
meso and macro levels of community pharmacy when making significant policy changes. The 
framework proposed in this study can be helpful tool to analyse the processes operating at these 
three levels and their influences on practice.  
Keywords: current situation; community pharmacy; macro, meso and micro level influences 
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Introduction 
For many years, community pharmacy has been described as being in a state of transition 
with a body of international research highlighting the inevitability of practice change (Roberts et 
al., 2008, Feletto et al., 2013). Significant historical transitions in community pharmacy have been 
marked by the loss of three of its four traditional mainstays. Community pharmacies were 
originally focused on procuring, preparing and evaluating their own drug products (Anderson, 
2001). However, the rise of pharmaceutical industries took over these activities leaving only 
dispensing – a role which is usually associated with the distribution and sales of pharmaceuticals 
(Traulsen and Bissel, 2004). In recent decades, in Australia, dispensing has been the core of the 
business model and the major contributor to remuneration in contemporary community 
pharmacy (Berbatis et al., 2007a). 
However, the ongoing Pharmaceutical Benefits Scheme (PBS) reforms along with the 
changing landscape of the Australian healthcare system have greatly affected the income that 
community pharmacy can derive from their dispensing role. Community pharmacy viability is 
under threat if the business model continues to rely on dispensing. In addition, the over-reliance 
on dispensing has discouraged community pharmacy from adopting a more active role in health 
care through providing Cognitive Pharmaceutical Services (CPS) such as medicines management, 
health promotion and screening, and chronic disease support (Pharmaceutical Society of 
Australia, 2014). It has been a concern of policy makers that the role of community pharmacists, 
as highly trained professionals, remains narrowly focused on dispensing medicines. Policymakers 
are calling for a greater contribution from pharmacists to healthcare, a challenge to which 
community pharmacy must respond (Lingam, 2013). Accordingly, community pharmacy again 
faces inexorable societal and economic pressures to change. 
It must be recognized that a community pharmacy is not simply a business entity. 
Although as with any business, a community pharmacy must be profitable, it also has a 
responsibility to meet the healthcare needs of the public (Chaar et al., 2005). One perspective of 
community pharmacy is that it is a setting for an individual pharmacist to apply their professional 
duties in healthcare (Rosenthal et al., 2015), whilst, at a broader level it has been increasingly 
seen as an effective instrument to control rising healthcare and pharmaceuticals expenditure 
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(Emanuel et al., 2012). These intertwined roles imply that the operation of community pharmacy 
encompasses multiple-levels such as the pharmacist as an individual practitioner (micro level), 
community pharmacy as institution (meso level) and community pharmacy as part of healthcare 
system (macro level). 
This study therefore sought to investigate the nature of the contemporary practice of 
community pharmacy in Australia, in particular the impact and the interaction of influences on 
practice at the micro, meso and macro levels. Secondly, this study examined the potential missed 
opportunities for Australian community pharmacy to assume an expanded role in health care. 
 
Community pharmacy in Australia 
There are approximately 5,450 community pharmacies across Australia, comprising 
mostly small and medium sized businesses. It is a $12 billion industry employing more than 
63,000 persons with around 78% of registered pharmacists working in community pharmacy 
(Health Workforce Australia, 2014). Over the years, community pharmacy has been a major 
facilitator of National Medicines Policy which aims to ensure that life-saving and vital medicines 
are distributed in a timely manner throughout Australia. 
Community pharmacies in Australia are seen as highly accessible, therefore it is not 
surprising that 94% of Australians, particularly those with chronic illnesses, visit community 
pharmacy every year. Although representing only 14% of the total population, the elderly 
account for 80% of pharmaceutical consumption (Korda Mentha, 2014). Dispensing of PBS 
medicines represents up to 60% of community pharmacy profit with the remainder derived from 
Over-the-Counter (OTC) medicines and other general retail products (Korda Mentha, 2014). 
While community pharmacists are still predominantly focused on their dispensing role, 
they may also participate in the provision of remunerated CPS including Home Medicine Reviews, 
Residential Medication Management Reviews, and Medschecks which are essentially medication 
management programs delivered in a patient’s home, at aged care facilities and in-pharmacy 
store, respectively (Pharmaceutical Society of Australia, 2011a, Pharmaceutical Society of 
Australia, 2011b, Pharmaceutical Society of Australia, 2012). In addition, under the Pharmacy 
Practice Incentive program, community pharmacies may receive payment for delivering Dose 
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Administration Aids and Staged Supply services for patients who are at risk for potential 
medication misadventure (Pharmaceutical Society of Australia, 2007, Pharmaceutical Society of 
Australia, 2011c). 
Internationally, there is growing trend for incorporating community pharmacy in primary 
care groups to provide services that meet the needs of local population through collaborative 
work with other members of the primary care team particularly in countries such as UK (Brown 
et al., 2014, Alsaleh et al., 2016) and Canada (Perepelkin and Manfrin, 2012, Jorgenson et al., 
2014). In Australia, inclusion of a pharmacist in a GP practice has recently been proposed as a 
new model of delivering team care in medication management. However, it is yet to be trialled 
and implemented (Page and Somers, 2015, Polasek et al., 2015).  
 
Methods 
Study design and setting  
This study employed a qualitative design which provides the opportunity to collect rich, 
in-depth information and to uncover “hidden information” about the topics of interest. To 
address the objective of this research, in-depth semi-structured interviews with a wide-range of 
key stakeholders within and beyond community pharmacy circles were conducted. These 
provided sufficient flexibility to explore the topics and concepts while still being guided by a 
specific interview framework (Anderson, 2010). 
Sampling and recruitment 
Purposive maximum variation sampling was used to select potential participants across 
the Eastern half of Australia. Participants were chosen to include wide-range representation of 
stakeholders from pharmacy practitioner, pharmacy owner, General Practices (GPs), academics 
and researchers, professional peak organisations related to pharmacy and the healthcare system, 
consumer groups, private insurers, and government representatives. Participants were also 
chosen to represent both genders, metropolitan and rural areas, pharmacy and non-pharmacy 
backgrounds, different pharmacy backgrounds (individual proprietor, banner groups and 
discount pharmacy) and different states (New South Wales, Victoria, Queensland, Australian 
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Capital Territory and South Australia). The involvement of participants from different 
backgrounds is critical in ensuring perceptions are gained from various points of view. 
Potential participants were identified in two ways. Firstly, the research team listed known 
influential key stakeholders relevant to community pharmacy practice. The names of the 
stakeholders were obtained from the researchers’ professional networks and key publications on 
the issues around practice change in community pharmacy. Secondly, a snowball sampling 
method was applied after the conclusion of each interview whereby participants were asked to 
nominate other candidates who were potentially suitable to the study, but who may not have 
been identified by the research team.  
Invitation letters including an information sheet and consent form were sent 
electronically to potential participants. Participants who did not respond to the e-mail were 
contacted by telephone. Once participants agreed, the interview was then arranged based on 
their convenience. Face to face interviews were the preferred method, however geographical 
and time constraints for some participants resulted in both telephone and Skype© interviews as 
alternatives. Consent was obtained from the participants before conducting the interview. Prior 
to the commencement of this study, ethics approval was obtained from Human Research Ethics 
Committee the University of Sydney. 
Data collection  
An interview guide was developed from the literature on practice change in pharmacy, 
understanding of the latest developments in Australian pharmacy and discussions among the 
researchers (Appendix 3). The guide was piloted with three stakeholders with research and 
practice experience and refined based on feedback. 
The interview commenced with a broad, open ended question about participants’ 
experience, their role, and with regards to community pharmacy operation. Participants were 
then asked to describe their perception of the current situation of community pharmacy practice 
in Australia and the contribution of community pharmacists to the public and the healthcare 
system. Social, economic and policy contexts in healthcare and pharmacy were explored, and 
participants were encouraged to express their thoughts on all issues related to community 
pharmacy, the arguments behind the issues and possible strategies to resolve the issues. 
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Two researchers AH/IK or AH/ES conducted the interviews. All interviews were audio-
recorded and transcribed ad verbatim. Interviews were conducted until saturation of themes was 
reached. Saturation was reached after 27 interviews, when no new themes emerged from the 
data (Mason, 2010).  
Data analysis 
Complete transcripts of the interviews were prepared and iteratively analysed together 
with the audio recordings of the interviews. Several transcripts of interviews which were 
considered have the richness of information were initially used to create a coding framework. 
Thereafter an inductive approach was used to explore the data and construct themes without 
pre-defined conceptions about the topics. The analysis broadly involved categorizing interview 
data based on initial coding, then clustering the code into categories, and finally merging them 
into themes and subthemes (Thomas, 2003).  
All researchers were involved in creating the coding framework. NVivo 10© was used to 
assist the coding process and management of data. The remaining transcripts were then read 
and thematically analysed using the initial framework. This technique allowed the authors to 
compare the data with the initial transcripts and find repeated key themes and subthemes. New 
themes were added to the framework where they gave different perspectives or did not fit to 
the existing themes. 
Further in-depth analysis of the data was then undertaken using a modified framework 
developed by Rogoff known as the “planes of analysis”, a framework developed to assist in the 
analysis of human interactions within their social context. Rogoff views “context and individual 
as jointly producing psychological events”(Rogoff, 1982), with which she argued that there is 
interdependence between individuals and their environment. For empirical practice, Rogoff 
developed “a three-fold analytic distinction between individual, group and community” that she 
describes as planes of analysis (Rogoff, 1997). While Rogoff proposed that each of these three 
planes cannot be described in isolation, she approached the exploration of each plane as a 
“current focus of attention” (Rogoff, 1997), with the plane of focus seen as foregrounded against 
the background of the other two. Using this approach, the analyst can “zoom in” on one plane at 
a time without losing the comprehensiveness of the whole. In other words, this concept offers 
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the perspective that three levels “are separable in practice but in principle not reducible to each 
other” (Sawyer, 2002). 
This paper modified the concept of planes of analysis by defining a different set of three 
planes, namely the micro level (individual pharmacist), meso level (community pharmacy as an 
institution or network of institutions) and macro level (community pharmacy as a part of 
healthcare system). This approach distinguishes the particular aspects of each plane while still 
maintaining the dynamic interdependence of the whole system. These three levels are neither 
hierarchical nor independent; rather the three are mutually interdependent and all are necessary 
to understand the operation of each. 
Results 
A total of twenty-seven in-depth interviews were conducted from December 2014 to 
August 2015. Fourteen participants were interviewed in person, seven over the telephone and 
six via Skype. On average, the duration of the interview was 71 min (range 43-93 minutes). The 
characteristics of the participants are provided in Table 5. 
 
Table 5. Characteristics of participants (Australian studies 1) 
Characteristics n = 27 
Male 20 
Background of profession  
Pharmacy practitioners and managers 8 
Other healthcare professionals 1 
Academics and researchers 3 
Policy makers and administrators 13 
Consumer representatives 1 
Insurance providers 1 
State  
Australian Capital Territory 3 
New South Wales 12 
Queensland 4 
South Australia 2 
Victoria 6 
Urban area 24 
Method of interview  
Face to face 14 
Over the phone 7 
Skype® video call 6 
Average duration of interview (min) 71 min (range 43-93 min) 
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From the interviews several key themes emerged which characterized the nature of 
influences on contemporary Australian community pharmacy practice, representing the social, 
economic and policy context of community pharmacy. These influences operate 
interdependently, and can be explored at the micro, meso and macro levels to generate a broad 
understanding of the ways in which community pharmacy operates and is changing in the current 
climate. 
 
SOCIAL INFLUENCES 
VALUE OF COMMUNITY PHARMACY TO SOCIETY 
Participants consistently expressed the view that community pharmacy offers substantial 
value to the community such as high accessibility to the public, being a first port of call for a 
health problem and as a source of unbiased healthcare information from highly trained 
professionals. These values are distinct from other healthcare providers and have resulted in a 
high degree of public trust.  
We're very readily accessible. You don't need an appointment. You can walk in and get access to and advice from a 
trained healthcare professional, in many instances seven days a week over extended hours.  We are the only 
healthcare professional that you can actually do that. Everyone else you have to make an appointment. Nine times 
out of 10 the advice is free. Value of Community Pharmacy (P05_FP) 
 
Participants also observed that possession of these unique attributes confers 
responsibilities on the community pharmacist and community pharmacy and compels them to 
act in certain ethically responsible ways. Therefore, in responding to societal healthcare needs, 
they are increasingly providing a range of CPS.  
 
OPPORTUNITIES FOR EXPANDING ROLES IN HEALTHCARE 
Demographic changes within the society characterized by an aging population and a 
higher prevalence of chronic illnesses have created a need for broader access in healthcare. 
Participants acknowledged that there are opportunities for community pharmacies to move 
beyond dispensing as they are ideally located to meet this changing societal-healthcare need.  
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We’re involved in lots of health-related things, we’re involved in screening programs, we’re involved in compliance 
checks, (and) we’re making sure that people have the information. I think there’s a lot of opportunity for pharmacists 
to do lots of things in community pharmacy. Expanded Professional Services (P14_FP) 
 
Although contemporary practice has shifted towards role expansion, a number of 
participants felt there were unmet needs in the society which necessarily required more effective 
use of pharmacist’s skills and knowledge. For instance, one participant highlighted the potential 
for community pharmacy to play a role in the transitions of patients post discharge from hospital. 
I don't think there is enough focus on transitions of care…from the community into hospital, or the hospital into the 
community, or hospital into the nursing home…there is a big opportunity to reduce medication errors and 
discrepancies in transitions of care to reduce errors and referrals at a higher levels of care…they [pharmacists] can 
take a structured and systematic approach for medication reconciliation, and review and coordinate and collaborate 
with other health professionals…I think that pharmacists underutilise in what they're specifically trained to do and 
can deliver a lot of benefit but it's something that slips through the cracks. Under-utilisation of Pharmacist’s Skills 
and Knowledge (P03_MP) 
 
POOR EXPECTATION AS A BARRIER 
A key factor cited by many participants as hampering the expansion of community 
pharmacy’s involvement in healthcare service delivery is low expectations of pharmacy and 
pharmacists by other stakeholders.  
Consumers really don’t understand a large part of what pharmacists do and…is reflected also in the way for example 
our politician and their government authorities feel about pharmacist. They don’t really understand the role and it is 
only few general practitioners who are really supportive about this role. In my practice, there are many opportunities 
for GPs to be doing more with their time…GPs just don’t have high expectation about what we can do either. I think 
all that background is related, that low expectation is really holding us back fundamentally. Poor Expectation 
(P23_MP) 
 
CROSS-SUBSIDISATION OF EXPANDED SERVICES FROM DISPENSING 
Whilst there is an impetus for providing expanded services, community pharmacy 
encounters difficulties for sustaining the services because the payment is not sufficient to make 
these services profitable.  
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The thing is in pharmacy there’s been this notion that everything is cross-subsidised by the profit that being marked 
up but that’s no longer the case. You can’t cross subsidise these services. So the model is changing but it still hasn’t 
changed fast enough to make it sustainable. That whole concept has been lost in translation…we (are) just not, it is 
disappeared and it could threaten the viability. Cross-subsidisation of CPS (P10_MP). 
 
ECONOMIC INFLUENCES 
THE RISE OF A NEW BUSINESS MODEL   
Despite the aforementioned challenges, the industry continues to grow particularly with 
the rise of the discount model pharmacy within the past five years. Some participants viewed 
community pharmacy in Australia as becoming increasingly polarised between discount model 
pharmacies which focus on cost leadership strategies and service model pharmacies that 
emphasise the delivery of CPS.  
On the one hand, the rise of discount pharmacies has been seen as advantageous by 
consumers as they offer a wide range of products at cheaper prices. On the other hand, as noted 
by the majority of participants, their expansion has put a lot of pressure particularly on small and 
independent pharmacies. In addition, a small number of participants indicated that discounters’ 
advertising campaigns which focus on their low-cost strategy has damaged the professional 
image of community pharmacy.  
…these kinds of movement of discount pharmacy which is difficult because they are becoming quite large and 
powerful in their advertising and their marketing to Australian consumer…which (is) very much about the cost and 
so it is making people focus more on that type of aspects. You can’t compete with that so you have got to try doing 
something different to draw people back to your pharmacy. Inter-pharmacy Competition (P07_FP) 
 
To remain viable over the longer term, independent and non-discount community 
pharmacies must differentiate themselves by adopting a more service-oriented health care 
model rather than relying on supply model. 
I think that there’ll be models like discounters who are just plain straight suppliers.  Come here, get your medicines, 
whatever you pay you pay, and then I think there’ll be specialised pharmacies…there’ll be a service driven model of 
pharmacy that are pharmacies that provide various services…whether they’re a diabetic specialist, an asthma 
specialist, a wound care specialist, aged care specialist. But I think that model will probably be the future of pharmacy. 
Emerging Business Model (P27_FP) 
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FINANCIAL VIABILITY UNDER THREAT 
Some participants acknowledged that a number of pharmacies have had reduced incomes 
due to intense inter-pharmacy competition. One participant clearly indicated that her pharmacy 
had experienced significant loss, forcing them to find other ways to offset the losses. 
I know our boss has said that he has a cut in income of the pharmacy about $40,000 last year and that’s probably a 
pharmacy that’s going very well so financially that’s quite difficult because that’s a huge cut in income and the 
challenge is to try to find other incomes from other places, so that’s one kind of challenge that gets tougher I suspect. 
Shrinking Community Pharmacy Income (P07_FP) 
 
One of the easiest ways to recover the loss is through rationing wages including that of 
employee pharmacists. One participant argued that employee pharmacist wages have 
diminished in real terms over the years and he felt that this is common throughout Australia. 
When I was managing community pharmacy 10 years ago, my staff pharmacists in Canberra were on $43 to $45 an 
hour. Ten years later, as a staff pharmacist, I’m getting $35 an hour, so the wages have actually gone down over the 
last 10 years, that’s in Canberra, which I’m sure would be very similar to a lot of capital cities. There’s still a bit more 
money to be made in rural and remote areas if you’re prepared to travel, but in the cities, it’s becoming pretty brutal. 
Declining Individual Wages (P10_MP) 
 
The declining wages in tandem with the increasing pressures in the working environment 
have been a source of growing dissatisfaction for employee pharmacists. The respondent in the 
previous quote continued to express his concern about pharmacists leaving the profession due 
to dissatisfaction with the current situation in community pharmacy. 
Well, there’s this group in Canberra, they’ve lost nine pharmacists this year from this group…Most of them have left 
pharmacy, they’ve joined department of health, not as a pharmacist, just as part of the bureaucracy, because they’re 
just fed up with the low wages and the poor conditions and the pressure to churn, so the cracks are there. Pharmacists 
Leaving the Profession (P10_MP) 
 
In addition, one participant expressed the view that many pharmacy graduates were not 
satisfied with their career development particularly the difficulty of owning their own pharmacy 
and some others opted to pursue education of another major for better career enhancement.  
I talk a lot with pharmacists okay and I see a lot of disgruntled recent graduates and they aren’t ever going to own a 
pharmacy so they’ll always be an employee. They’re very intelligent people. They get out of University and they go, 
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“Is this all there is?”…And there’s a number of pharmacists I’ve worked with in public health who’ve gone and got 
public health qualifications and have taken their skills somewhere else. So the pharmacy agreement unfortunately 
doesn’t allow for career developmental and also role enhancement. Lack of Opportunities for Career Development 
(P21_MNP) 
 
POLICY INFLUENCES 
PRICE DISCLOSURE 
Whilst community pharmacies operate in a hypercompetitive market, their profitability is 
also under external pressure from PBS reforms, particularly the Price Disclosure policy. The 
policy, which was introduced in 2007 and gradually accelerated in 2013 has been viewed by all 
participants to have had a great impact on the income of community pharmacy. Some 
participants indicated that dispensary profit will start to decline as price disclosure reduces the 
cost of PBS medicines to an extent whereby the Government will need to subsidise fewer 
medicines in the longer term. However, although Price Disclosure is generally seen as hurting 
pharmacy, some participants also felt that the policy actually acts as a driver of change to 
restructure business toward a service focused model. 
Let’s be realistic, we had a great time before, and it was inevitable this was going to happen and why would the 
Government pay the same price for generics which we were paying significantly less as an owner pharmacist, why 
would they continue to pay us the same price as they would for the innovators…So price disclosure and the continual 
eroding of prices of drugs is just a fact of life and pharmacy needs to restructure and that’s what everybody’s 
scrambling to do, is to restructure so that we can afford to continue to provide the services that we’ve always done. 
The Impact of Price Disclosure (P27_FP) 
 
COMMUNITY PHARMACY AGREEMENTS (CPAs)  
Participants in this study acknowledged the key role of consecutive Community Pharmacy 
Agreements (CPAs) as the underpinning policy framework in Australian community pharmacy. 
Under the agreements, community pharmacy receives funding for dispensing and providing CPS. 
The agreements since 1990, according to the majority of participants, have provided a stable 
basis for the operation of community pharmacy at least for the next five years. Within this 
continuum, community pharmacy owners have the certainty to run, redesign or expand their 
business. More importantly, the agreements have ensured timely and reliable access to PBS 
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medicines through the community pharmacy network as a key plank of the National Medicines 
Policy. This role is vital as no other business model can cover such a wide range of areas 
throughout Australia. In addition, the agreements have contributed to some innovation in 
community pharmacy as there have been investments in Research and Development in 
pharmacy practice particularly within the last three agreements (3rd, 4th and 5th CPAs). 
Absolutely, it gives certainty to the industry…there are billions of dollars of privately invested funds within the 
community pharmacy network…It allows you to recapitalize your business…It allows you to sign leases…you have 
access to the pharmaceutical benefit scheme and in my belief is that no other groups, no other organizations could 
provide those services to the level of community pharmacy does. If everyone wants to play on that games, Coles, 
Woolworths, everyone but they won’t provide that services in Brewarrina [an indigenous town in New South Wales], 
(that means) they won’t provide that service at Fitzroy Crossing [a small town of indigenous population] in Western 
Australia that community pharmacy does. The Benefits of the CPAs (P20_MP) 
 
However, concern about the shortcomings of the CPAs was also expressed. According to 
several participants the agreements have limited the opportunity to obtain funding from other 
sources since the Government and health insurance providers consider that all funding for 
community pharmacy is provided in the “bucket” of CPAs. The agreements, according to one 
participant, have lacked flexibility and have constrained the development of other services that 
are not listed in the agreement. This is because the funding has been capped for certain services 
within the five years of the CPA. In addition, some participants described their concern that the 
agreements have preserved the over-reliance on the dispensing model as the largest portion of 
the funding is allocated for payment for dispensing of PBS medicines with only a small portion 
dedicated to professional pharmacy services. 
The problem would always be whenever we inform the government about what pharmacy can do, “oh no we 
[government] have done pharmacy, (and) we have got the CPA signed for five years so we don’t need to think about 
it”. So you don’t have any other opportunities to try to get other new areas of funding because they think that they 
[the funding] are all in here [the CPA]. Whilst, it is great that there is guaranteed funding pharmacy through the CPA, 
it is also a detriment for other events or opportunities. Limited Flexibility of the CPAs (P07_FP) 
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Discussion 
The findings of this study highlight the complex, and dynamic nature of Australian 
community pharmacy practice today and the interrelatedness of influences operating at the 
individual practitioner level (micro level), the community pharmacy (meso level), and the 
healthcare system (macro level). Without an in-depth understanding of such a complex, 
interdependent and dynamic process, it is difficult to propose a holistic policy approach as the 
system in community pharmacy is composed of heterogeneous and interacting entities. For 
example, it is inappropriate to focus only on the price disclosure policy at the macro level without 
consideration of its negative impact on the salaries of individual pharmacists working at the micro 
level. Moreover, to assume that the establishment of the CPAs at the macro level has been 
responsible for a broad expansion of the health care role of community pharmacy at the meso 
level is not supported by the evidence. The aim of this paper was to demonstrate that changes 
at any one level have significant potential to, and have had, unintended and unpredictable 
consequences on practice. 
The framework used to analyse the data provides a plausible explanation of the slow pace 
of practice change in community pharmacy. Moreover, it can be used as a means to analyse the 
processes operating at three levels, which are mutually interdependent.  
A helpful starting point for the analysis is the operation of community pharmacy (meso 
level), which as many participants agreed provides unique opportunities to serve the community 
at both an individual and healthcare (macro) level. The respondents described potential roles 
that can be played by community pharmacy in healthcare which accord with previous findings 
(Brown et al., 2012, Blalock et al., 2013), and include those facilitated by the CPA such as 
remuneration for medication management services (Carter et al., 2012b, White et al., 2012) and 
Pharmacy Practice Incentives (PPI) program (Haaywood et al., 2011, Krass et al., 2011a). The 
government (macro) has acknowledged that, with the challenges faced by the health system from 
an aging population and increases in prevalence of chronic disease, there is a genuine need to 
maximize the potential of community pharmacy (meso). Whilst there is some evidence of role 
expansion in community pharmacy as a result of successive CPAs, this has been offset by 
pharmacist (micro) dissatisfaction with the ways in which the agreements have been 
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administered and the limited extent to which they have benefited the profession (meso). Since 
the largest proportion of the money is allocated to dispensing of PBS medicines, the CPAs have 
continuously preserved a reliance on the supply model. In this sense, the CPAs – notwithstanding 
their benefits – have discouraged a shift to provision of expanded services, and thus indirectly 
inhibited the very progress that they were designed to promote. In other words, the cross-
subsidization of CPS by profits from dispensing - which is intrinsic to the CPA - has a significant 
impact on the capacity of community pharmacy (meso) to deliver and maintain the viability of its 
professional services.  
At the same time, increases in healthcare expenditure, including the cost of subsidizing 
PBS medicines, have become an impetus for PBS reforms in terms of the price disclosure policy 
at the macro level. Since community pharmacy (meso) has been surviving on the profits from 
supplier discounts over many years, price disclosure represents a key policy change that has 
generated ongoing concern surrounding the financial viability of community pharmacy. 
Moreover, tension at this meso level has been exacerbated with the emergence of the discount 
model pharmacy making the business landscape more competitive. Consumers may prefer to 
visit discount pharmacies as they offer cheaper prices. At this level, price disclosure (macro) 
together with inter-pharmacy competition and capped funding through the CPAs have 
significantly reduced the incomes of pharmacies, particularly small and independent pharmacies. 
The erosion in incomes has motivated some change of direction among some community 
pharmacies. Whilst changes might be difficult for the majority, there are examples of pharmacies 
that have been able to successfully transform their business by leveraging opportunities provided 
by the CPAs through funded CPS such as Home Medicine Reviews, Medscheck, Dose 
Administration Aids etc., as well as implementing innovative services addressing the health care 
needs of their local community.  
However for most pharmacies, the shrinking of income has led to significant cuts in 
operation including funding of pharmacist wages at the micro level. In addition, the legislative 
restrictions of pharmacy ownership (macro) which have remained mostly unchanged over 
decades limit the opportunity for graduates to open their own pharmacy (meso). Both of these 
outcomes have contributed to growing dissatisfaction among practitioners and have led some 
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pharmacists (micro) to depart the profession. This decision to leave the profession has the 
potential to affect the capacity of community pharmacy (meso) to meet changing societal needs 
(macro). In a nutshell, the implementation of policies at the macro level have affected individual 
pharmacists at the micro level in relation to their professional responsibility to the public and 
community pharmacy role at the meso level in the sense of fulfilling government expectations 
(macro). Changes at the meso and micro levels have also interdependently impacted the system 
at the macro level as shown in the case of CPAs and price disclosure. 
It is important to recognize, however, that much optimism was expressed by the 
participants, in addition to their reflections on the current situation. This study has demonstrated 
that there is opportunity, and indeed willingness, for community pharmacy to play a greater role 
in healthcare. For example, several respondents’ views on opportunities to become a primary 
care provider and health hub destination are consistent with other findings (McMillan et al., 
2013, Roberts, 2014). Nevertheless, this paper analysis of the current situation has clearly 
demonstrated that responding to these opportunities will involve more than simply 
implementing isolated policy and funding changes at the macro level. A number of previous 
studies have identified and highlighted barriers to change (Berbatis et al., 2007b, Mak et al., 2012) 
including poor public awareness and expectations of pharmacist’s expanded role and lack of fund 
models to support provision of the expanded services. These barriers which are consistent with 
this study have been persistent within the practice of community pharmacy, indicating that the 
contemporary policy approach is insufficient to offer a potential solution. This paper argues that 
in a complex, interrelated and dynamic system such as community pharmacy, any policy and 
funding decisions will influence all three levels in an interdependent fashion, and therefore there 
is a need to consider the mutual impacts at each level in the formulation and implementation of 
policy.  In other words, it is not sufficient to identify barriers, facilitators or drivers to practice 
change without an in-depth analysis of their mutual interdependence. This may result in the need 
for in-depth modelling using an analytical framework such as the one which is utilized in this 
paper. 
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This study was not without limitations. This paper used a purposive and snowball 
sampling strategy which if repeated with a different group of participants may yield different 
results. However the interviews were continued until data saturation was achieved.  As context 
plays an influential role the findings of this study, they may not be extrapolated to other cultures. 
Finally, despite their increasing impact within the industry, this study was not able to attract 
participants from warehouse-style or discount pharmacy. The researchers invited and followed 
up on a number of key informants with this background but none responded to the invitation. 
This may be taken into consideration for conducting the future research. To compensate the 
absence of key persons from the discount pharmacy model, this study interviewed other 
stakeholders who closely worked and understood how discount pharmacy operates. 
In addition, there have been some policy changes since the completion of data collection 
for this study. The administration of the 6th CPA which took effect on 1 July 2015 is likely to change 
the picture. Likewise, the proposal of the Pharmaceutical Society of Australia (PSA) and the 
Australian Medical Association (AMA) to put non-dispensing pharmacists into GP practices is 
likely to have a significant impact on the role expansion of pharmacists outside dispensary 
practice (Pharmaceutical Society of Australia, 2015). Furthermore, the latest policy adopted in 
January 2016 that allows up to one-dollar discount on the patient co-payment for eligible PBS 
medicines is likely to influence the business viability of pharmacy. Whilst the outcome of these 
policies has not been evaluated, they will undoubtedly have an impact on the three levels. 
 
Conclusions 
The current situation in Australian community pharmacy is complex, interrelated and 
dynamic with several key elements from the social, economic and policy context impacting on 
the micro (individual pharmacist), meso (community pharmacy) and macro level (healthcare 
system) of community pharmacy. Although community pharmacy has untapped potential in 
primary health care, it has been slow to change to meet opportunities available in the current 
situation, and if not addressed, this will continue to hinder the development of pharmacy as a 
key player in health care. In order to optimise the potential of the system, future policy decisions 
must consider the impacts at the micro, meso and macro levels in a holistic manner. 
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The findings and analysis presented in this paper contribute not only to “knowing what is 
going on” in the current state of community pharmacy, but they also provide a means of 
exploring and understanding the complexities, interrelatedness and dynamics of the practice in 
Australian community pharmacy both now and into the future.  
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5.2. The operation of the Research and Development (R&D) program and its 
significance for practice change in community pharmacy 
 
This section comprises the following publication: 
“Hermansyah A, Sainsbury E, Krass I (2017) The operation of a Research and Development (R&D) 
program and its significance for practice change in community pharmacy. PLOS ONE 12(9): 
e0184954. https://doi.org/10.1371/journal.pone.0184954” 
The publication evaluates the operation of Research and Development programs funded 
under the consecutive Community Pharmacy Agreements and the extent to which the programs 
have influenced practice in community pharmacy. This publication was submitted in January 
2017, accepted for publication and available online in September 2017. The published version of 
the paper is presented in appendix 8. 
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The operation of a research and development (R&D) program and its significance for practice 
change in community pharmacy 
Andi Hermansyah, Erica Sainsbury, Ines Krass 
 
Abstract 
Background: Community pharmacy practice in Australia is changing and Research and 
Development (R&D) in community pharmacy plays an important role in contributing to the 
changes. A range of Cognitive Pharmaceutical Services (CPS) were developed from R&D 
programs, yet their implementation has been minimal indicating slow practice change within 
community pharmacy. Given the vital role of R&D, little is known about the operation and the 
extent to which it has been effective in supporting practice change in community pharmacy.  
Methods: In depth, semi-structured interviews were conducted with 27 key stakeholders in the 
pharmacy and healthcare system in Australia. All interviews were audio-recorded, transcribed ad 
verbatim and analysed using an inductive approach.  
Results:  
Participants perceived that the R&D program has played an important role in the advent of CPS. 
Furthermore, they considered that evidence generated by the R&D projects is a critical influence 
on policy formulation, funding and implementation of CPS into practice. However, policy 
decisions and subsequent implementation are also influenced by other factors associated with 
context and facilitation which in turn foster or inhibit effective Knowledge Translation (KT) in the 
community pharmacy sector. 
Conclusion: While R&D programs have been viewed as essential for supporting changes in 
community pharmacy practice through development and funding of CPS, the overall impact has 
been small, as contemporary practice continues to be predominantly a dispensing model. Given 
the complexity and dynamic nature of the community pharmacy system, stakeholders must take 
into account the inter-relationship between context, evidence and facilitation for successful KT 
in community pharmacy practice. 
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Introduction 
Community pharmacy practice is under pressure to change. Over recent years, the 
revenue generated from dispensing prescriptions has become constrained, profit margins are 
falling and the sales of non-pharmaceutical products are diminishing (Brooks et al., 2008, Scahill 
et al., 2010, Anscombe et al., 2012, Singleton and Nissen, 2014). There is a clear imperative for 
community pharmacies to change their business model beyond dispensing and sales of 
pharmaceuticals (Richardson and Pollock, 2010, Chapman and Braun, 2011, Singleton and Nissen, 
2014). Internationally, there is a growing body of evidence which shows that community 
pharmacy has increasingly turned to providing expanded health-related services as a revenue 
stream to offset the losses from traditional dispensing practice (Roberts et al., 2005b, Hopp et 
al., 2006, Feletto et al., 2010b). 
With regards to the practice change paradigm, Research and Development (R&D) in 
community pharmacy has been increasingly acknowledged as a driver for the development of 
new Cognitive Pharmaceutical Services (CPS). In Australia, R&D in community pharmacy has been 
funded through the consecutive Community Pharmacy Agreements (the CPAs) which are five-
year agreements between the Australian government and the Pharmacy Guild of Australia. 
Commencing in 1990, the agreements have provided funding of over $45 billion to support a 
viable network of community pharmacies throughout Australia including funding support for the 
R&D program (Table 6) (Australian National Audit Office, 2015). 
 
Table 6. Proportion of funding under the consecutive CPAs 
 1st CPA 
(1990-1995) 
2nd CPA 
(1995-2000) 
3rd CPA 
(2000-
2005) 
4th CPA 
(2005-
2010) 
5th CPA 
(2010-
2015) 
6th CPA 
(2015-
2020) 
Total fundinga, (% increase 
from previous CPA) 
$3.286 billion $5.497 
billion 
(↑67%) 
$8.804 
billion 
(↑60%) 
$12.158 
billion 
(↑38%) 
$15.610 
billion 
(↑28%) 
$18.886 
billion 
(↑21%) 
Funding for Pharmacy 
Remunerationb, (% within 
the CPA) 
Not Available 
Not 
Available 
$5.6 billion 
(63%) 
$11.1 
billion 
(91%) 
$13.8 
billion 
(89%) 
$14.8 
billion 
(78%) 
Funding for CPS, (% within 
the CPA) 
$114 
million 
(1.29%) 
$241 
million 
(1.98%) 
$427 
million 
(2.77%) 
$368 
millionc 
(1.94%) 
Funding for R&D, (% 
within the CPA) 
$5 million 
(0.1%) 
$15 million 
(0.17%) 
$19 million 
(0.16%) 
$11 million 
(0.06%) 
$50 milliond  
(0.26%) 
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aActual expenditure under each agreement was not publicly reported. These numbers were obtained from the Audit 
Report on the Administration of the 5th CPA; 
bFunding that was related only to payment for supplying the medicines (e.g. dispensing fee, pharmacy mark-up, 
premium fee dispensing incentives, extemporaneous preparation etc.); 
cApproximately $613 million was invested in the 6th CPA under funding for Community Pharmacy Programs. 
However, only half of this funding was allocated for provision of professional pharmacy services as indicated in 
Appendix B of the agreement. Additional funding up to $600 million will be provided based on the recommendations 
of the Health Technology Assessment Body after evaluating the outcome of the Pharmacy Trials Program. 
d Funding for the R&D program was ceased in the 6th CPA and shifted to fund the Pharmacy Trial Program.  
 
The R&D program funded two types of projects (Figure 8): Investigator Initiated Grants 
(IIGs) and Commissioned projects. In the IIG, researchers designed projects aligned with their 
own research or interests within each CPA. On the other hand, Commissioned projects were 
announced for public tender with the research program already pre-determined by an Expert 
Advisory group encompassing key stakeholders in pharmacy (Calder et al., 2006, Pharmacy Guild 
of Australia, 2010a). 
 
Figure 7. Distribution of R&D Projects under the CPAs 
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Despite the importance of the R&D program, there has been concern expressed about 
the way the program has been funded, operated and its effectiveness in supporting practice 
change in community pharmacy. For instance, only a very small proportion of the total CPA 
funding was invested in the R&D program with the majority having been allocated to fund the 
supply of medicines including the allocation for dispensing fees of Pharmaceutical Benefits 
Scheme (PBS) medicines (Table 6). In fact, the amount of funding for R&D fell steadily from the 
3rd CPA onwards, and was ceased in the current CPA (the 6th). However, there was funding 
provided to trial new and expanded community pharmacy services under the Pharmacy Trial 
Programs. Furthermore, there was a trend within the most recent agreements towards funding 
Commissioned projects which limited opportunities for independent innovative research in the 
community pharmacy sector (Figure 8).  
 
From research to practice: The case of DMAS, PAMS and HMR 
The implementation of CPS involves a long and complex process from the design and 
development of the research, to evaluation of the impact on clinical, humanistic and economic 
outcomes of a variety of CPS, dissemination of the research findings to stakeholders, to the 
adoption and implementation which leads to sustainable delivery of CPS in community 
pharmacy. In the R & D phase of previous CPAs there was scant attention paid to development 
of a strategy to achieve knowledge translation using principles of implementation science. 
Within this section, we describe three case studies of pharmacy services funded under 
R&D program of the consecutive CPAs. They are Diabetes Medication Assistance Service (DMAS), 
Pharmacy Asthma Management Service (PAMS) and Home Medicines Review (HMR). These 
services were trialled using rigorous research designs (e.g. randomized controlled trials), thereby 
providing a body of sound evidence of benefit in community pharmacy. While these benefits 
supported the possibility for larger scale implementation, the policy decision was not to proceed 
with the implementation of these services in community pharmacy reflecting the long process 
and complexity for developing R&D in community pharmacy.  
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The Diabetes Medication Assistance Service (DMAS) and Pharmacy Asthma Management 
Service (PAMS) were two research projects examining the clinical and cost effectiveness of 
chronic disease management support services provided by community pharmacists for patients 
with type 2 diabetes and asthma respectively (Mitchell et al., 2011, Saini et al., 2004). These 
services were initially funded as small trials, and subsequently tested in randomized controlled 
trials in the 3rd CPA. Under the 4th CPA, the funding for DMAS and PAMS was continued for 
national pilot programs. Despite the success of the pilot programs, funding for neither of these 
CPS was continued in the 5th CPA. 
When it was funded for small trials as part of the Pharmacy Diabetes Care Program under 
the 3rd CPA, DMAS was found to be operationally and clinically effective (Krass, 2005, Krass et al., 
2007). Under the 4th CPA, the service was then rolled out for a two-stage pilot program, first to 
90 pharmacies and then 800 pharmacies across Australia. In the first stage, the benefit of DMAS 
was demonstrated in terms of improved clinical outcomes and acceptance by patients, 
pharmacists and GPs (Department of Health and Ageing, 2010, Krass et al., 2011b, Mitchell et al., 
2011). However, the uptake of the service in stage 2 was limited. The evaluation of stage 2 DMAS 
identified operational problems such as poor interaction with other health professionals 
including GPs, difficulties in recruiting patients which were predominantly related to lack of 
interest from patients, limited time and capacity of pharmacists to provide the services and mixed 
patient health benefits with only marginal improvement in clinical outcomes and lifestyle factors 
(Hales et al., 2010). As a result, continuation of DMAS in its original form was not considered to 
be necessary or economical (Hales et al., 2010).  
In the 5th CPA, DMAS was modified into Diabetes Medscheck, a one-off meeting with a 
pharmacist to review the medication and management plan for a patient with type 2 diabetes 
(Pharmaceutical Society of Australia, 2012). The modification removed the most valuable part of 
DMAS which was patient support and monthly monitoring to facilitate better self-management 
for patients with established diabetes (Krass, 2010). The Evaluation report on Medscheck and 
Diabetes Medscheck demonstrated mixed perceived benefits.  Although there was an increase 
in consumers’ knowledge about their medication regimens, the programs may not have reached 
their targeted patients such as high-risk patients, patients with chronic diseases, and patients 
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taking multiple medications. In addition, in contrast to DMAS and PAMS there was no evidence 
demonstrating clinical and cost-effectiveness of these services to justify their funding 
(PricewaterhouseCoopers, 2015).  
Research for PAMS originated from the Pharmacy Asthma Care Program (PACP), also 
funded under the 3rd CPA. The research demonstrated significant improvement in asthma control 
and quality of life of patients with asthma and the service was found to be cost effective (Armour 
et al., 2007). The project was rolled out as PAMS for a pilot program under the 4th CPA and 
involved several consultations with the pharmacist in the pharmacy over a period of 6 months. 
The service included assessments of asthma severity, inhaler technique, medication adherence, 
the use of spirometry, patient counselling on asthma triggers, goal setting and referral to GPs as 
appropriate (Saini et al., 2011, Emmerton et al., 2012). The pilot was initially designed in two 
stages. The evaluation of stage 1 which involved 100 pharmacies showed that clinical outcomes 
and substantial economic efficiencies would be achieved if PAMS were implemented in a broader 
community pharmacy setting (Wallace et al., 2010). However, after stage 1 was concluded, a 
decision was made by the Department of Health, in consultation with the Pharmacy Guild, not to 
proceed with stage 2 (Wallace et al., 2010). There was no explanation publicly available 
concerning the reason for not continuing the PAMS project. 
Even the implementation of reasonably well-established CPS such as Home Medicines 
Review (HMRs) has not been without problems. HMRs have been part of CPS in Australian 
community pharmacy since 2001 and have proven to be sustainable to date. HMRs are provided 
jointly by doctors and accredited pharmacists specifically for patients who may benefit from a 
medication management plan. Research on HMRs has shown that it is an evidence based and 
cost-effective service that prevents and resolves medication related problems (Roughead et al., 
2003, Gowan, 2006, Hilmer et al., 2010). In addition, there is evidence that HMRs are cost saving 
to the healthcare system (Stafford et al., 2009).  
Funding for HMRs was initially allocated under the 3rd CPA, however the increasing uptake 
of the services since 2002 has resulted in growth in demand significantly outstripping the funding 
allocation (Tenni, 2011, Gilbert, 2014). This was particularly evident during the 5th CPA, when 
funding for HMRs was exhausted before the conclusion of the Agreement. The decision not to 
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provide additional funding for the service reduced the effectiveness of the service, affected 
particularly vulnerable patients and threatened the sustainability of medication management 
programs in the future (Gilbert and Rigby, 2013, PricewaterhouseCoopers, 2015).  
Stakeholders’ thoughts and opinions about the operation of the R&D program and its 
significance for practice change have not yet been explored in the literature. Therefore, this study 
aimed to analyse the operation of the R&D program funded under the Community Pharmacy 
Agreements and its impact on knowledge translation in Australian community pharmacy 
practice. 
 
Materials and Methods 
In-depth, semi structured interviews with a wide range of key stakeholders within and 
beyond community pharmacy were employed to address the aim of this study. The participants 
represented multiple actors in pharmacy and the healthcare system including practicing 
pharmacists, professional peak pharmacy and medical organizations, GPs, consumer 
organizations, private insurance companies and the government. The participants also 
represented both genders, different States within the eastern half of Australia (Queensland, 
Australian Capital Territory, New South Wales, Victoria and South Australia), various pharmacy 
backgrounds (banner pharmacy group, discount chemist and sole proprietor) and metropolitan 
to rural areas. 
The participants were firstly selected using purposive sampling and the snowball sampling 
method was used to expand the initial sample; at the end of each interview, participants were 
asked to nominate other potential candidates for the study. Face to face interview was the 
interview method of choice, but a number of participants were interviewed by telephone and 
Skype video. Written consent was obtained from participants prior to the interviews. This study 
was approved by the Human Research Ethics Committee of the University of Sydney. 
The interview was based on a series of key questions that were developed from the 
literatures on R&D and implementation science, the contemporary situation of pharmacy 
practice in Australia and discussions among investigators. Several literatures highlighted the 
complexity and variation in the implementation process including the presence of both 
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opportunities and challenges from which the investigators developed the interview guide 
(Dobrow et al., 2004, Glasgow and Emmons, 2007, Maher et al., 2014, Almarsdóttir et al., 2014). 
The guided questions were piloted with three different key stakeholders and revised based on 
their feedback. There were no changes concerning the content of the interview questions. 
Improvement was made in relation to wording, order of the questions and how to probe 
respondents’ comments. The guided questions asked about stakeholders’ perceptions and 
experiences of the R&D program under the CPAs and the contribution of the program to 
community pharmacy practice and the healthcare system (see appendix 1). Each interview was 
conducted by two investigators, AH/ES or AH/IK. All interviews were audio-recorded and 
transcribed verbatim. The interviews continued until data saturation was reached, when no new 
themes or information emerged. 
Complete transcripts of the interviews were analysed iteratively together with the audio 
recordings. This study employed an inductive approach to the meaning of the data, and themes 
were constructed without pre-determined topics. Several transcripts that were considered to 
have particular richness of information were selected to create the coding framework, which was 
constructed collaboratively by all investigators. Data were initially broadly categorized into an 
initial coding scheme, the codes were clustered into categories, and the categories classified into 
themes and sub-themes. This technique allowed the investigators to modify the coding 
framework and add new themes as they emerged from the data. 
 
Theoretical Approaches 
There are numerous models, theories or frameworks analysing variable factors 
contributing to successful implementation of an intervention or research (Ellen, 2012, 
Patwardhan et al., 2014, Moullin et al., 2015). However, the application of such models, theories 
or frameworks depends on the objective, context, interaction of actors and the complexity of the 
system in which the research is conducted. The Promoting Action on Research Implementation 
in Health Services (PARIHS) framework was developed as a tool to explain the success or failure 
of implementation programs (Kitson et al., 1998, Harvey and Kitson, 2016) and was considered 
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appropriate for analysis of the multi-dimensional elements of knowledge translation in 
community pharmacy practice.  
The PARIHS framework suggests that successful implementation of Evidence Based 
Practice (EBP) is a function of the relationship among Evidence (E), Context (C) and Facilitation 
(F). Evidence in the PARIHS framework can be derived from a variety of sources particularly 
research, clinical experience, patient experience and local data/information. Context refers to 
the environment or setting in which the research is to be implemented which is influenced by 
economic, social, political, historical, fiscal and psychological factors. Furthermore, the PARIHS 
framework defines culture, leadership, monitoring and evaluation as central to determining the 
context for change. Facilitation in the PARIHS framework relates to processes which enable the 
implementation of evidence into practice. Within the facilitation element, facilitators, who can 
be individuals or teams, from internal or external sources, play key roles in affecting the context 
in which the research is implemented and with their skills, knowledge and roles, help other 
individuals, teams or organisations to apply the evidence into practice. 
The three core elements (E, C, F) are dynamic, equal and simultaneously interrelated. 
Each element encompasses a range of potentially applicable conditions or sub-elements that 
determines the status of the three core elements on a weak (low level) to strong (high level) 
continuum. The framework uses a three dimensional matrix to show that the three core elements 
can influence the implementation in either a positive (high: H) or negative (low: L) way (Kitson et 
al., 1998). Assuming that high quality evidence is available, (notwithstanding that low evidence 
may be useful in conditions where other elements are favourable), the matrix demonstrates that 
successful implementation of an innovation is most likely to occur when the context is supportive 
of change and there is strong facilitation for change. In contrast, less successful implementation 
is most likely when the context is not receptive to change and there is inadequate facilitation. In 
a condition when one of the two elements, for instance, context, is low, it may be overcome by 
the appropriate facilitation or vice versa. This implies that improvement, for example, in 
infrastructure may be required to change the context or staff development and training is 
perhaps needed to ensure appropriate facilitation of the innovation.  
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Results 
A total of twenty-seven key stakeholders participated in the interviews between 
December 2014 and August 2015 (Table 7). 
 
Table 7. Characteristics of participants (Australian studies 2) 
Characteristics n = 27 
Male 20 
Background of profession  
Pharmacy practitioners and managers 8 
Other healthcare professionals 1 
Academics and researchers 3 
Policy makers and administrators 13 
Consumer representatives 1 
Insurance providers 1 
State  
Australian Capital Territory 3 
New South Wales 12 
Queensland 4 
South Australia 2 
Victoria 6 
Urban area 24 
Method of interview  
Face to face 14 
Over the phone 7 
Skype® video call 6 
Average duration of interview (min) 71 min (range 43-93 min) 
 
Three broad themes were identified from the interviews: the value and role of R&D, the 
operation of the R&D program, and the uptake and challenge for effective implementation. 
The Value and Role of R&D 
Participants expressed the view that investment in the R&D program under the CPAs was 
essential for developing and strengthening community pharmacy practice. R&D has been 
recognized as an important element for driving innovation and the long term incremental quality 
improvement of services provided in community pharmacy. 
“All services that we have today have the seed planted maybe 20 years ago with some R&D. You just don’t wake up 
and roll out that service so I think there has to be the seed somewhere, it has to be developed and it has the fruit so 
I would say R&D is integral part of the long-term strategy” (P01_MP). Value of R&D in driving innovation. 
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More importantly, the R&D program generated evidence that was critical to 
demonstration of the efficacy of changes in community pharmacy, and thus to act as a driver of 
change. 
“Unbelievably important. I mean it’s what we use as the reason why we make a decision to implement a service…We 
need to show evidence of, particularly when it’s not widespread and we don’t have it across every pharmacy in 
Australia, we need to continue that research and development” (P06_MP). R&D as driver for change. 
The Operation of R&D program 
A range of views was expressed about the way the program operated, and particularly 
how the funding model changed across successive agreements. Several participants in this study 
expressed concerns about the small quantum of money allocated for funding R&D especially 
under the 5th CPA. Moreover, the trend towards funding commissioned projects was criticized as 
it limited opportunities for innovation. 
“We haven’t seen the development of new services or better way of doing things as a result because they have 
tailored, also we have seen net reduction in amount of investment in R&D as a total proportion of the funding and 
that very much has been tailored to answering questions that the stakeholder on the agreement wants to know 
rather than what might be something that is more useful broadly and might be needed” (P02_FP). Shifted funding 
towards Commissioned project and small proportion for funding R&D 
Some participants expressed their disappointment with the discontinuation of funding 
under the 6th CPA. One participant questioned the source for pharmacy to innovate and change 
practice in the future when there is no funding available for R&D. 
“I think it’s disappointing. It doesn’t appear to be in the agreement. I think over the successive agreements R&D has 
been one of the key drivers of improvement and the evolution of new services and it’s very disappointing it’s not there 
so where does funding for research into pharmacy then come from” (P08_FP). Discontinuation of R&D program 
under the 6th CPA 
However, according to one participant, rather than continuing to fund new R&D, the 
purpose of the 6th CPA is to generate high level evidence to facilitate implementation of CPS 
which have already been developed through R&D in previous agreements. 
“This agreement has ceased funding for the research and development program. However, instead of doing the R&D 
program, that’s where the $50 million trial programs are going to come into play…under the Sixth Agreement what 
you might actually do is continue on with that work, but rather than funding it as an R&D project, you might actually 
fund it as an implementation pilot and trial” (P25_MNP). Funding trial of R&D projects under the 6th CPA 
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The Uptake and Challenge for Effective Implementation 
The majority of participants perceived that CPS had been widely adopted by community 
pharmacy in daily practice but that the quality and consistency of provision have been variable. 
Few participants claimed to know whether the provision of CPS led to better health outcomes 
for patients. 
“If you measure the signup rate then they were really well adopted because every pharmacy is registered to record 
clinical interventions, to receive payment for Dose Administration Aids and so on. If you think about whether they are 
regularly and genuinely delivering services like Medscheck and making a difference to the people who they are 
delivered to, I think that is a different question and I am not sure we can answer the question with data we have 
available” (P02_FP). Uptake of R&D into practice 
Some participants stated that provision of CPS has contributed to more income for their 
pharmacy, however, the income gained from providing CPS is much smaller than income from 
dispensing. 
“The more you drive the professional income, the bigger your wages budget you'll get...but it is still a very, very small 
part compared to dispensing, and in a lot of our business we have a strong, very strong retail offer but compared to 
our dispensing it is still very small part” (P22_FP). Profitability for delivering CPS  
Furthermore, a number of factors that act as barriers to implementation were identified. 
One participant mentioned the lack of patient demand, pharmacists’ ability to deliver, and 
funding as barriers that need to be addressed, and pointed out that all were important in the 
successful implementation of CPS. 
“There’s an implementation barrier… You need the patient demand, you need a pharmacist’s ability to deliver on that 
demand, and then you need a funding for that position, or the owner that will take the lead and do that.  So you 
could have the two of those and without the third it’s not going to happen. So yeah, we could have the funding, we 
could have the pharmacist ready to deliver, but if you don’t have the patient demand yeah, I guess we’re not going 
to see that” (P06_MP). Barriers in Effective Implementation 
Reflecting on the case of DMAS and PAMS, where the demonstration of high quality 
evidence provided a strong argument in favour of ongoing funding, the difficulties associated 
with service practicalities were raised by some participants as a key counter argument to 
continuation of funding. 
“With those two particular programs, there was a strong case that they were valuable services. However, I think in 
their conception they were over engineered. There was a reliance with the DMAS on absolute cooperation with GPs, 
with HbA1C readings. If you couldn’t engage with the doctors, then you couldn’t access the doctors. So it was in some 
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ways the design was a fail. The principle behind it was very good. The same with the Asthma thing that involved some 
spirometry and some training” (P20_MP). Practicability of R&D project 
The majority of participants argued that R&D projects must be able to demonstrate cost 
savings along with the improved clinical outcome to justify further implementation. One 
participant involved in HMR research posited that HMR was adopted for implementation as it 
has evidence of both clinical benefits and cost savings for government.  
“We did that original research (and) we are able to demonstrate there is benefit that outweighs the cost and that's 
the reason they got out. And sure that was good thing for pharmacists to do but ultimately for government they 
looked at the benefit outweighing cost, they're looking for savings. So to me the fact the way I actually did that work 
and we're able to demonstrate the value was just, was probably the factor that allows us to get up” (P09_MP). Cost 
Saving value of R&D Project 
Furthermore, some participants suggested that patient acceptance was a determining 
factor for whether a R&D project was funded for widespread implementation. Patients were 
often unaware of the role of pharmacists in delivering the new CPS and the benefit gained from 
the provision of the CPS, and thus chose not to access the services. 
 “There’s been examples of failed programs where the program has looked great on paper, but there’s actually been 
very low consumer subscription because they don’t necessarily perceive that as being the role of a pharmacy or as a 
pharmacist” (P25_MNP). Patient’s acceptance 
In the end, the majority of participants indicated that political commitment had the 
greatest influence in deciding whether a CPS achieved ongoing funding or not. Despite strong 
research evidence of efficacy, it was essentially political agreement among the involved 
stakeholders within the decision-making process that determined whether or not further 
implementation occurred. 
“I think at the end of the day it came to what the Minister was more interested in. Although that’s not what they’re 
saying now but the reality is that how it was…I don’t believe that it’ll be totally evidence based now, I reckon it’s 
going to be money driven as well. But the other thing is that it’s negotiated by two parties, the Guild and the 
Government, and unless there’s perceived to be a groundswell interest the warmth of the Guild to negotiate for 
anything is going to sort of drive what happens. If the Guild doesn’t perceive that pharmacy is interested in doing it, 
then they’re not going to argue for it and in my experience the Government has not yet ever said well this is what we 
need to do” (P27_FP). Political supports in decision making process 
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Discussion 
This study confirms that the R&D program under the consecutive CPAs has played an 
important role in driving some changes through innovation and development of new services in 
Australian community pharmacy. The CPS generated from the R&D program have created an 
impetus for role expansion of community pharmacy, and in general, stakeholders had positive 
views about the value of R&D programs and their benefit to community pharmacy practice. 
Without R&D projects, it was perceived to be very difficult for community pharmacy to generate 
evidence that demonstrates value for money of the CPS which is critical to securing funding 
within the CPAs. Whilst the provision of CPS provides an additional revenue stream to that 
provided by dispensing PBS medicines, to date, the revenue has been insufficient to foster a 
major overhaul of the pharmacy business model based on dispensing to a health services focus.  
Using the PARIHS framework described earlier in this paper, the influence of the multiple 
factors at play (evidence, context, facilitation) in determining which CPS are implemented and in 
what manner is explored. According to this framework, evidence plays a key role in determining 
the effective implementation and this is a central element in our findings. With respect to 
evidence, participants described it as a critical factor for successful adoption of research into 
practice. The fact that several CPS funded under the CPAs were generated from the R&D program 
has supported this notion. However, at the same time there is a range of factors relating to 
context and facilitation, which shape the ways evidence is – and is not – translated into general 
practice including practicability, incentives for delivery of CPS, patient acceptance, cost saving 
and value to healthcare and political support for implementation as identified in this study. The 
PARIHS framework provides an excellent tool for explaining the interplay of these three factors. 
Evidence collected under carefully controlled conditions, such as in the R&D programs, is 
therefore essential for supporting practice change. However, the views of participants were 
strongly supportive of the notion that evidence should not be restricted to that described in 
research or controlled trials alone. Practical evidence as a means to explore practicability of 
research which involves exploration and consideration of both clinical and patient experiences of 
a particular service, is also vital in determining the likelihood of successful implementation. With 
particular reference to DMAS and PAMS, it is clear that the research evidence that was generated 
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indicated that the programs resulted in clinical, economic and humanistic outcomes being met 
when the context was supportive. Within small scale-controlled trials, the impact of many 
practical variables was able to be minimized, and the support and facilitation provided by the 
research team was instrumental in maintaining the necessary incentive to continue. However, 
wider scale rollout resulted in more variability within the context, and a dilution of the effect of 
facilitation as pharmacists were required to maintain their own motivation to continue.  With 
respect to the DMAS a lack of interest from patients in combination with time and capacity 
constraints of the pharmacists, rather than any deficiency in the program itself, was responsible 
for the lower than expected uptake of the service (Hales et al., 2010). Likewise, despite high level 
satisfaction among pharmacists and patients with PAMS research, the decision to cease funding 
for further PAMS research also played a key role in undermining the potential for knowledge 
translation (Wallace et al., 2010). Therefore, participants in this study viewed that knowledge 
translation resulting from the R&D program was critically dependent on context and facilitation, 
rather than on the evidence alone, as outlined in the PARIHS model. 
Importantly however, the participants also identified a wider range of aspects of context 
and facilitation, consistent with prior research, contributing to the translation of evidence into 
practice. A number of studies into the broad area of practice change in community pharmacy 
have highlighted enthusiasm both from pharmacy stakeholders and policy makers as 
fundamental to the adoption of changes in practice. (Noyce, 2007, Mossialos et al., 2013, Strand 
and Miller, 2014, Mossialos et al., 2015). This is consistent with the PARIHS framework, since high 
commitment and receptivity to change are key contextual facilitators, and these were very 
apparent in the initial phases of both DMAS and PAMS where many pharmacists eagerly signed 
on to participate in both stages of the national pilot. However, our findings also highlighted a 
range of barriers to practice change in pharmacy, from both internal and external contexts, as 
reported in many other studies. These include lack of pharmacists’ capacity due to increased 
workload (Lounsbery et al., 2009), poor patient demand (Carter, 2012), limited practicability of 
the research (Peterson et al., 2009), and lack of incentive for providing the services (McMillan et 
al., 2013). In addition, transformation of DMAS into Medscheck suggested that while an 
evidence-based CPS may be refashioned, it is fundamental to maintain its core components – the 
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aspects with proven effectiveness – in any new services. The core components must be 
implemented with high fidelity and remain untouched while allowing for adjustment for non-
core components to adapt with the context or local needs. Furthermore, the small investment in 
R&D programs and remuneration for CPS under the consecutive CPAs has corresponded to slow 
practice change in most community pharmacies. As a result, participants perceived that to date, 
provision of CPS has not been able to significantly contribute to the viability of community 
pharmacies which remain highly reliant on income from dispensing. This highlights the need for 
a priori funding of research based on principles of implementation science to inform a strategic 
approach to knowledge translation of evidence-based CPS.   
Perhaps an important aspect contributing to facilitation and context is the political 
commitment from peak pharmacy organisations and the government supporting practice 
change. For instance, the Pharmacy Guild of Australia and the Australian government influenced 
practice change through negotiation of the successive CPAs within which billions of dollars have 
been invested including for the R&D program and payment for delivering CPS. However, the 
community pharmacy sector is a complex and dynamic system with influential elements 
interacting at the micro, meso and macro level (Hermansyah et al., 2017a). In this type of system, 
indirect or less obvious facilitators must also be taken into account. For example, despite not 
being involved directly in the negotiation for the CPAs, other organisations have been able to 
push their change agenda in parallel. One example, is the role of the Pharmaceutical Society of 
Australia in facilitating community pharmacy change through education and targeted practice 
programs which may or may not receive recognition from the policy perspective.  Within this 
complex system the activities of different pharmacy groups, have been influential, albeit often 
indirectly or weakly (Zellmer, 2001). Gauging their relative influence on practice change is 
difficult, however, what is clear is that in order to be effective the various pharmacy organisations 
need to work in unison with other health professions and the consumer to drive practice change 
(Ferguson, 2000, Zellmer, 2001).  
A further impact of government policy as facilitator and constraint can be seen in several 
programs that have been funded in recent CPAs, and which have little or no research evidence 
to support them. This has been particularly apparent in the decision to fund CPS such as 
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Medscheck, Diabetes Medscheck (in itself a much abbreviated version of DMAS) and Clinical 
Interventions, despite these services not being supported by any solid evidence for better health 
outcomes in the context of the Australian healthcare setting (Gilbert, 2014). Although like HMR, 
these services were capped near the conclusion of the 5th CPA, their introduction clearly 
demonstrates that evidence is not the only factor considered by policy makers. 
This study clearly identified that in the contemporary context, all three aspects of the 
PARIHS model must be taken into account when attempting to understand why some programs 
are successfully adopted and others are not. The use of the PARIHS framework demonstrates 
that change is a process resulting from the interaction of evidence, context and facilitation, and 
provides a plausible explanation of the current situation. Despite sound evidence of the potential 
for efficacy from the DMAS and PAMS research programs, constraints tended to exceed 
facilitators within a context which was already resistant to change. Political policy based on 
pressure to create financial savings, poor patient understanding of the potential roles of 
pharmacists in broader health care, limitations associated with pharmacists themselves, the 
siloed nature of the health care system, and a willingness of policy makers to downplay the value 
of evidence combined to overshadow evidence. These multiple factors demonstrated that 
decision making for adopting research into practice is a “complex, messy and demanding task” 
(Rycroft-Malone, 2004).  
One of the lessons of this study is that policy makers might be more willing to favour 
funding of CPS when there is evidence of significant potential savings to the healthcare system 
such as reduced medication costs (e.g. reduced claims of PBS dispensing), reduced number of 
hospitalizations, or reduced number of doctors’ visits. With rising healthcare expenditure, 
governments are concerned to curb the growth in expenditure without adversely affecting health 
outcomes. However, for the research to be successfully translated and services to be delivered 
by pharmacists, it is also important to take account of the economic/business implications for 
pharmacies and whether or not pharmacists perceive that they have the capacity to implement 
the CPS. In other words, pharmacists need to believe that implementing practice change to focus 
on delivery of CPS is going to be economically beneficial to ensure the sustainability of the 
practice, the investment for the pharmacy and income of the individual pharmacist(s). 
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The PARIHS framework has often been used to analyse knowledge translation in a small-
scale setting such as a company, organization or work division. The utilization of the PARIHS 
framework in a broader context as proposed in this study is a novel discussion and some 
important insights were gained when the framework was used to meet the aim of this study. 
Furthermore, this study used empirical data in the form of opinions from the stakeholders to 
seek to explain the relationship between the framework and the real-world situations. It confirms 
that utilization of the PARIHS framework might be applicable as a strategy for analysing actual 
cases.  
Strengths and Limitations 
This study included a wide range of key stakeholders with particular experiences and 
views about the R&D program in community pharmacy. While we may not necessarily have 
captured the full spectrum of behaviours, attitudes and influences in policy making and 
implementation, the diversity of opinions elicited nevertheless reflected the complexity and 
multifactorial nature of influences on knowledge translation in community pharmacy, a topic 
which has not been widely explored in the current pharmacy literature. There have been some 
policy changes since the completion of data collection for this study, including the 
commencement of the Pharmacy Trials Program under the 6th CPA and the ongoing review on 
pharmacy remuneration and regulation, which to some extent have raised questions about the 
contribution of R&D programs to community pharmacy services. Nevertheless, these two policies 
were excluded from consideration as they took effect after 1 July 2015. These policies 
undoubtedly will have an impact in the future implementation of R&D funded services in 
community pharmacy. 
 
Conclusion 
This paper summarizes the perceptions and experiences of key stakeholders regarding 
the operation of an R&D program funded under the CPAs in Australian pharmacy, and its 
significance in fostering practice change. While R&D programs have been viewed as essential for 
supporting changes in community pharmacy practice through development and funding of CPS, 
the overall impact has been small, as contemporary practice continues to be predominantly a 
 142 
dispensing model. The utilization of the PARIHS framework in this study also served to shed light 
on the complex relationship between evidence, context and facilitation and CPS funding policy 
decisions and subsequent knowledge translation into community pharmacy practice.   
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Interview guide 
1. How do you view the current situation in Australian Community Pharmacy? 
Delivery of CPS in community pharmacy 
2. What are your opinions on each of the following CPS funded under the CPA:  
a. Home Medicine Reviews;  
b. Dose Administration Aids;  
c. Medscheck and Diabetes Medscheck;  
d. Clinical Intervention? 
3. How well the CPS have been adopted?  
4. What do you think of the way they are structured?  
5. What do you think of the contribution of CPS to practice of community pharmacists and 
viability of community pharmacy? What about the impact to healthcare system? 
The administration of R&D program under the consecutive CPAs 
6. What do you think of the key argument to actually fund specific CPS in the CPA? How 
important to have evidences for these services? 
7. What is your opinion about funding for R&D under the CPA? Do you think it has been effective 
to support evidence for professional services? 
8. What do you think of the relevance between R&D and practice? 
9. What do you think of programs which have been trialled such as DMAS and Asthma services? 
What were the reasons they were not funded for further implementation?  
10. Specific for DMAS, how do you compare DMAS and Diabetes Medscheck today? What are the 
reasons DMAS becoming truncated into Medscheck Diabetes? 
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5.3. Chapter Conclusion 
This chapter provides the results of the interviews involving key stakeholders in Australian 
community pharmacy and healthcare system. The findings informed two important topics 
namely practice change in the contemporary pharmacy situation and the operation of funded 
R&D program and its significance to practice change in pharmacy.  
Overall, community pharmacies in Australia were and have been under pressure to 
change. The planes of analysis framework used in this chapter informed the complexity, 
interrelation and dynamic of community pharmacy sector and more importantly the pressures 
to change within the contemporary situation. The current situation has affected the micro, meso 
and macro level of community pharmacy system and reflecting a need for future policy decisions 
that considers these three levels in a holistic manner.  
Accordingly, this chapter also provided evaluation on the operation of funded R&D 
programs under the CPAs which have been an essential platform for practice change in Australian 
community pharmacy. The R&D programs have been vital to help decision makers in formulating 
policy for the development of community pharmacy. However, the operation of R&D program 
has not succeeded in driving widespread practice change in community pharmacy. Using the 
PARIHS framework, this chapter provides insight on how to successfully translate research into 
practice by considering the complex relationship between evidence, context and facilitation.  
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CHAPTER 6. THE INDONESIAN STUDIES 
This chapter comprises three publications which discusses the findings of the Indonesian 
studies. The first publication (chapter 6.1) discusses the introduction of the Universal Healthcare 
coverage program and its impact on the community pharmacy sector, the second publication 
(chapter 6.2) evaluates of the current policy initiatives in community pharmacy and the third 
publication (chapter 6.3) proposes recommendations to advance community pharmacy practice 
in Indonesia. 
Data in the first (chapter 6.1) and the second (chapter 6.2) publication were collected 
through a number of in-depth semi structured interviews involving twenty-nine key stakeholders 
in Indonesian community pharmacy and healthcare sector. The interview guide can be viewed in 
appendix 4. The third publication (chapter 6.3) reported the results of a nominal group discussion 
involving thirty-four participants representing key stakeholders in Indonesian community 
pharmacy system.  
 
6.1. Investigating the Impact of the Universal Healthcare Coverage Program on 
Community Pharmacy Practice 
This section comprises the following publication: 
“Hermansyah A, Sainsbury E, Krass I (2018) Investigating the impact of the universal healthcare 
coverage programme on community pharmacy practice. Health & Social Care in the Community. 
26:e249-260. https://doi.org/10.1111/hsc.12506”. 
In this study, we reported the impact of the new Indonesian health financing system in 
the form of the Universal Healthcare Coverage program (JKN) on community pharmacy practice. 
This study was submitted in March 2017, accepted for publication in September 2017 and 
available online in March 2018. The published version of the paper is presented in appendix 9. 
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Investigating the Impact of the Universal Healthcare Coverage Program on Community 
Pharmacy Practice 
Andi Hermansyah, Erica Sainsbury, and Ines Krass 
 
ABSTRACT 
The introduction of Universal Healthcare Coverage (JKN) in 2014 has changed the landscape of 
the Indonesian healthcare and affected the community pharmacy sector. This paper investigates 
perceptions of healthcare and pharmacy stakeholders about the impact of JKN on the practice of 
pharmacists and pharmacy in both public (Puskesmas) and private (Community or Retail 
pharmacy) settings. In-depth semi structured interviews were conducted from February to 
August 2016 involving twenty-nine participants representing key stakeholders from different 
provinces in Indonesia. While JKN was actually designed with good policy objectives for pharmacy 
integration within primary care network, it has created some unintended and unanticipated 
distortion in the healthcare system which may be detrimental to the community pharmacy 
sector. In fact, community pharmacy practice is still limited to dispensing and continued to be 
hampered by ongoing challenges mainly pharmacists’ absence, lack of clinical competence and 
limited support from regulation changes. It is a missed opportunity for pharmacists to play a 
greater role in primary care services indicating the need for an overhaul to pharmacy education 
and policy system. 
Key words: Universal Healthcare Coverage, Community pharmacies, Pharmacists, Indonesia 
 
What is known about this topic: 
 Indonesia implemented Universal Healthcare Coverage (JKN) since January 2014 
 Changes in the health financing system have always had impact to healthcare and 
affected the community pharmacy sector 
What this paper adds: 
 While policy implementation of JKN has been designed to reform healthcare, it did not 
address key ongoing problems within the community pharmacy sector  
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 Community pharmacy practice in Indonesia has not moved significantly beyond 
dispensing practice even after the introduction of JKN 
 Community pharmacy continues to be hampered by structural and fundamental issues 
which in the main, do not relate to the policy changes provided by JKN 
 
INTRODUCTION 
Community pharmacy has long been recognized as an important community setting for 
healthcare delivery. It is often the first port of call for patients with minor ailments. In addition, 
community pharmacists are authorised to manage pharmaceuticals which constitute a significant 
proportion of healthcare expenditure. Therefore, changes in a healthcare system will inevitably 
influence the practice of community pharmacy and pharmacists (Mak et al., 2012).  
On January 1st, 2014 Indonesia introduced Universal Healthcare Coverage (Jaminan 
Kesehatan Nasional- JKN) with an ambitious intention, to cover all Indonesians under a single 
health insurance program by 2019 (estimated at 270 million people) (Jung, 2016, Plummer and 
Boyle, 2016). After a long delay since the initial passing of the law in 2004, the roll out of JKN has 
raised many concerns about the ability and commitment of Indonesia to implement such large-
scale changes in its healthcare system (Pisani et al., 2017). The introduction of JKN was marked 
by three significant changes: expanded insurance coverage to the whole population; 
reconfiguration of the primary care network; and integration of multiple health insurance 
schemes into a single payer for health care (Mboi, 2015, Sparrow et al., 2017). Notably, the new 
national insurance provider, BPJS Health, has included community pharmacies as an integral part 
of the primary care network. Pharmacists, comprising  the fourth largest health profession in 
Indonesia, are viewed as highly trained professionals yet they are underutilized (Ministry of 
Health Indonesia, 2016a). The integration of pharmacists within the JKN scheme may create 
opportunities to embrace primary care roles which is a novel approach in Indonesia and evidence 
supporting this role is limited. The next section provides an overview of the relevant changes in 
Indonesian healthcare and community pharmacy. 
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A new landscape of Indonesian healthcare and community pharmacy  
Indonesia is a vast archipelago of more than 17,000 islands, and the fourth most populous 
country in the world (260 million people). The country is divided into 34 provinces composed of 
514 districts and municipalities, each with its own administrative function, including budgeting 
and legislating for health, as a result of a decentralization policy introduced in the late 1990’s. 
Classified as a Lower Middle Income country, GDP per capita is US$ 3,491 with 2.9% of the GDP 
invested for health expenditure (United Nations, 2017).  
Prior to JKN, the Indonesian healthcare system was characterized by a mix of public and 
private management on the supply side, and a mix of public and private financing with a 
significant portion of out of pocket payment on the demand side (Bambang Brodjonegoro et al., 
2015). On the supply side, private General Practitioner (GP), specialists, health clinics, 
government-owned community health centres (Puskesmas), small or large hospitals owned by 
private or public companies co-existed and were accessible to patients. A sick patient could go to 
their facilities of choice regardless of the level of care. In practice, the large hospitals were often 
inundated by patients who perceived that hospital treatment was better and more 
comprehensive even for minor illnesses compared to treatment in Puskesmas. Thus, the 
Puskesmas were under-utilized (Rokx et al., 2009).  
On the demand side, various public and private insurance providers existed to service 
customers with very similar types of benefits albeit with different premiums. The system was 
quite fragmented with different public insurance providers only covering certain groups of 
people particularly based on their profession. For instance, ASKES only covered civil servants, 
JAMSOSTEK covered formal private workers, ASABRI covered the armed forces, TASPEN covered 
pensioners, and insurance for poor people came under the umbrella of the social security net 
program (JAMKESMAS). This did not include a number of healthcare protection programs funded 
by provincial and district governments (Holzhacker et al., 2016). Moreover, the proportion of out 
of pocket payments was high as insurance coverage was limited and people preferred to pay as 
they go. It was estimated that more than 30% of Indonesians were not insured, which contributed 
to extremely high out of pocket expenditure and led to further impoverishment of very poor 
families (Sparrow et al., 2013). 
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With the introduction of JKN, reorganization of the primary care system has been the 
main priority (Figure 9). Puskesmas, GPs, Dentists and primary clinics now hold strategic 
responsibility as the gatekeepers of primary healthcare delivery (Ministry of Health Indonesia, 
2013). This means they are the first point of contact for patients and act as a referral point to 
specialized healthcare services. Furthermore, various public insurance schemes and providers 
both at the local and national level have been unified under JKN and are operated by BPJS Health 
as the sole agency responsible for the management of healthcare coverage, recruitment of 
insurees and paying for healthcare (Jung, 2016). In addition, membership in JKN has been opened 
to cover others such as informal workers and individuals who must pay premiums on a regular 
basis.   
As a means of controlling the quality and the cost of pharmaceuticals, the government 
through the Ministry of Health introduced the National Formulary containing a list of approved 
drugs covered under JKN (Ministry of Health Indonesia, 2016b). Only a small number of registered 
pharmaceuticals (586 of 13,564 marketed drugs), claimed to represent safe, effective, quality 
and affordable medicines for JKN insures, were approved. In addition, healthcare facilities 
providing pharmaceuticals, including community pharmacies, Puskesmas and hospitals, are 
required to purchase medicines through an e-catalogue purchasing system. The system, 
managed by the National Public Procurement Agency (LKPP), aims to improve the accountability, 
transparency and efficiency of pharmaceutical purchasing (Ministry of Health Indonesia, 2014a).  
Pharmaceutical services in the community in Indonesia are delivered by two main 
institutions: Puskesmas and community-based pharmacy (hereafter called community 
pharmacy). They differ in ownership, operation and scale yet under JKN, there are some activities 
which are common to both institutions. The Ministry of Health launched standards for good 
pharmacy practice in both Puskesmas (Ministry of Health Indonesia, 2014b) and community 
pharmacy (Ministry of Health Indonesia, 2014c) described minimum standards for 
pharmaceutical services in both settings. 
Most patients treated in Puskesmas are likely to receive medicines at the end stage of the 
service cycle. Therefore, the pharmacy unit in Puskesmas plays an important role in ensuring the 
availability of pharmaceuticals and provision of pharmacy services. However, only 17.5% of 8,980 
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Puskesmas in Indonesia have a pharmacist-in-charge with the remainder employing either 
pharmacy assistants or non-pharmacy workers (Badan Penelitian Depkes RI, 2012). 
Community pharmacy in Indonesia is mostly situated in the private sector and ranges 
from small independent pharmacies to networks of large chain pharmacies. Ownership of 
pharmacy is not restricted to pharmacists however non-pharmacist owners must employ 
pharmacists prior to opening a pharmacy. As in many other countries, pharmacists hold the main 
authority and sole responsibility for the operation of community pharmacy such that the 
pharmacy requires the presence of pharmacists at all times. However, in practice, pharmacists’ 
absence is common – studies indicated only 14-23% pharmacists work on a full-time basis – with 
pharmacy services being delivered particularly by pharmacy assistants (Purwanti et al., 2004, 
Kartinah et al., 2015, Dominica et al., 2016). Community pharmacies derive their income from 
general pharmacy business and sales such as dispensing prescribed medicines, providing 
pharmacy and over-the counter medicines, and other healthcare and retail products 
(Hermansyah et al., 2012, Tri Murti Andayani and Satibi Satibi, 2016). However, under JKN, 
community pharmacies have the opportunity to be involved in two schemes: 1) as a pharmacy 
affiliated with the primary care network (Apotek Jejaring) and 2) as a pharmacy contracted by 
BPJS Health (Apotek Rujuk Balik). These two schemes provide different scope of services under 
different contractors, yet an individual community pharmacy can apply to become either or both.  
An affiliated pharmacy (Apotek Jejaring) is an independent community pharmacy which is 
partnered with a primary care provider such as GPs, Dentists or Clinics. Under this scheme, the 
community pharmacy is responsible for the supply of medicines prescribed by the primary care 
providers. They receive a portion of the capitation payment which is paid by BPJS Health through 
the provider. The level of payment may vary between affiliated pharmacies and is dependent on 
negotiation with the primary care provider as their contractor, but predominantly it covers the 
cost of medicines and a small fee for dispensing services.  
Unlike an affiliated pharmacy, a pharmacy which is contracted by BPJS Health (Apotek 
Rujuk Balik) provides more limited services. They are only responsible for providing 
pharmaceutical services for patients discharged from secondary care providers such as hospitals 
or specialists, by dispensing medicines for up to 30 days of supply for patients suffering certain 
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chronic diseases (BPJS Health, 2014). These pharmacies can claim for their provision of 
pharmaceuticals and services directly from BPJS Health.  
Despite the increasing number of community pharmacies formally engaged with JKN, they 
only represent a very small fraction of total community pharmacies in Indonesia (8.5% of 25,339 
community pharmacies) (BPJS Health, 2015, Ministry of Health Indonesia, 2017b). The large 
majority of pharmacies are operated independently outside JKN.  
 
Figure 8. Summary of the changes in community pharmacy sector after the introduction of 
JKN 
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Given this background, it is evident that the introduction of JKN affects the operation of 
community pharmacy and the professional practice of pharmacists in Indonesia. However, no 
studies to date have critically examined this impact. The objective of this study was to investigate 
perceptions of health care and pharmacy stakeholders about the impact of JKN on the role and 
practice of pharmacists and pharmacy in both public and private settings.  
 
METHODS 
A qualitative study design using in-depth semi structured interviews was developed to 
gain understanding of key stakeholders’ perceptions of the current practice of community 
pharmacy under JKN. Ethical approval was obtained from the authors institute prior to data 
collection. 
The study included a wide range of key stakeholders from practicing pharmacists in both 
community pharmacy and Puskesmas, peak pharmacy organizations, consumer groups, medical 
associations, BPJS Health to local and national health authorities. A purposive sampling strategy 
was undertaken to ensure maximum variation of the sample based on gender, role within 
pharmacy, and geographical representativeness. This study selected potential participants both 
from the most populous regions of Indonesia (e.g. Java island including Greater Jakarta, East Java 
and Yogyakarta) and the least developed regions outside Java island (e.g. Central Sulawesi). 
Contact with initial participants was obtained from the network of the researchers and experts 
in the community pharmacy sector. Participants were firstly contacted in person, via email or 
telephone, and informed about the research and the expected duration and the method of the 
interview. Candidates who declined to be interviewed were asked to nominate other potential 
candidates or were substituted by another participant with similar characteristics. Candidates 
who agreed to be interviewed were provided with the Participant Information Statement and 
consent form and their signed consent was obtained prior to the interview.  
The interviews were conducted either in Bahasa Indonesia or English, using face to face, 
over the telephone or video conference via Skype©. The study sample was expanded using the 
snowball method by asking each participant to nominate other suitable candidates. The 
interviews were continued until data saturation was reached in that no new themes emerged 
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from the data analysis. A sample size of at least 20-30 individuals is recommended to achieve 
theoretical saturation (Creswell, 2013). Despite the different backgrounds and work settings of 
the respondents, they can be considered a relatively homogenous group given their interest and 
affiliation to community pharmacy sector. 
The interview guide was developed from the review of the literature, exploration of 
media coverage on current issues and discussions within the research team. The interview guide 
in general comprised of a series of open ended questions regarding the healthcare system before 
and after the implementation of JKN, its impact on the current practice of community pharmacy, 
the challenges and enablers for practice within the current situation, strategies to advance 
practice and expectations for the future. Several pilot interviews were conducted to test and 
refine the interview materials and technique. 
The interviews were audio-recorded and subsequently transcribed verbatim. Interviews 
conducted in Indonesian were back-translated to English by the lead investigator and a proof-
reader was engaged to check the quality of the translation. The transcripts were iteratively 
checked against the audio recordings to ensure the completeness of information. NVivo 10 
software was used to assist the management of the data.  
 
Data analysis  
An inductive approach was used to analyse the data. Initially, several interview transcripts 
which were considered to have richness and “uniqueness” of information were used to build the 
coding framework. Each investigator was asked to structure their own coding framework. The 
framework was then discussed within the research team. In this way, a coding framework was 
developed based on consensus among the team to ensure the internal consistency of the 
findings. The analysis of the data continued along with data collection. Similar content from 
different transcripts was grouped together under sub-themes which were then aggregated into 
a main theme. A new theme was created if a selected content did not fit an existing theme. The 
progress of the analysis was reported in regular research team meetings to ensure reliability and 
to determine when data saturation occurred.  
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Theoretical Framework 
Changes in healthcare systems including in the community pharmacy sector have been 
variously described as complicated, dynamic, non-linear and often leading to unpredictable and 
unintended consequences (Hermansyah et al., 2017a). One approach that has been considered 
useful in elucidating the impact of change in health systems is to consider the impact in each level 
of the system; the individual or smallest element of the system (micro level), (e.g. patients, 
healthcare professionals or carers); the organization or group including hospitals, primary care 
providers, GPs network including community pharmacy network (meso level) and the larger 
healthcare system in which individuals, group and organization are embedded (macro level). 
Accordingly, the “planes of analysis” framework has been applied in the analysis of the 
data to explain the operation of changes in each level, zooming in to unique or specific effects, 
yet without losing the bigger picture in which the changes occur as a whole (zooming out). The 
“planes of analysis” approach was developed by Barbara Rogoff to investigate human 
interactions within their social context (Rogoff, 1997) and classifies  the interaction of individuals 
within their environment in a three-fold analytic distinction between individual, group and 
community. Rogoff described each plane as interdependent rather than isolated, with each plane 
able to be the focus of particular attention without losing the coherence and dynamic 
interdependence of the whole system. 
 
RESULTS 
A total of twenty-nine key stakeholders were interviewed from February to August 2016 (Table 
8). 
Table 8. Characteristics of participants (Indonesian studies 2) 
Characteristics n = 29 
Male 
Background of education: 
Pharmacists 
Non-pharmacists 
Background of profession: 
Practicing pharmacists 
Other health care professionals 
Academics and researchers 
Pharmacy managers 
Policy makers and administrators 
18 
 
25 
4 
 
10  
1 
4 
3 
8 
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Characteristics n = 29 
Consumer Representatives 
Insurance providers 
Province 
Greater Jakarta 
Yogyakarta 
East Java 
Central Sulawesi 
Metropolitan/Urban City 
Method of interview 
Face to face 
Over the phone 
Average duration of interview (min) 
1 
2 
 
8 
6 
14 
1 
23 
 
25 
4 
77 min (range 35-116 min) 
 
The impacts of JKN on community pharmacy practice were analysed in three planes, 
namely: (1) individual pharmacists (micro level); (2) organisational context of pharmacy (meso 
level) and (3) external pharmacy environment (macro level). Illustrative quotes for each level are 
provided in Table 9. 
 
Table 9. Illustrative quotes of participants reflecting the themes of the study 
Topic Puskesmas Community/retail Pharmacy 
Individual Pharmacists (micro level) 
Scope of practice “Pharmacist handles more than 150 
outpatients a day…Most of what they do 
now are technical tasks, such as taking 
records, managing stock, and writing 
reports. They have very little 
communication and consultation with 
patients; (P03_MP).  Too many 
administrative and technical tasks 
“We often go to Posyandu (Integrated 
Healthcare Post) for elderly people and 
educate the elderly about medicine use. We 
also teach patients for CBIA (Active 
Individual Learning Method) and Prolanis 
(Management of Chronic Diseases 
Program)” (P024_FP). Puskesmas 
pharmacists involved in health promotion 
and education 
“I think pharmacist’s role is inconsistent. If 
the pharmacy has full time pharmacists, 
they can give counselling especially for 
those with chronic diseases.  Some 
pharmacists even visit a patient 
house…they monitor drug use and check 
the random blood glucose levels…but there 
are lots who do nothing for the patient” 
(P029_MP). Variation in pharmacy services 
“We have a quality assurance department 
to ensure pharmaceutical services are 
correctly delivered. We have many tools for 
supervising and reporting whether services 
are correctly provided or not…” (P01_FP). 
Pharmacists role in chain pharmacy 
Perception of 
pharmacists 
“At Puskesmas, patients always ask for 
pharmacists. If I do not appear, they look 
for me…initially there was resistance from 
doctors. Now he often asks about dose, asks 
why this why that, therefore he often comes 
to pharmacy” (P024_FP). Puskesmas 
pharmacists viewed positively for their 
professional roles 
“…, usually I only meet the staff member 
who gives me the medicines. I know that 
person is not pharmacist but sometimes she 
consults with the pharmacist and go out 
with another recommendation” 
(P023_MNP). Pharmacists perceived as 
“invisible” healthcare professional in 
community pharmacy 
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Topic Puskesmas Community/retail Pharmacy 
“People consider pharmacy is a business 
that will survive in the present economy 
because everyone thinks people will always 
need medicine” (P02_FP). Pharmacy 
perceived as profitable business 
Remuneration “Pharmacists can breathe a bit more freely 
because they’re given fees…for service 
provision and promotion-prevention 
initiatives during health education 
sessions.” (P03_MP). Puskesmas 
pharmacists received increased 
remuneration 
“For the first five months, all the 
prescriptions from clinic went through to 
my pharmacy. But after five months, they 
didn't send patients at all. The clinic 
purchased medicines directly (from 
supplier) so the contract is useless, it is just 
a formality” (P013_MP). Community 
pharmacy experienced reduced 
profitability within affiliation of care 
 
Organisational Context of Pharmacy (meso level) 
Workforce 
availability 
“The reality is, many Puskesmas are lacking 
pharmacists. Therefore, Puskesmas employs 
non-pharmacists to assist in the 
services…Ironically in Yogya, the universities 
produce thousands of (pharmacists) 
graduates every year but it is quite difficult 
to recruit pharmacist. T” (P011_FP). 
Shortage of pharmacists in Puskesmas 
“There is no increase in the number of 
Puskesmas staff…I asked some pharmacists 
in Puskesmas and they said “I can’t do my 
other roles. I can’t give counselling, there is 
no time because I am tied up with 
dispensing” (P027_FP). Understaffing of 
pharmacists constraining pharmacy 
services.  
“Pharmaceutical practices at Puskesmas are 
mostly assisted by non-pharmaceutical 
personnel…” (P03_MP). Puskesmas 
pharmacists were often assisted by non-
pharmacy personnel 
“In franchise pharmacies ….they each have 
their own pharmacists; so no pharmacist no 
service. In independent pharmacies, most of 
them have pharmacists’ names listed but 
no actual person who goes by those names. 
Almost 90% of them commit this forgery” 
(P03_MP). Discrepancy of Pharmacists’ 
attendance in independent pharmacies 
and chain pharmacies 
“Every pharmacy has an actual real 
pharmacist. We have APA (First pharmacist-
pharmacist in charge) and 2 AA 
(technicians) and also APING (second 
pharmacist) who is also the vice” 
(P018_FNP). Pharmacists presence in chain 
pharmacy 
Position of 
pharmacy within 
the primary care 
system 
“Although the government regulation 
51/2009 article 21 point 2 clearly states 
that pharmacy practice and dispensing can 
only be conducted by pharmacists, ..not 
every Puskesmas has pharmacists. 
Government does not invest in recruiting 
more pharmacists although the mandate on 
the regulation is clear” (P029_MP). Lack of 
policy awareness to employ more 
pharmacists for Puskesmas 
“When everything goes on track, a doctor 
will prescribe and the pharmacy dispenses 
the medicines. However, within one year of 
JKN, there are pharmacies which receive all 
the prescriptions, there are others receiving 
none…there is a case of a GP affiliated with 
a pharmacy that is far from his practice. 
Due to the distance, patients don’t want to 
travel to the pharmacy, and they can’t 
obtain medicines from the closest 
pharmacy because it is not affiliated with 
the GP. GP then dispenses the medicine to 
the patient” (P05_MP). Violation to 
contract within affiliation of care 
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Topic Puskesmas Community/retail Pharmacy 
“Government said BPJS Health would only 
involve pharmacies that were previously 
affiliated with ASKES. They don’t require 
additional pharmacies. This statement has 
let us down, it’s as though we are denied an 
opportunity to serve in JKN” (P02_FP). 
Limited number of pharmacies contracted 
by BPJS Health 
 
External pharmacy environment (macro level) 
Access to 
pharmaceuticals 
“Due to limited stock, a pharmacist ends up having to save drugs; so they reduce the 
quantity from 10 to 5, for example if a geriatric patient is meant to receive 3 daily dosages 
for 2 weeks, they reduce it to one week” (P03_MP). Shortage of pharmaceuticals in 
Puskesmas 
“The main problem is pharmacy often runs out of medicines because there is delay on the 
procurement, in the e-catalogue purchasing…we can do nothing for the procurement 
because it is completely managed by the local health office…” (P024_FP). Problem of 
procurement in Puskesmas 
“Sometimes the price of medicine is not matched with e-catalogue price; sometimes the 
price is good but the item is not available; sometimes the price is good, the item is 
available but the supplier is troublesome. Sometimes, there is a new (pricing) regulation 
but its conditions differ so I often get confused” (P017_FP). Structural issues with e-
catalogue purchasing system 
Policy 
enforcement 
“On one hand, pharmacy is a legal setting, there is a pharmacist and they are restricted 
with so many regulations. But on the other hand, there are many people selling medicines 
in the drug stalls…many healthcare professionals also feel responsible for managing 
medicines” (P017_FP). Lack of law enforcement for illegal medicine selling 
“Many pharmacists caught behaving illegally turn out to be staff of [name of Indonesian 
authorities] which means they’re supposed to be the regulators…I feel ashamed seeing my 
colleagues like this” (P03_MP). Collusive enforcement 
Pharmacy 
competence and 
education 
“There is one school in [name of a city] which has 400 students…In public universities, we 
only receive 150 students and are already stretched with these numbers; how can they 
deliver courses to 400 students? A few days ago, I became evaluator for graduates’ 
competency examination and I was shocked. I said to them “you have to learn, there is 
plenty of time to learn because you actually know nothing about medicines in pharmacy, 
you don’t know about drugs” (P027_FP). Shortcoming in the graduate’s competence 
“Previously only a few good universities but now there are 120 universities offering B. 
Pharm and only 29 universities offering Apothecary [only faculties which are accredited A 
and B can offer an apothecary program]…the remainder of 29 universities have poor 
quality students…there is a wide discrepancy between education and practice …the 
education system does not create pharmacists to be pharmacists. The education system is 
overloaded with too many science courses” (P015_MP). Mismatch between education and 
practice 
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Individual Pharmacists (micro level) 
The improvement in the referral system has made Puskesmas a first choice for care 
among many patients and has resulted in a significant increase in patient visits. This in turn has 
increased the workload of all healthcare personnel including pharmacists. In contrast, despite 
their inclusion in the primary care network, pharmacists in community pharmacies have not 
experienced any substantial change in their daily activities. In fact, this study revealed that 
pharmacy affiliation to primary care has not translated into improvements in profitability or to 
any enhancement in their professional role.  
 
Scope of practice 
Participants highlighted the commonalities of pharmacists’ activities in Puskesmas and 
community pharmacy which are predominantly focused on the preparation and dispensing of 
pharmaceuticals. The increase in patient visits to Puskesmas has contributed to an increase in 
workload and reduced the opportunity for pharmacists to interact with patients. Nevertheless, 
JKN offers an opportunity for pharmacists to educate the community through health promotion 
and education programs, which take place in community settings. In contrast, pharmacists’ 
practice in the community pharmacy varies depending on the availability of a pharmacist and 
their individual interest in delivering care to patients. In general, participants reported a wide 
variation in services delivered by small independent pharmacies. Some pharmacies have been 
very proactive in providing services beyond dispensing such as home visits and continuous 
chronic disease monitoring. However, this is not the case among the majority of community 
pharmacies.  
 
Perceptions about pharmacists 
There were mixed perceptions of the pharmacist’s role and position under JKN. 
Pharmacists in Puskesmas were generally perceived more positively than their counterparts in 
community pharmacy. Participants mentioned that pharmacists in Puskesmas were often sought 
for consultation about medications by patients and doctors. In contrast, pharmacists in 
community pharmacy were described as an “invisible” healthcare professional because they only 
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appear outside the dispensary if there is a problem. This may also relate to the other findings in 
this study which highlight the common absence of a pharmacist on duty during pharmacy hours, 
which has become a significant issue over the past years. Moreover, the public often focuses on 
community pharmacy as a profit-making business which in turn degrades the professional image 
of pharmacists. 
 
Remuneration 
Some participants commented on the improved remuneration in Puskesmas under JKN. 
They receive more income due to increased patient numbers and additional payments for 
providing health promotion and education programs. In community pharmacy, JKN has provided 
no equivalent impact on remuneration. In fact, being an affiliated pharmacy has not necessarily 
been profitable for community pharmacists and pharmacy because the involved parties, 
especially GPs and clinics, tend to maximize their own share of the capitation fund by directly 
purchasing and dispensing their medicines, thereby bypassing community pharmacies. As a 
result, remuneration for affiliated pharmacies is decreasing as are the number of prescriptions 
dispensed. 
 
Organisational context of pharmacy (meso level) 
The introduction of JKN has brought in new ways of working for community pharmacies 
such as becoming an affiliated pharmacy or BPJS contracted pharmacy. Interestingly, the majority 
of participants in this study considered that JKN had not changed the practice of pharmacy 
because of some structural issues which discourage pharmacy involvement within primary care. 
In addition, traditional issues such as the poor record of pharmacists’ presence in the community 
pharmacy and shortages of pharmacists were identified by most participants as obstacles to 
effectively integrating pharmacies and pharmacists within the primary care network. The 
introduction of JKN has not been able to solve these structural problems.  
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Pharmacy workforce  
Pharmacy practice in Puskesmas has been hampered by a shortage of pharmacists. 
Despite the increasing workload under JKN, under-staffing of pharmacists has been responsible 
for their minimal involvement and contribution to patient care. Pharmacists in Puskesmas spend 
most of their time dispensing medications. They are even assisted by non-pharmacy personnel 
to cope with the overwhelming workload. This differs from practice in community pharmacy 
where the perennial issue of poor attendance of pharmacists in pharmacy persists and is 
unrelated to JKN. It was noted that the majority of pharmacies, particularly independent 
pharmacies, are operated without regular pharmacists’ attendance.  
 
Position of pharmacy within primary care  
Participants ascribed the lack of pharmacists in Puskesmas to be a consequence of 
governmental attitudes to the limited value of pharmacists in the health care team and a low 
level of priority attached to increasing pharmacy staff. As a result, recruitment of pharmacists in 
Puskesmas is quite limited. Some participants also noted that being an affiliated pharmacy had 
not benefited community pharmacy operation. Violation of the affiliation contract, particularly 
in the form of doctor dispensing, is widespread and has jeopardized the relationship of 
community pharmacy with both general practice and patients. In addition, BPJS Health as the 
sole payer for JKN only contracted pharmacies which previously worked with ASKES (prior version 
of BPJS Health) for providing discharge referral services, which in turn has limited the opportunity 
of other pharmacies to participate in JKN. 
 
External pharmacy environment (macro level) 
Most participants perceived that JKN has not had a significant impact on the industry and 
was not designed to resolve the ongoing issues such as shortages of pharmaceuticals and poor 
law enforcement. Participants implied an imperative to tackle these persistent issues as a 
precursor to the effective implementation of JKN in the macro level. 
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Access to pharmaceuticals 
 The increased demand for pharmaceuticals as a consequence of health coverage 
expansion has not been accompanied with sufficient availability of pharmaceuticals. Participants 
mentioned that Puskesmas often run out of medicines due to limited stock or delays in 
procurement. In addition, procurement of medicines is undertaken by the local health office 
leaving Puskesmas with limited options to buy medicines directly. Likewise, procurement of 
medicines in community pharmacy is also problematic because the e-catalogue system does not 
work efficiently. 
 
Policy enforcement 
 Participants expressed concern that despite the massive changes brought by JKN there 
has been no serious attempts through enforcement to tackle the problem of illegal selling of 
medicines. In fact, the introduction of JKN may have created another issue for policy 
enforcement; namely the illegal dispensing of medicines by some primary care providers 
especially GPs, notwithstanding their contractual obligations to a particular pharmacy. In 
addition, participants felt that the lack of enforcement may occur as a consequence of collusive 
relationships and conflicts of interest between practicing pharmacists and regulatory bodies. This 
may pose a dilemma for authorities who may be reluctant to impose punishment on their own 
close colleagues. 
 
Pharmacy education 
 There was an expectation among participants that pharmacists could play more prominent 
roles under JKN. In this sense, education and pharmacists’ competence are pivotal to enable 
pharmacists to engage with healthcare changes. However, some participants argued that 
pharmacists were not prepared for the changes. Participants were concerned with that while 
there are many universities offering pharmacy courses, only a few schools of pharmacy have 
received high level accreditation, indicating that the majority are not appropriately qualified to 
deliver pharmacy courses. This has influenced the quality and the competence of graduates of 
these programs. Moreover, the current curricula of pharmacy courses are very heavily weighted 
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towards science content with limited content addressing clinical knowledge and practice skills 
development. As a result, current pharmacy education does not produce enough pharmacists 
with the competencies required to deliver patient-centred pharmaceutical care in practice. 
 
DISCUSSION 
The impact of JKN on community pharmacy practice has highlighted three key issues. 
Firstly, the policy making process of JKN did not adequately consider the role and the professional 
practice of pharmacists especially in the community or retail pharmacy setting. Secondly, the 
implementation of the new funding model through capitation payments to primary care 
networks has set up unintended consequences and additional problems, leading to concerns 
about the ongoing viability of the community pharmacy network and pharmacists’ contribution. 
Thirdly, the changing system under JKN did not address key ongoing problems within the 
pharmacy sector such as shortages of pharmaceuticals and illegal selling of medicines. A helpful 
starting point to discuss these three points is to analyse the situation from the organizational 
level (meso level) with which the individual (micro level) and healthcare system (macro level) are 
interdependent. 
Within the era of JKN, Puskesmas appear to have been revitalized and currently play a 
central role in primary care services particularly as gatekeeper and referral for higher level care. 
This study found that the strengthening of Puskesmas has significantly increased pharmacists’ 
workloads and provided opportunities to deliver more value in patient care. However, the policy 
changes did not take into account the fact that Puskesmas were understaffed with pharmacists, 
and pharmaceutical supply is undependable. Likewise, the introduction of affiliated and BPJS 
contracted pharmacies was perceived to be an initiative to integrate community pharmacy within 
the primary care network. The scheme appeared to have encouraged a more multidisciplinary 
approach with the possibility for pharmacists to play a greater role in delivering pharmaceutical 
care to patients within the network. However, given the fact that only a very small portion of 
community pharmacies are funded under JKN, there are doubts as to whether the initiatives were 
genuinely intended to provide access to a more comprehensive multidisciplinary service. The 
small number of pharmacies engaged with JKN shows that despite the outcomes sought by the 
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policymakers (i.e. wider access to care), JKN has not adequately invested in the community 
pharmacy network and in the quality use of medicines.  
The introduction of capitation payments to GPs and other primary care networks under 
JKN was touted as a mechanism for constraining healthcare costs. Under a typical contract with 
BPJS Health, GPs and primary care networks received funding to be administered regardless of 
the amount of services provided. In addition, the capitation funding includes all professional 
services provided to patients spanning a range of providers from GPs to affiliated pharmacies. In 
this way, efficiency in healthcare funding and flexibility of delivery might be achieved as the new 
model shifted financial risk to providers, and providers have the freedom to address patients’ 
needs, respectively (Lagomarsino et al., 2012). Furthermore, contracting out private health care 
providers can improve access to primary care services as highlighted in several countries 
implementing universal healthcare coverage (Liu et al., 2008). On the one hand, the new funding 
model has meant that the role of pharmacists in the management of prescribed medication 
should become more important. This also means the role of the community pharmacy network 
should be even more critically important particularly to manage the supply and the 
administration of medicines to patients. However, in practice, shifting funding administration to 
healthcare providers has somewhat backfired for affiliated pharmacies. Firstly, in some cases, it 
has stimulated illegal doctor dispensing as the doctor controls the finance. It is appealing to 
doctors to protect their income by reducing other expenses such as for pharmaceutical services 
notwithstanding the violation of contractual obligations to the affiliated pharmacy. Secondly, as 
the control for negotiating the amount of payment shifted to providers, an affiliated pharmacy 
may receive varying amounts depending on their ability to negotiate with their contractor. 
Thirdly, it adds administrative complexity especially for GPs and may increase GPs workloads. 
Several studies have shown that only 13-35% of the capitation payment was used to pay for 
pharmacy and pharmacists’ contribution within the primary care network suggesting that 
community pharmacies may not always obtain a significant financial benefit from participation 
in JKN (Dewa Ayu Putu Satrya Dewi et al., 2015, Wasis Budiarto and Lusi Kristiana, 2015). Our 
findings suggest that changes in the funding model which were actually designed with good policy 
 163 
objectives, may have created some unintended and unanticipated distortion in the healthcare 
system which may be detrimental to the community pharmacy sector. 
Prior to JKN, the pharmacy sector in Indonesia was already tainted with ongoing issues 
such as shortages of pharmaceuticals, illegal selling of medicines and collusive enforcement. 
While the introduction of JKN provided momentum to improve healthcare delivery, it did not 
address these existing problems. As a result, these challenges continue to hamper achievement 
of JKN’s goals of providing quality care for patients. The community pharmacy network which is 
at the forefront of pharmaceutical services has been hardest hit by these challenges. Evidence 
from international studies emphasises that medicines are the crucial piece to promote health 
and achieve sustainable development under universal health coverage schemes (Wagner et al., 
2014, Wirtz et al., 2017). Therefore, access to essential medicines must be the priority in the 
healthcare needs of the population. Governments must ensure that the population receive safe, 
effective and affordable medicines and obtain the best outcome of the use of the medicines, and 
these are the domain of pharmacists and community pharmacy. This study concluded that 
Indonesian community pharmacy has the potential to address such demand, yet there is a need 
for thorough examination of the policies to recognize and develop solutions for the entrenched 
problems. 
The findings of this study, on the one hand, have confirmed the importance of 
pharmacists becoming members of the primary care team which is consistent with many 
international studies (Silcock et al., 2004, Bradley et al., 2008, Jorgenson et al., 2014, Dosea et 
al., 2017). With a health system moving towards an interprofessional approach to primary care, 
pharmacists may contribute value to the team by delivering comprehensive medication 
management, providing health education and drug information for team members, patients and 
populations, and enhancing system efficiencies through cost-effective and quality use of 
medicines (Dolovich et al., 2008). For this reason, implementation of JKN can be a lever to 
promote such integration. 
However, on the other hand, there are at least three paramount barriers to be overcome. 
Firstly, the common practice of operating a pharmacy without a pharmacist is a serious problem 
from both a legal and professional standpoint. Legally, the presence of a pharmacist is 
 164 
mandatory, and professionally the absence of a pharmacist leads to poorer quality care being 
delivered by non-pharmacists. We argue that this is a huge opportunity loss for the profession to 
advance to the next level. Pharmacists have been shown to be effective in improving patient 
outcomes through successful collaborative care within the healthcare team. For example, 
pharmacist-led intervention has been able to identify patients at risk of chronic diseases and 
improve detection of drug related problems (Avery et al., 2012, Tan et al., 2014, Tsuyuki et al., 
2016). Furthermore, the introduction of pharmacists into GP practice has inspired by the role 
development of clinical pharmacists in hospital settings has been increasingly advocated by 
pharmacy stakeholders to facilitate pharmacists’ accessibility and contribution to primary care 
services. Indeed, this is under trial in a number of countries including the UK, Canada and 
Australia (Farrell et al., 2008, Freeman et al., 2012, Tan et al., 2013).  
Secondly, the education of pharmacists has not kept pace with increasing clinical 
opportunities, meaning that Indonesian pharmacists currently have a limited clinical capacity to 
embrace expanded roles. Unfortunately, this is a common barrier to pharmacy role development 
in many developing countries and requires a significant overhaul of pharmacy education (Kheir 
et al., 2008, Miller and Goodman, 2016). Whilst improvement of pharmacists’ skills can be 
achieved through training and continuing professional development, the root cause lies in the 
University curricula which currently do not fully prepare pharmacists for clinical practice. For 
example, several Indonesian studies found poor communication skills among pharmacists, 
specifically in relation to gathering information about symptoms and providing drug information 
to patients. Critically, the pharmacists’ skills were not significantly different from those of other 
staff members. (Puspitasari et al., 2011, Brata et al., 2015). Although poor communication cannot 
be solely attributed to deficiencies in education, these studies nonetheless demonstrated the 
need for inclusion of increased social and clinical content in the pharmacy curriculum.  
Thirdly, the current legislation and regulation changes have not supported an expansion 
of pharmacists’ scope of practice. Our findings highlighted that community pharmacy practice in 
both Puskesmas and community pharmacy has not moved significantly beyond dispensing 
practice even after the introduction of JKN, albeit for different reasons. The current system 
indeed only focuses on pharmaceuticals and has not invested in developing pharmacy practice 
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and the pharmacy network. Internationally, changes in the community pharmacy system are not 
possible unless driven by policy. For example, the governments in UK, Australia, Canada and New 
Zealand have been proactive in implementing major reforms in community pharmacy through a 
number of policy documents (Ministry of Health New Zealand, 2007, Department of Health, 2008, 
Commonwealth of Australia and Pharmacy Guild of Australia, 2015), reports (Canadian 
Pharmacists Association, 2011, Australian National Audit Office, 2015) and reviews (Anderson et 
al., 2003, Department of Health and Pharmacy Guild of Australia, 2017) highlighting the current 
and future roles for community pharmacy. In addition, professional organisations have also 
published visions and roadmap documents outlining themes of change for community pharmacy 
within the primary care sector (Pharmaceutical Society of New Zealand, 2004, Canadian 
Pharmacists Association, 2008, Pharmacy Guild of Australia, 2010b). The changes in the policy 
and regulatory framework have been critical in creating opportunities for pharmacists to 
overcome classic barriers including lack of time, limited funding, low public expectation and 
inadequate pharmacists’ clinical competence which are found in the current study. This study 
strongly suggests that community pharmacy and professional bodies in Indonesia need to 
advocate compellingly for community pharmacy development as a means of promoting better 
healthcare outcomes. 
To our knowledge, this is the first study that has explored changes in the community 
pharmacy sector since the introduction of JKN in Indonesia. In addition, the framework applied 
in this study provides a way to focus on particular issues within the system without neglecting 
their mutual interdependence with other aspects. Nevertheless, there are several limitations to 
this study. Firstly, the views expressed by participants cannot be assumed to be representative 
of all stakeholders in community pharmacy and the health sector in Indonesia, and the purposive 
selection of the respondents may have limited the breadth of the perceptions presented. The 
respondents, however, were selected to represent a broad range of stakeholders working in or 
affiliated with the community pharmacy sector from which we sought complementary views 
regarding the operation of community pharmacy within the early years implementation of JKN. 
Secondly, this study only involved stakeholders residing in four provinces, raising the question 
whether the impact of JKN might be different in other provinces. However, JKN is a nationwide 
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program and delivery of the program is managed by BPJS Health at the national level irrespective 
of policy in the local area, therefore implementation of JKN is expected to be consistent across 
the country. Thirdly, taking into account policy decentralization in Indonesia, there is a caveat 
that there might be local policies regulating community pharmacy which have not been identified 
and included in this paper.  
 
CONCLUSION 
The introduction of JKN has brought changes in the way community pharmacy operates and 
pharmacists practice. Pharmacy and pharmacists in Puskesmas have experienced significant 
changes with respect to active participation in the delivery of pharmaceuticals, better 
remuneration and positive recognition for their roles. In contrast, despite changes which were 
introduced to integrate community pharmacies within the primary care network, community 
pharmacy continues to be hampered by structural and fundamental issues which in the main, do 
not relate to the policy changes provided by JKN. It is imperative for the profession of pharmacists 
and community pharmacy network to work to improve this situation.  
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6.2. Multiple policy approaches in improving community pharmacy practice: the 
case in Indonesia 
 
This section comprises the following publication: 
”Hermansyah, A., Sainsbury, E., & Krass, I. (2018). Multiple policy approaches in improving 
community pharmacy practice: the case in Indonesia. BMC Health Services Research. 18(1): 449. 
https://doi.org/10.1186/s12913-018-3258-8.” 
In this study, we reviewed a number of policy approaches aiming to improve Indonesian 
community pharmacy sector and evaluated their effectiveness based on the perspectives of 
pharmacy and healthcare stakeholders in Indonesia. This study was submitted in November 2017 
and available online in June 2018. The published version of the paper is presented in appendix 
10. 
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Multiple policy approaches in improving community pharmacy practice 
Andi Hermansyah, Erica Sainsbury, and Ines Krass 
 
Abstract 
Background 
Health reform has been on the main agenda in many countries with community pharmacy is 
increasingly gaining attention for contributing to healthcare improvement. In Indonesia, multiple 
policy approaches were introduced to improve community pharmacy practice yet no studies 
evaluated their effectiveness. Therefore, the first objective of this study was to identify and 
collate information on approaches intended to improve practice in Indonesian community 
pharmacy. The second objective was to examine the perceptions of key stakeholders in 
healthcare and community pharmacy about these approaches and the extent to which they have 
affected community pharmacists as a profession and resulted in practice change. 
Methods 
This study reviewed grey literatures related to community pharmacy policy approaches published 
by government and pharmacy organisations in Indonesia since 2009 and broadened with other 
relevant databases searches. In-depth semi structured interviews were also conducted to wide 
range of key stakeholders in pharmacy and healthcare between February and August 2016 to 
evaluate these policy approaches. 
Results 
Seventeen policy documents were identified with the majority published by Indonesian 
Pharmacists Association (8 documents) and Ministry of Health of Indonesia (6 documents). Most 
documents (15 documents), either updated or new policy, were published since 2014 indicating 
recent enthusiasm of pharmacy stakeholders to improve community pharmacy practice. Twenty-
nine key stakeholders participated in the study highlighted three main themes: barriers to 
effective policy implementation, expectation to policy changes and strategies to cope with policy 
 169 
challenges. Poor policy enforcement was commonly expressed by participants as a major 
challenge with participants expected a unified stakeholder vision to improve the current 
situation. Interestingly, despite lack of evidence for their outcome, participants mentioned 
several local initiatives claimed to improve practice of community pharmacy and pharmacists. 
Conclusion 
The introduction of policy initiatives within the past ten years has highlighted the enthusiasm of 
policy makers and pharmacy stakeholders to improve community pharmacy practice in 
Indonesia. However, some of the initiatives were conceived and enacted in a piecemeal, 
sometimes conflicting and uncoordinated way. Overall, fundamental and entrenched barriers to 
practice need to be overcome to create a more professional climate for the practice of pharmacy 
in Indonesia. 
Keywords 
Community pharmacy practice, policy approaches, policy evaluation, Indonesia 
Background 
Governments around the world face increasing pressure to provide effective, efficient 
and equitable healthcare services to their populations. Health reform has been on the main 
agenda in many countries with similar approaches applied to improve access to health care and 
the overall performance of the health system within the constraints of needing to curb the 
growth in health expenditure (Kruk and Freedman, 2008). One reform that is increasingly gaining 
attention is to incorporate community pharmacists within the broader healthcare system. 
Community pharmacists have the potential to not only contribute to improving patients’ 
outcomes through safe and effective use of drugs, but also to reduce the cost of healthcare by 
resolving drug related problems and promoting public health issues (Keen, 2009, Matzke, 2012).  
At the same time, the nature of pharmacy practice and community pharmacy is also 
changing. Over the past four decades, scholars have acknowledged a shift in community 
pharmacy practice beyond dispensing activities to provision of a broader array of health services 
(Mossialos et al., 2015). These simultaneous changes have resulted in complexity for all 
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stakeholders, requiring them to adapt to rapidly evolving circumstances. As a result, community 
pharmacists have consistently been challenged with pressures to meet professional standards, 
to provide patient-centred services, and to work with other healthcare professionals within the 
large healthcare system while keeping profitable in a highly-regulated environment.  
Policy makers also face complexity in attempting to encompass both an increase in the 
utilization of community pharmacists, while maintaining some control over the increasing health 
care budget. Policy documents since the Nuffield report in 1986 (Clucas, 1986), including more 
recent blue prints or road maps for the future of pharmacy, highlight the multiple approaches 
and strategies that have been directed towards harnessing a greater contribution by pharmacy 
to health care (Canadian Pharmacists Association, 2008, Pharmacy Guild of Australia, 2010b). The 
Nuffield report in particular has become a key stimulus to a movement for pharmacists’ role 
transition towards much more clinically and patient-focused role. The report concluded that “the 
pharmacy profession has a distinctive and indispensable contribution to make to health care that 
is capable of still further development” (Clucas, 1986). The years after the report was published 
showed a significant progress in the attempts to extend pharmacists’ roles including the famous 
pharmaceutical care concept described by Hepler and Strand (Hepler, 2004).  
Despite the growing number of initiatives to improve the practice of community 
pharmacy, the literature on policy evaluation is sparse. In addition, much less attention has been 
directed to determining how stakeholders in community pharmacy perceive the impact of these 
policy statements and initiatives on pharmacy practice. Furthermore, policy development in 
expanding the role of community pharmacists has not always been supported by relevant policy 
evidence which in turn has raised questions about the extent to which these policies have been 
appropriate, effective and sustainable particularly for stakeholders in community pharmacy 
(Mossialos et al., 2015). 
The lack of policy evaluation has been common in both developed and developing 
countries. However, the situation is arguably more acute in developing countries. There is limited 
capacity among stakeholders, particularly government, to fund and produce quality research 
which examines the practice of community pharmacists and pharmacy. Furthermore, regulatory 
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evaluation is also constrained by a myriad of factors encompassing limited government staff, 
small budgets, fragmented delivery of healthcare and pharmacy practice, poor control over the 
regulation and the absence of a regulatory evaluation framework which may not be the case in 
developed countries. Thus, there is an urgent need to evaluate the impact of various policy or 
program initiatives designed to influence pharmacy practice in developing countries. This paper 
aims to address this using Indonesian community pharmacy as a case study.  
The Indonesian health system has undergone significant changes over the past decade 
including the establishment of a decentralization policy in 2001 and the recent introduction of 
universal healthcare coverage (JKN) in 2014. With respect to community pharmacy, multiple 
approaches and regulations intended to advance the practice of community pharmacy have been 
enacted within the past decade. These approaches include legislation, incentivization policies, 
campaigns and education. Prior to critically examining the effectiveness of these multiple 
approaches, it is important to contextualize the policy and practice environment in Indonesia in 
order to understand the nature of the system and challenges to implementation. 
Policy environment of Indonesian community pharmacy sector 
Community pharmacy practice in Indonesia is regulated under the Ministry of Health 
(MoH) at the national level, and the Local Health Department office as the extension of MoH at 
the provincial and district (Kabupaten/Kota) level. In addition, the 2001 decentralization policy 
transferred the responsibility for services delivery and fiscal autonomy, including health, from 
the central government to the local government. At the same time, the operation of community 
pharmacy is supervised by BPOM (Indonesia National Agency of Drug and Food Control) as the 
government agency responsible for the administration and control of food and drugs. Further, 
the authority for overseeing drugs and therapeutic products in the market is also part of the duty 
of the police. The police with or without BPOM often conduct surprise inspections of healthcare 
facilities including pharmacy particularly when they suspect illegal activities such as selling of 
prescribed medicines without a doctor’s prescription, selling of expired medicines and selling of 
unlicensed medicines. Importantly, it should be noted that there is no legal restriction preventing 
pharmacists who work in regulatory or supervisory bodies from also practicing in community 
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pharmacy, despite the potential for a conflict of interest to arise. However, the chairman of 
BPOM recently issued a directive to BPOM staff prohibiting them from working in any facilities 
under the supervision of BPOM including community pharmacy (BPOM Indonesia, 2016). As a 
result, the majority of the staff have resigned from their employment in any pharmacy settings 
in order to retain their position in BPOM (BPOM Indonesia, 2017). 
From the professional practice point of view, the Indonesian Pharmacists Association (IAI) 
is the sole peak pharmacy organization representing pharmacists, with the main role being to 
maintain pharmacists’ competence, advocate for pharmacists and advance the profession. 
Within the IAI, there are several peer groups based on work setting and professional interest 
including a group of community pharmacists (HISFARMA) which is responsible for coordinating 
and advancing the practice of pharmacists in the community as defined by IAI. Another important 
body is the Indonesian Pharmaceutical Association (GP Farmasi) whose membership includes 
business owners in the pharmacy sector comprising pharmaceutical industries, wholesalers, 
pharmacies and retail drug outlets. Since the ownership of community pharmacy in Indonesia is 
not restricted to pharmacists, members of GP Farmasi representing community pharmacy 
include non-pharmacists. Responding to the introduction of JKN in 2014, both IAI and GP Farmasi 
worked together to establish a community pharmacy association (ASAPIN) as an organization to 
represent the whole community pharmacy network in the negotiation of tariffs within JKN. 
However, despite its vital mission, the MoH to date has not included ASAPIN in the legislation of 
healthcare facilities negotiating for JKN. Consequently, pharmacists and the community 
pharmacy network are underrepresented in the JKN payment scheme. Another organization 
which has a role in determining the quality and competence of pharmacists is the National 
Pharmacy Board (KFN) which manages the registration of pharmacists and oversees the 
Association of Schools of Pharmacy (APTFI) which deals with the development of pharmacy 
education curricula and competence of graduates. 
The foregoing discussion has highlighted the complexity of the management and 
oversight of community pharmacy and pharmacists in Indonesia. Multiple regulators and 
professional organisations play overlapping, and sometimes conflicting roles in influencing the 
practice of pharmacy, and the way it is evolving. Each of these institutions has advocated top-
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down policies, standards and legislation which are parallel to the mission of other institutions. 
Therefore, the first objective of the current study was to identify and collate information on 
initiatives intended to improve practice in Indonesian community pharmacy. The second 
objective was to examine the perceptions of key stakeholders in community pharmacy about the 
multiple approaches advocated by the government and pharmacy organisations, and the extent 
to which these approaches have affected community pharmacists as a profession and resulted in 
practice change. 
Methods 
Document collection and analysis 
We searched websites of relevant government departments and professional 
organisations in particular the websites of the Ministry of Health of Indonesia, BPOM, IAI, GP 
Farmasi, APTFI and KFN. These websites were searched for relevant information, reference 
publications and databases describing pharmacists’ role and responsibility and community 
pharmacy practice. The search process was broadened to include grey literature obtained from 
databases of other government institutions. As most government documents and professional 
organizations’ policies were published in the Indonesian language, this study used the following 
combination of search terms in the Indonesian language: apotek OR apotik OR farmasi (meaning: 
community pharmacy); apoteker OR farmasis OR tenaga AND farmasi (meaning: pharmacists); 
praktek OR praktik OR pekerjaan OR pelayanan AND farmasi (meaning: pharmacy practice or 
pharmacy services); kebijakan OR peraturan OR hukum OR keputusan OR standar OR pedoman 
OR rencana AND farmasi (meaning: legislative framework in pharmacy); peran OR kinerja OR 
tanggungjawab AND apoteker AND apotek OR apotik (roles and responsibility of pharmacists or 
pharmacy). In addition to the web search, investigators contacted key personnel in government 
agencies and professional organizations for further information/clarification and to request 
copies of relevant documents if necessary. This study purposively selected grey literature, and 
used an exploratory approach because there has been limited research published in the peer 
reviewed literature, in the field of policy evaluation of community pharmacy practice in 
Indonesia. 
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In terms of the inclusion and exclusion criteria, this study only included formal and legal 
documents from official authorities such as policy documents, legislative frameworks, standards 
and directives. We limited the search for documents published in the Indonesian language from 
2009 onwards. The 2009 start date was selected because this was the year in which Health Law 
2009 was issued. It was the first law accommodating the practice of pharmacy in Indonesia 
(article 108). The implication of this law was the enactment of the Pharmacy Practice Act 2009 
which became the main policy framework underpinning the practice of pharmacy including 
community pharmacy in Indonesia. Details of literatures search and screening process are shown 
in Figure 10. 
The study retrieved 60 documents, of which 17 contained relevant information on policies 
and strategies aimed to improve pharmacy practice in Indonesia. The selected documents were 
reviewed based on their objectives and relevance to the support of community pharmacy 
practice either by: (1) providing a legal framework for practice, (2) reducing barriers in practice, 
(3) increasing the role and recognition of pharmacists, (4) promoting the uptake of pharmacy 
services, (5) contributing to the sustainability of community pharmacy operation. The criteria 
used to review the documents were developed from the recommendations of several systematic 
reviews reporting on pharmacy practice in developing countries (Lowe and Montagu, 2009, 
Smith, 2009a, Smith, 2009b, Miller and Goodman, 2016, Hermansyah et al., 2016b).  
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Figure 9. Flow diagram of articles selection process using PRISMA 
Stakeholder collection and analysis 
Between February and August 2016, in-depth semi structured interviews were conducted 
with a wide range of key stakeholders in pharmacy and healthcare representing community 
pharmacists, physicians, peak pharmacy and medical organisations, insurance companies, 
consumer group associations and governments in the local and national setting. Ethics approval 
was obtained from the authors institute prior to data collection. Purposive sampling was used to 
select the initial respondents and expanded using the snowball method. Candidates who agreed 
to participate were required to provide signed consent prior to the interview. The respondents 
were asked questions primarily focused on the current situation of healthcare and the 
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community pharmacy sector, approaches introduced by governments and pharmacy associations 
to cope with the changes and challenges of the current situation, their expectations and 
strategies to adapt to the challenges. All interviews were audio-recorded and transcribed 
verbatim. Content analysis was performed to analyse the findings. Each investigator initially 
developed a coding framework from some of the transcripts which were considered unique and 
“rich of information”. Subsequently, the main coding framework which included themes and sub-
themes was mutually agreed. The interviews were continued until data saturation was achieved. 
NVivo 10 was used to assist data management. 
Results 
Collation of documents 
Of the 17 documents which were eligible for inclusion, the majority were published by IAI 
(8 documents) and the Ministry of Health of Indonesia (6 documents). The remainder were issued 
by KFN (1 document), the Presidential office (1 document) and a group of organisations – IAI, 
APTFI and KFN (1 document). According to the hierarchy of legislation in Indonesia, the 
Presidential Act is the highest level of legislation, followed by Ministry of Health decrees, and 
professional organizations’ regulations as subsidiary legislation, respectively. This means most of 
the approaches collated in this study were applied in a narrow setting and have limited legislative 
power. For instance, the initiative to set minimum remuneration for pharmacists enacted by 
several branches of IAI was only applicable to pharmacists within the region covered by the 
branches. 
Most documents concerned approaches which were commenced from 2014 onwards (15 
documents). However, some of these were updated versions of previous legislation (6 
documents). This means that some approaches have changed over a long period of time. For 
example, the Community Pharmacy Decree was first introduced in 1953, and subsequently 
revised in 1965, 1980, 1993, 2002 and currently in 2017. It is also important to note that some 
approaches have certain degree of overlap with other approaches. For example, drug use 
campaign programs such as Gema Cermat, Dagusibu and GKSO were in essence devised to 
convey similar public educational messages surrounding self-management and basic education 
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on the use of medicines although they were initiated by different organisations. As a result, 
community pharmacists may undertake one single public education activity and offer it as part 
of all three programs, thus gaining multiple CPD credits for the same activity. Some approaches 
also form part of the process of other policy initiatives. For example, pharmacists who wish to 
renew their practice license must deliver practice as defined by standard of pharmacy practice 
and pharmacy services, participate in CPD programs and collect a certain amount of credits. Table 
10 is a compilation of the multiple approaches advocated by government and professional 
organisations in Indonesia.  
Table 10. Multiple approaches to improve community pharmacy operation and practice of 
pharmacists 
Approaches (initiating bodies, 
year introduced/updated); 
References 
Objective Process to achieve objective 
Type of approaches: Incentivization 
Minimum rates for 
pharmacists’ remuneration 
(branches of IAIa, introduced in 
2015); 
(Ikatan Apoteker Indonesia-
East Java, 2015, Ikatan 
Apoteker Indonesia-South 
Sumatera, 2015, Ikatan 
Apoteker Indonesia-Jakarta, 
2016) 
Ensuring 
pharmacists receive 
adequate and fair 
income 
Pharmacy employer must pay employee pharmacists 
based on the minimum rate. The amount and 
composition of the income must be validated by IAI 
and become the consideration for issuing 
recommendation letter for pharmacists to practice 
Payment for pharmacy services 
(MoH, updated in 2016); 
(Ministry of Health Indonesia, 
2016d) 
Reimbursing 
pharmaceuticals and 
incentives for 
pharmacy services 
Community pharmacies working under the JKNb 
scheme receive payment for dispensing prescribed 
medicines and incentives for delivering pharmacy 
services. The method for distribution, the amount and 
the coverage of the payment can vary depending on 
the classification of pharmacy (e.g. pharmacy 
affiliated with primary care providers, contracted by 
BPJS Health or both). 
Type of approaches: Campaigns and communication 
Gema Cermat - Community 
awareness campaign in using 
medicines (MoH, introduced in 
2015); 
(Ministry of Health Indonesia, 
2015) 
Raising peoples’ 
awareness on 
proper use of 
medicines 
National campaign including workshops, group 
discussions and distribution of information (e.g. 
books, posters, modules and audio-videos). Certain 
pharmacies and community pharmacists are invited to 
deliver public education such as talks, lectures and 
community outreach. 
Dagusibu - Pharmacists 
campaign on self-management 
of medicines (IAI, introduced in 
2014); 
Public education on 
self-management of 
medicines 
Community pharmacies are encouraged to provide 
educational materials such as leaflets, brochures and 
posters in the pharmacy. With the phrase “Ask your 
pharmacist”, consumers are educated to obtain, use, 
store and dispose of medicines as advised by 
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Approaches (initiating bodies, 
year introduced/updated); 
References 
Objective Process to achieve objective 
(Ikatan Apoteker Indonesia, 
2014a) 
pharmacists. Participating pharmacists are rewarded 
with credits (SKPc) for license renewal. 
Gerakan Keluarga Sadar Obat 
(GKSO) - Campaign for raising 
family awareness in using 
medicines (IAI, introduced in 
2014); 
(Ikatan Apoteker Indonesia, 
2014a) 
Raising family 
awareness on self-
management of 
medicines 
Run in tandem with Dagusibu program, GKSO targets 
the health of family through lectures, simulation and 
role play, CBIAd (active individual learning), training of 
pharmacists as trainers and recruitment of family 
members as health advocates. Topics for learning also 
include safe and proper use of cosmetics, food, 
beverages and narcotics/psychotropics. Participating 
pharmacists are rewarded with credits (SKP) to count 
towards their license renewal. 
Image building of pharmacists 
(IAI, introduced in 2014); 
(Ikatan Apoteker Indonesia, 
2014e) 
Increasing 
pharmacists’ 
recognition 
Pharmacists are encouraged to wear pharmacist coat 
and name badge during practice in community 
pharmacy. The pharmacy must also display a sign 
board showing pharmacists’ names and practice 
hours. Credits (SKP) are awarded for pharmacist’s 
license renewal. 
 
 
Type of approaches: Standard, policy and regulation 
Registration, certification and 
licensure of pharmacists (MoH, 
updated in 2016); 
(Ministry of Health Indonesia, 
2016c) 
Ensuring that 
pharmacists practice 
in a professional and 
ethical manner 
Community pharmacists are required to obtain four 
legal documents to practice; certificate of 
competence and recommendation letter issued by IAI, 
registration letter (STRAe) from the National Board of 
Pharmacy (KFNf) and license to practice (SIPAg) from 
the MoH.  
In order to obtain certificate of competence, new 
graduate pharmacists must pass a competency exam 
while registered pharmacists must collect a quantum 
amount of credits (SKP) during each five years of 
practice. The certificate is a pre-requisite to obtain 
STRA. Once the STRA has been issued, pharmacists 
must apply for a recommendation letter. The letter of 
recommendation and STRA are part of the application 
for SIPA. The license is valid for five years and a 
pharmacist can practice in up to three different 
pharmacies. Prior to expiration, pharmacists must 
renew the license by firstly obtaining a new certificate 
of competence. The updated regulation has allowed 
pharmacists to practice in up to three community 
pharmacies. 
Collection of SKP (IAI, 
introduced in 2014); 
(Komite Farmasi Nasional, 
2014) 
Indicator for 
pharmacists’ 
participation in 
practice 
Pharmacists must collect minimum of 150 credits 
(SKP) during each five years of practice as a 
requirement for license renewal. In general, the 
credits are distributed to participation in continuing 
education program (e.g. CPD, workshop and peer 
group discussion) minimum 60 credits, undertaking 
professional practice (indicated by attendance report 
and record of providing services) minimum 60 credits, 
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Approaches (initiating bodies, 
year introduced/updated); 
References 
Objective Process to achieve objective 
involvement in community outreach program (e.g. 
public campaign) minimum 7.5 credits, and voluntary 
participation in publishing ideas and knowledge 
development (e.g. conducting research, writing book 
and article) maximum 37.5 credits. 
Pharmacy Practice Act (MoH, 
introduced in 2009); 
(Government of Indonesia, 
2009) 
Legislating pharmacy 
practice 
The Act which underpins pharmacy practice in 
Indonesia regulates different settings of pharmacy 
practice from manufacturing and distribution to 
service provision including community pharmacy. It 
also classifies the pharmacy workforce into two main 
groups: pharmacists and pharmacy technicians, with 
their designated responsibilities. The act legislates 
that pharmacy practice can only be conducted under 
responsibility and supervision of pharmacists. 
Standard of pharmacy services 
in community pharmacy (MoH, 
updated in 2016); 
(Ministry of Health Indonesia, 
2016e) 
Setting minimum 
services delivered in 
pharmacy 
The standard describes two main roles conducted by 
community pharmacists: management of 
pharmaceuticals and healthcare devices, and 
provision of clinical pharmacy services. The first role 
relates to the management cycle of pharmacy items 
from planning and procurement to disposal, record 
keeping and reporting. The second role covers 
pharmacy services which should be provided by 
pharmacists such as prescription assessment, 
dispensing, drug information, counselling, home 
pharmacy care, drug use monitoring and surveillance 
for adverse drug reactions. 
Standard for pharmacy practice 
(IAI, introduced in 2014); 
(Ikatan Apoteker Indonesia, 
2014c) 
Developing standard 
for pharmacists to 
practice 
The standard consists of 9 (nine) key activities which 
must be conducted during practice: (1) providing 
fundamental pharmacy practice, (2) conducting drug 
assessment and review, (3) dispensing medicines and 
health devices, (4) compounding dosage form (specific 
to pharmacists in the pharmaceutical industries), (5) 
providing drug information and counselling, (6) 
delivering health promotion, (7) management of 
pharmaceuticals and health devices, (8) management 
of pharmacy settings, (9) maintaining skills and 
competencies. 
The standard sets minimum activities for pharmacists 
in the practice site. 
Standard competency of 
pharmacists (IAI-APTFI-KFN, 
updated in 2016); 
(Ikatan Apoteker Indonesia et 
al., 2016) 
Setting the 
minimum 
competency of 
practicing 
pharmacists 
The standard comprises 10 (ten) main competencies 
which means pharmacists must be competent in: (1) 
delivering the practice of pharmacy in an ethical and 
professional manner, (2) optimising the use of 
medicines, (3) dispensing medicines and health 
devices, (4) providing information about the 
medicines and health devices, (5) mastering skills and 
knowledge of formulation and production of 
pharmaceuticals, (6) contributing to preventive and 
promotive community health, (7) management of 
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Approaches (initiating bodies, 
year introduced/updated); 
References 
Objective Process to achieve objective 
medicines and health devices, (8) delivering effective 
communication, (9) active involvement in the 
organization and maintaining inter-personal 
relationship, (10) striving to improve competency. 
Graduate pharmacists must meet the minimum 
competency as defined by the standard. 
Community pharmacy Decree 
(MoH, updated in 2017); 
(Ministry of Health Indonesia, 
2017a) 
Establishing 
regulation for 
community 
pharmacy operation 
The decree is the main framework regulating the 
opening, license issuance and operation of community 
pharmacy. A community pharmacy can be opened by 
pharmacists with or without investment from other 
parties (individual, group or organization). An 
approval from the MoH, which can be delegated to 
the district government, is required before opening a 
pharmacy. In addition, district government has the 
right to manage the location and distribution of 
community pharmacy. Premises, facilities, and 
equipment of the pharmacy must meet certain 
standards and be approved prior to operation. The 
practice of pharmacy must comply with the regulation 
as similarly stated in the Pharmacy Practice Act and 
Standard of Pharmacy Services in Community 
Pharmacy. Each pharmacy must have a First-
pharmacist as pharmacist in-charge for the operation 
and practice of pharmacy who can be assisted by 
other pharmacists (as second-pharmacist), technician 
and/or administrative employee. 
 
Type of approaches: education and training 
Continuing Professional 
Development (IAI, introduced 
in 2014); 
(Ikatan Apoteker Indonesia, 
2014d) 
Improving 
pharmacists’ 
competence and 
knowledge 
Pharmacists are encouraged to participate in CPD 
program. Pharmacists undertaking CPD program are 
rewarded with credits (SKP) which are essential for 
license renewal 
Pharmacists Competency 
Examination (KFN, updated in 
2016); 
(Ministry of Health Indonesia, 
2011, Ikatan Apoteker 
Indonesia, 2016) 
Entrance to practice 
as pharmacists 
Graduate pharmacists must undertake the 
Competency Examination comprising a Computer 
Based Test (CBT) followed by an Objective Structured 
Clinical Examination (OSCE). The exam assesses 
pharmacists’ knowledge, cognitive skills and 
professional, legal and ethical decision-making. An 
alternative was given for pharmacists who graduated 
before 2011 who did not have a certificate of 
competence to undertake the OSCE (for pharmacists 
working in community pharmacy and hospital) or 
OSPE (Objective Structured Pharmaceutical 
Examination) for pharmacists working in 
pharmaceutical industries and wholesalers. 
aIkatan Apoteker Indonesia; bJaminan Kesehatan Nasional = Universal healthcare coverage program; cSatuan Kredit Partisipasi; 
dCara Belajar Insan Aktif; eSurat Tanda Registrasi Apoteker; fKomite Farmasi Nasional; gSurat Ijin Praktek Apoteker. 
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Stakeholders’ interview 
Twenty-nine key stakeholders took part in the interviews between February and August 
2016. Characteristics of the interview participants are provided in Table 11. 
Table 11. Characteristics of participants (Indonesian studies 2) 
Characteristics n = 29 
Male 
Educational background 
Pharmacists 
Non-pharmacists 
Professional background 
Practicing pharmacists 
Other health care professionals 
Academics and researchers 
Pharmacy managers 
Policy makers and administrators 
Consumer Representatives 
Insurance providers 
Province 
Greater Jakarta 
Yogyakarta 
East Java 
Central Sulawesi 
Metropolitan/Urban City 
Method of interview 
Face to face 
Over the phone 
Average duration of interview (min) 
18 
 
25 
4 
 
10 
1 
4 
3 
8 
1 
2 
 
8 
6 
14 
1 
23 
 
25 
4 
77 min (range 35-116 min) 
 
Three main themes emerged in the analysis of the data: barriers to effective 
implementation approaches, expectation for policy changes and coping strategies for the 
challenges of existing initiatives. Illustrative quotes of the findings are described in table 12. 
Barriers to effective implementation 
Several barriers to implementation approaches were identified by the participants. One 
commonly expressed barrier is the lack of enforcement. Participants believed the approaches 
were created with good intention, yet the practice was not strongly encouraged or enforced. 
When there is a discrepancy between policies and practice, no firm response has been taken by 
the authorities to discipline the poor practice. The poor enforcement is also associated with a 
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lack of trust in the integrity of the regulatory and supervisory bodies, since individuals in these 
institutions who violate the policies have not been sanctioned for their misconduct. However, on 
the other hand, professional pharmacy organizations have also been subject to criticism and 
participants expressed mixed responses towards them. Several participants criticized them as 
being unable to advocate the interest of community pharmacists, and instead seeking their own 
power and financial gain. Others mentioned that the establishment of peer groups within the 
professional organisation is useful although they are still limited in their influence.  
One participant who worked for a multi-national chain pharmacy company expressed her 
concern regarding the lack of accountability around policy implementation. The operation of 
community pharmacy has been influenced by a number of policies created and supervised by 
several different organisations. While community pharmacy has traditionally operated under a 
highly-regulated environment, the involvement of additional organisations in the monitoring and 
execution of the policies has increased the complexity and diluted the impact of policy decisions. 
In addition, government which should play a role in facilitating policy implementation has been 
viewed by some participants as being lacking in the power to play such role. They highlighted 
several policies which have been created but not enforced, due to a lack of empowerment and 
support for the practice. 
Scepticism about the impact of these approaches was also expressed by the participants 
in relation to the imperative for pharmacists to participate in the CPD program. One respondent 
suggested that participation in CPD is merely seen as a way to collect the required credits (SKP) 
and not as a means to improve or develop as a professional. She referred to the opinion of some 
pharmacists who viewed CPD as a gathering or reunion of colleagues and peers. They attended 
CPD to gain sufficient SKP to renew their license without thinking about the essence of CPD to 
develop pharmacists’ knowledge. 
Expectation for policy changes 
While respondents acknowledged that several policies were still ongoing, there was a 
general consensus that overall insufficient progress has been made. Therefore, they expected 
further changes to improve the situation. One major expectation is to have a unified vision of 
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stakeholders in pharmacy. One participant highlighted the need for collective responsibility to 
create a vision for the improvement of community pharmacy practice in Indonesia. She urged 
key stakeholders such as universities, governments and IAI to sit around a table together and 
create a plan for the advancement of pharmacists. Other participants argued that collection of 
evidence in community pharmacy is necessary as it is a means to showcase pharmacists’ 
contribution to the healthcare system. One participant regretted the fact that no evidence can 
be provided to show pharmacists’ impact. However, another participant perceived that it is 
impossible to collect evidence as only a few pharmacists practice regularly. Therefore, some 
participants highlighted the need to duplicate good practice in some pharmacies and amplify it 
into a policy action. These participants argued that community pharmacy is lacking good role 
models, and therefore policy supporting the dissemination of good model practice is required. 
The majority of respondents anticipated the need for major changes in the pharmacy 
curricula which are currently still focused on the pharmaceutical sciences. Participants 
considered that pharmacists are not ready to interact with the patients as they are trained 
predominantly in laboratory work, and lack exposure to practical and clinical experience. This 
was linked to poor pharmacists’ attendance in the pharmacy. Some participants highlighted the 
need for a supportive policy that is intended to make pharmacists and pharmacy as a first point 
of contact and venue for resolving patients’ problem with medication. 
Strategies initiated by locals to cope with existing challenges 
Despite a number of centrally administered approaches designed to regulate community 
pharmacy practice, interestingly, some respondents mentioned several local initiatives, led by 
individuals or local associations, independent of the government and national organization 
agendas. They claimed that these programs were able to support the role development of 
community pharmacists, and aimed to increase pharmacists’ participation and presence in 
community pharmacy. 
For instance, the IAI and local health office in Yogyakarta have implemented a star rating 
system to measure the quality and performance of a community pharmacy. Community 
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pharmacies with the best performance are awarded 4 stars, with the lowest receiving 1 star. This 
was perceived as an incentive for community pharmacies to increase their performance.  
Pharmacy leaders in some regions of East Java have encouraged new pharmacist 
graduates to open a pharmacy by offering assistance in the procurement of medicines and 
management of pharmacy. Participants viewed such support as essential to help new 
pharmacists start professional practice and become competent in the business of pharmacy. 
Some pharmacy leaders in Jakarta have developed a collective network to help pharmacists in 
managing their medicines stocks. They also use the network to empower each other, thus 
pharmacists have a channel to communicate about their practice. In a region outside Java, the 
leaders of IAI used an interpersonal approach and their leadership to motivate pharmacists to 
practice while advocating the interests of community pharmacists. In this way, participants 
expressed that pharmacists are much confident and feel secure as they know that they are 
supported by their leaders. In addition, participants mentioned the importance of a leader in 
pharmacy to become a role model for their colleagues, and avoiding unscrupulous and collusive 
practice. 
One participant representing a chain pharmacy business used a quality assurance system 
to maintain the quality of pharmacy services delivered in her pharmacy and to improve the skills 
and knowledge of employee pharmacists. 
Table 12. Illustrative quotes of the findings 
Topic Quotes 
Challenges to policy 
implementation 
“When we look at policy changes there are too many hands involved…as you go every 
layer decisions get diluted, accountability gets diluted, execution gets diluted so there is 
no strong line for accountability. Who is truly accountable for change of healthcare in 
Indonesia? Is it the Ministry of health or the police in the region? and you also have very 
regional influences. You have the region of governance“ (P018_FNP). Lack of 
accountability in the implementation 
“We do have policies, standards, regulations on one hand but on the other hand…we see 
with our eyes that there is no pharmacist (in pharmacy)…There is no one who pushes the 
policy, facilitates the policy which means that there is a lack of facilitation especially from 
government to ensure that the policies are running well. They don’t support it so it is up to 
pharmacy…” (P029_MP). Lack of facilitation from government 
“We’re only undertaking CPD because we have no choice, it’s not because we want to 
improve our competence. It’s just because we have the awareness that (collecting) SKP is 
a prerequisite to continue practicing pharmacy. That is why CPDs and seminars are being 
treated like reunions…Whether they (pharmacists) practice is another matter. They say, “I 
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Topic Quotes 
get SKP so I can extend my STRA (registration), I need STRA to get my SIPA (license), and 
no SIPA means no salary. Whether I show up for work is my business with my employer; 
IAI should mind their own business” (P01_FP). Sceptical to the impact of the policies 
“We always look for scapegoats when we do something wrong…The popular excuse when 
committing violations has been “I can do this because others have done the same and 
they don’t get punished”. When violations go unpunished, people end up considering 
these violations as normal” (P02_FP). Lack of enforcement for successful policy 
implementation  
“Many pharmacists from [name of government bodies] work in pharmacy. I ask them to 
quit but it is difficult to ask people to become good role models in Indonesia…I ask them to 
be consistent, consistent with their own policies (they created). It is really shameful if 
individuals from [name of government bodies] should have been present in the pharmacy 
three times in a week but it turns out he comes only once in every three weeks. It is 
embarrassing” (P027_FP). 
“[name of professional organization] cannot become agents of change because there are 
many people with various interests in [name of professional organization]. There are 
people who have interests in obtaining official appointments (e.g. becoming a 
commissioner for a state-owned enterprise, or director for state owned enterprise). 
Therefore, it is difficult.” (P028_MP). Lack of trust in pharmacy stakeholders 
Expectations for 
policy changes 
“We were challenged by MoH when we had a coordination meeting. They said “If you 
could show us the evidence of what can pharmacists do when they practice then we can 
discuss about their fees”. To date, we are unable to show this evidence” (P05_MP). 
“We can’t use the word evidence at the moment because we (pharmacists) don’t practice, 
am I correct? The number of practicing pharmacists is very low…Nowadays, they 
(pharmacists) only talk about business or sales” (P015_MP). Collection of evidence 
“We try to look for role models. For instance, IAI [name of region] covers five branches 
and I asked each branch to look for a community pharmacy which can be role model. Then 
we can replicate the success to other pharmacies, one becomes two, three and so on” 
(P027_FP). Search for pharmacy role model 
“There is a wide discrepancy between education and practice because universities are still 
polyvalent (of knowledge)…Frankly speaking, the education system does not create 
pharmacists to be pharmacists. The education system is overloaded with too many 
science courses…there is no practice values within the course” (P015_MP). Changing 
pharmacy education curricula 
 “I think they should have collective responsibility but right now they don't talk each other. 
So, the universities don't exactly know where they want to take healthcare to the next 
stage. The government policy does not have support what comes out and then the IAI also 
just kind of, I think they are great in showing best practices but not again not execution. I 
think there is a little bit of within any political manoeuvring there are the egos, who should 
be responsible? which other parties should be responsible for?” (P018_FP). Lack of a shared 
stakeholder vision 
“(we need) policy that makes pharmacists proud of working in pharmacy, policy that 
supports pharmacy as the first point of contact with patients, policy that makes pharmacy 
is a setting to listen to patient’s problem related to medication. That’s all. It is a great 
thing if we have those three policies” (P028_MP). Policy advocating pharmacists 
Coping strategies 
initiated by locals 
“we have accreditation system by giving pharmacy star rating from 4 to 1 star…the 
accreditation evaluates the workforces, facilities, legality for practice, service provision and 
administrative matters. We give different score for each aspect with service provision is the 
highest…we do it once in every one or two year and we publish the results regularly…the 
stars must be displayed in the pharmacy” (P016_MP). Pharmacy star rating model – 
applied in Yogyakarta 
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Topic Quotes 
“When a pharmacist wants to open pharmacy and they have difficulty in purchasing, I 
offer them my stock at a cheap price. I don’t take profit. That is to push pharmacist 
practice. When there is pharmacist who opens a pharmacy, I endorse colleague to guide 
the pharmacist from the scratch, help them with how to provide good service and even 
they are not yet sustainable for procurement, they can buy to another pharmacy” 
(P05_MP). Peer support and assistance – applied in East Java 
“If pharmacist is unable to order medicine such as Imodium (brand name of Loperamide) 
because the price of one tablet is 6 thousand rupiah (approximately 60 cents)…your 
pharmacy can buy from me. What important is you have the stock of the medicine. We 
make a network so we can help other small pharmacies. Other cases, for example your 
pharmacy can’t sell a medicine. By having network you can distribute it to other 
pharmacies which may be able to sell it. We can help each other so we can minimize loss 
due to expired medicines” (P027_FP). Networking and collective approach – applied in 
Greater Jakarta  
“The head of IAI must be strong character person, with vision and knowledge and a 
resolve to enforce the regulations…It really depends on the leadership, that’s why he 
should be above any matters involving conflict of interest.” (P025_MP). Leadership 
influencer and support – applied in Central Sulawesi 
“We have a quality assurance division to ensure pharmaceutical services are correctly 
delivered. We have many tools for supervising and reporting whether services are 
correctly provided or not…Home care needs to be done once a week, and every week 5 
Patient Medication Records (PMR) need to be filled out…we have records of how many 
hours spent for patient consultations…we learn something new every time, we have an 
update training every 3 months minimum. Our skills are up to date, the system is good” 
(P01_FP). System of quality assurance – applied in Chain Pharmacy 
 
Discussion 
To the best of our knowledge, this is the first study which has collated and evaluated the 
impact of multiple initiatives designed to influence community pharmacy practice in the context 
of a developing country. The detailed overview of the major approaches that have been 
implemented to improve the practice of community pharmacy and pharmacists in Indonesia 
presents important data to inform the development of future intervention strategies to effect 
practice change. The findings also contribute to an understanding of policy development and 
implementation in the Indonesian community pharmacy sector which is currently lacking in the 
literature.  
In collating and summarizing recent policy and other initiatives, it has become apparent 
that the multiple approaches and regulations introduced into the Indonesian community 
pharmacy sector over the past ten years reflect an enthusiasm by both policy makers and 
pharmacy stakeholders to support pharmacists’ role development. Encouragingly, the broad 
range of the approaches have also demonstrated a significant level of commitment by both 
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groups to improving the current practice in community pharmacy, and a clear recognition of the 
untapped capacity and potential for community pharmacy to make a greater contribution to the 
healthcare system overall. This is particularly important in relation to a developing country such 
as Indonesia where there is limited acknowledgement of the pharmacy profession and the role 
of community pharmacy in health care as reflected in the low levels of effort to support practice 
change (Tri Murti Andayani and Satibi Satibi, 2016). 
Our findings demonstrate that a clear legal framework exists for the regulation and 
enforcement of the practice of community pharmacy and pharmacists, specifically through the 
Pharmacy Practice Act and Community Pharmacy Decree, which define the core domain of 
pharmacy practice which is specific and unique to pharmacists’ role, expertise and authority. 
Further legislation reinforces the set of skills required to be mastered by community pharmacists 
as outlined in the Competency Standards. These may then be translated into a range of pharmacy 
services as regulated by the Standard of Pharmacy Practice and Standard of pharmacy services. 
Thus, a template for potential practice change and development is present in a formal and 
supposedly enforceable sense; however a lack of prior supporting research evidence made it very 
unclear how well (or if at all) these approaches have achieved their policy objectives or 
adequately addressed the needs of the profession. Our qualitative study was designed to begin 
to address this gap.  
In relation to the second objective, this study reflects the expressed opinions and 
attitudes of a sample of stakeholders in Indonesia and has provided an insight into the 
implementation of multiple approaches to advance pharmacy practice as advocated by 
government and pharmacy professional organization. A number of specific findings are discussed 
in this section. 
This study has highlighted that a number of the initiatives, while relevant and appropriate 
in themselves, were conceived and enacted in a piecemeal, sometimes conflicting and 
uncoordinated way. For example, the requirement for pharmacists to undertake the CPD 
program has not been effective in achieving its policy objective. While it is widely believed that 
CPD is an effective avenue for improving pharmacists’ competency by targeting both educational 
and experiential learning for the participants, it is clear that the learnings from CPD among 
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Indonesian pharmacists have not been translated into practice. As expressed by respondents in 
this study, even mandatory participation in CPD has not been a pathway for improving practice. 
It is viewed as a way to accumulate a certain number of the credits required to maintain licensure. 
Moreover, the CPD activities which are available are knowledge-based rather than skills-based 
or practice-focused and do not necessarily correlate with the pharmacist’s scope of practice.  For 
example, pharmacists working in pharmaceutical industry are able to undertake CPD on the 
management of hypertension focusing on clinical knowledge more suited to practicing 
pharmacists in the hospital or community pharmacy setting. 
Lack of coordination is also seen in the attempt to set minimum remuneration rates by 
some local branches of IAI, rather than by the association at the national level. Whilst the reason 
for the absence of similar initiatives at the national level is unknown, it reflects a lack of consensus 
regarding minimum remuneration for community pharmacists. Similarly, the initiatives to 
improve recognition of pharmacists’ role in health care are undermined by the continuing poor 
level of attendance of pharmacists in many community pharmacies (Hermansyah et al., 2012). 
This latter finding also highlights the lack of enforcement of legislation, which is the second major 
finding from this study. There are two factors contributing to the lack of enforcement as 
expressed by participants. Firstly, there is a strong perception that pharmacists who have violated 
the law will go unsanctioned. Secondly, this perception is reinforced by the observation that 
some pharmacists working in government authorities whose responsibility it is to enforce the 
regulation, have also been guilty of its violation and not been sanctioned. Apparently, these two 
factors – misuse in practice and abuse of power – have not been addressed by current legislative 
frameworks which demotivates pharmacists from being present in the pharmacy. Whilst 
recognition of this issue has been put forth in the conception of some approaches such as 
indicated in the collection of credits (SKP) which includes evaluation for regular attendance, 
progress is still far from sufficient. The approach of the Chairman of BPOM through a directive 
prohibiting BPOM staff from working in community pharmacy as mentioned in the introduction 
of this study might go some way towards redressing the problem.  
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This study has highlighted a number of key attitudinal barriers to the implementation of 
practice change approaches, notably strong perceptions of poor policy enforcement, lack of trust 
in the role of the governing bodies and scepticism towards the impact of the programs. These 
barriers are not uncommon in developing countries (Lowe and Montagu, 2009, Babar and Scahill, 
2014), and therefore there is a need to address all these issues - which are notoriously difficult 
to change - in order to create sustainable and successful policy implementation influencing 
practice change. 
Relatedly, this study highlights the desire of stakeholders for a shared vision describing 
best practice in Indonesian community pharmacy. The commitment to a shared vision ranging 
from individuals, group of individuals to organisations is essential to overcome the preceding 
barriers. In addition, the presence of a shared vision particularly between peak pharmacy 
organisations and the government as regulator will facilitate the development of a role model of 
community pharmacy and support the collection of evidence through research in community 
pharmacy. In many developed countries, a shared vision has become common sense for 
stakeholders in the community pharmacy sector to build a mutual understanding of the future 
of community pharmacy practice (Canadian Pharmacists Association, 2008, Pharmacy Guild of 
Australia, 2010b, Pharmacy Stakeholders Forum, 2014) 
Accordingly, there was a need to design strategies that can be successfully and sustainably 
implemented in the setting of community pharmacy. However, with top-down approaches, there 
also needs to be a recognition that programs with good policy objectives may result in 
unintended and unwanted consequences. Our previous study analysing the contemporary 
situation in community pharmacy in Australia highlighted that knowing the problem or 
understanding the mechanism to resolve the problem does not guarantee good implementation 
of a policy. This is particularly because community pharmacy operates in a complex and dynamic 
system with several key elements from social, policy and economy context influencing the micro 
(individual pharmacists), meso (community pharmacy as an institution and network of 
institution) and macro level (healthcare system) of community pharmacy (Hermansyah et al., 
2017a). With respect to Indonesia, community pharmacy continues to face a number of 
underlying issues such as a shortage of pharmacists, limited clinical competency of pharmacy 
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staff, counterfeit drugs and illegal supply of medicines available from street vendors to 
healthcare professionals, which is consistent with the situation in many other developing 
countries (Fathelrahman et al., 2016). As community pharmacy and the health system are inter-
connected, the impact of poorly implemented programs in the community pharmacy sector may 
undermine policy initiatives and create poor outcomes elsewhere in the health system, and 
therefore policy makers and stakeholders in pharmacy must look at broader scope of the 
program. This study reinforced the argument that simply adding new policies or strategies will 
not improve the situation without resolving the underlying problems of the past. 
The findings of this study also highlight the potential feasibility of a national scale-up of 
local interventions. The successful local initiatives described by participants illustrate a range of 
novel and different ways to enhance pharmacists’ roles, tailored to the specific context in which 
they operate. In addition, these initiatives reflect a desire and willingness of local organisations 
to address the challenges of policies designed at the national level. Expanding this bottom up 
approach will undoubtedly require a good understanding of local situations and may be unique 
in every region. However, some key characteristics of successful approaches have emerged. Most 
of the local initiatives included in this paper involved a collective approach through networking 
and mentoring to encourage pharmacists to practice. Others relied on the critical role of leaders 
in recognising the need to support and encourage individual pharmacists. A few initiatives 
involved the application of a quality assurance system by ensuring adequate resources for 
pharmacy operations and maintaining the quality of the services by implementing pharmacy 
rating star model as a showcase for consumers and patients. While these local strategies were 
not supported by robust evidence of effectiveness, they may act as catalysts for change whereby 
local pharmacists’ communities work together for a common purpose and for better results. 
Another lesson is that sustainable changes are often achieved through an understanding of local 
health care needs. The UK experience in introducing the Healthy Living Pharmacy program which 
allows an individual pharmacy to tailor services to local needs despite the pharmacy being 
contracted under the NHS scheme is an example (Brown et al., 2014). This is also similar in 
Australia where a number of pharmacists under Health Destination Pharmacy program have 
changed their practice by adopting a bottom up approach where they can be innovative and 
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adapt to the changing demand in the current state of healthcare (Pharmaceutical Society of 
Australia, 2017). 
Finally, and underpinning all aspects of practice change, is the urgent need to transform 
the current pharmacy education system which has hitherto primarily focused on pharmaceutical 
sciences rather than on pharmacy practice. In responding to the changes in pharmacy which 
focus on the role of pharmacists in medication management and patient centred care, the 
education system in Indonesia - which consists of four-years undergraduate and one-year 
apothecary program - must be reshaped to better prepare pharmacists, not only for future 
changes, but also for the current situation. Reflecting on our findings, it is imperative to devote 
more time, effort and resources to developing the clinical knowledge and experience of 
pharmacy students to allow them to face and meet the challenges in healthcare that they will 
experience during their careers. 
The interpretation of the study results should take into consideration a number of 
limitations. Firstly, the assessment of the policy or program was limited to reporting experience 
and perception of stakeholders with no quantitative measurement showing quality performance 
of the policies. While providing such data is also of importance, we were interested to capture 
the key aspects of the lived experience of program functioning and its impact on community 
pharmacy. Secondly, the study only identified the approaches delivered by national organizations 
or central government authorities without including assessment of policy at the lower 
bureaucratic level such as policies created by local government. Hence, underreporting of 
strategies within this paper is possible. We did not attempt to analyse the policies or programs 
at the lower level although they are likely to influence community pharmacy. One of the reasons 
was due to the scarcity of available information about the policies. However, assessing the 
national policy agenda has enabled an overarching understanding of the broad spectrum of 
initiatives that have been undertaken to improve community pharmacy practice in Indonesia. 
Thirdly, it might be argued that each individual study participant would be expected to have only 
a relatively narrow and specialized understanding or experience of the Indonesian health 
care/pharmacy system, however the number and diversity of the participants meant that a wide 
range of perspectives was obtained. In fact, the breadth of the stakeholder cohort was a strength 
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of this study since the policies of interest could be interrogated from multiple angles. Finally, new 
policies have been introduced following the research underpinning this paper, for example, the 
implementation of a policy allowing pharmacists to work in a maximum of three different 
pharmacies as regulated under the Decree for registration, certification and licensure of 
pharmacists. On the surface, it seems unlikely that that this policy will have a significant impact 
on the practice in community pharmacy, however, it is important to keep tracking such changes 
to see the impact in the future. 
 
Conclusion 
The introduction of a plethora of policies, regulations and initiatives within the past ten 
years has highlighted the enthusiasm of policy makers and pharmacy stakeholders to improve 
community pharmacy practice in Indonesia. However, some of the initiatives were conceived and 
enacted in a piecemeal, sometimes conflicting and uncoordinated way. Despite the good policy 
objectives of the initiatives, it appears that poor enforcement, lack of trust of pharmacy 
stakeholders and scepticism regarding the impact of the initiatives have significantly undermined 
the success of these initiatives, and remain the predominant challenges for successful policy 
implementation. This study suggested some attempts to resolve these challenges focusing on the 
need to have a shared vision among peak pharmacy stakeholders defining best practice in 
community pharmacy. Some local initiatives highlighted the bottom-up approach in the system 
and potential for scaling up at the national level. Overall, it is clear that some fundamental and 
entrenched barriers to practice will need to be overcome in order to create a more professional 
climate for the practice of pharmacy in Indonesia. 
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Interview guide 
1. How do you view the current situation in Indonesian Community Pharmacy? 
2. Do you acknowledge some changes in the landscape of community pharmacy sector? 
Policy framework in community pharmacy 
3. What do you think is the main policy framework that underpins the contemporary practice 
of community pharmacy? 
a. How influential are the policies or regulations for supporting contemporary practice? 
b. Have they been enforced adequately? Who does hold the authority for enforcement? 
c. Are there any other policies influencing the practice of community pharmacy? 
4. What do you think are the challenges for implementing the policies as you mentioned? 
a. Are these barriers common to pharmacy practices? Yes, are they pertinent issues? No, 
please explain? 
b. Why do you think these barriers occur? Can they be prevented? 
5. What is your effort to cope with the challenges presented by the policy changes? 
a. Do other pharmacies or pharmacists have the same ideas as yours? If Yes, please 
explain? If No, why others don’t? 
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b. How applicable do you think your solution for other pharmacies/pharmacists? 
6. Given the changing nature of pharmacy, do you see any need for establishing new policies to 
improve the practice of community pharmacy? If Yes, why and what are the policies needed? 
If No, why not? 
7. What is your expectation to improve the current practice of community pharmacy? who 
should be responsible for that and what is your suggestion for them? 
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6.3. Prioritising recommendations to advance community pharmacy practice 
 
This section comprises following publication: 
“Hermansyah, A., Pitaloka, D., Sainsbury, E., & Krass I. (2018). Prioritising recommendations to 
advance community pharmacy practice. Research in Social & Administrative Pharmacy. 
https://doi.org/10.1016/j.sapharm.2018.02.003”. 
In this study, we reported the findings of four nominal group discussions attended by 
nationwide pharmacy stakeholders in Indonesia. These nominal discussions were conducted to 
identify and systematically prioritise recommendations for advancing Indonesian community 
pharmacy practice. This manuscript which was submitted in November 2017 and accepted for 
publication in February 2018. The published version of the paper is presented in appendix 11. 
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Prioritising recommendations to advance community pharmacy practice 
Andi Hermansyah, Dyah Pitaloka, Erica Sainsbury, Ines Krass 
 
Abstract 
Introduction The nature of community pharmacy in many countries has changed. Despite the 
significant efforts made to change practice, there is a paucity of literature that highlights 
consensus on the approaches that should be prioritised for advancing practice particularly in the 
context of developing countries. 
Objective To systematically identify and prioritise a range of potential recommendations to 
improve practice in Indonesian community pharmacy from the perspective of pharmacy 
stakeholders. 
Methods Qualitative research using Nominal Group Technique (NGT) was conducted in July 2017 
involving 34 nationwide pharmacy stakeholders. Participants were assigned to four nominal 
group discussions based on the areas for action as developed by researchers. The results were 
thematically analysed. 
Results Nine priority recommendations were generated from the group discussion reflecting four 
main themes to advance community pharmacy sector, namely improving professional pharmacy 
practice, reforming pharmacy education, enforcing policy and regulation and enhancing public 
recognition of pharmacists. The analysis using the culture-structure-agency approach highlights 
that the top down structure in terms of policy and regulatory framework has not been effectively 
enforced. In addition, the role of pharmacists as the central agency in delivering pharmacy 
services has been limited due to their common absence from practice. The approach, however, 
provides an alternative to advocate changes by locating the role of pharmacists and community 
pharmacy as central agency within the challenging health system structure. 
Conclusions The recommendations generated from and approach used in this study provide an 
impetus to advance community pharmacy practice in Indonesia. Amongst the important 
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solutions, there is substantial need to provide evidence of pharmacists’ contribution to 
healthcare. 
Keywords: Community pharmacy; pharmacists; nominal group technique; Indonesia 
Introduction 
The nature of community pharmacy in many countries has changed within recent 
decades. Community pharmacy has evolved from a place, known as the “chemist”, where people 
only obtained pharmaceuticals, to a health hub destination where people have the opportunity 
to consult with a pharmacist on a wide range of health care concerns (McMillan et al., 2013). 
Increasingly, community pharmacists are offering a range of clinical, diagnostic and public health 
services targeted to their patient and community base (Pande et al., 2013, Perraudin et al., 2016).  
The imperative and rationale for community pharmacy to evolve has been reported in 
many publications, together with a range of ways of achieving practice change, initiated at 
individual (pharmacist) level (e.g. behavioural and attitudinal modification) (Awaisu and Alsalimy, 
2015), at organisational (pharmacy) level (e.g. change management) (Feletto et al., 2013) and at 
healthcare system level (e.g. implementation of evidence based practice) (Blalock et al., 2013) 
and remuneration for professional services (Bernsten et al., 2010). While practice change in 
community pharmacy has been the agenda in developed countries, the pace of change has been 
slow in many developing countries (Miller and Goodman, 2016). 
There are a number of factors hampering practice of pharmacists in developing countries 
ranging from an under-developed healthcare system to a lack of professional regulations 
supporting practice of pharmacists (e.g. they are less well equipped educationally, professionally 
and economically) (Babar and Scahill, 2014, Hermansyah et al., 2016b). The situation in these 
countries reflects the need for an overhaul in the healthcare and pharmacy system with some 
significant efforts required to change practice. Unfortunately, there is a paucity of literature that 
highlights consensus on the approaches that should be prioritised for implementation 
particularly in the context of developing countries where community pharmacy and pharmacists 
are often marginalised and under-recognised within the healthcare system. This paper addresses 
this gap. 
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The practice of community pharmacy in Indonesia is changing rapidly, particularly since 
the introduction of the Universal Healthcare Coverage Program (JKN) in 2014. Under JKN, a small 
number of community pharmacies are now affiliated with a primary care network and are able 
to supply pharmaceuticals and provide access to some non-dispensing pharmacy services such 
as home care pharmacy and disease screening and monitoring. However, the vast majority of 
pharmacies have not been included in this scheme thereby creating a gap in service quantity, 
financial benefits and practice quality between the affiliated and unaffiliated pharmacies 
(Hermansyah et al., 2018b). 
We recently conducted a project investigating the impact of the introduction of JKN on 
practice change in Indonesian community pharmacy (Hermansyah et al., 2018b). Having 
interviewed a wide range of stakeholders in community pharmacy and the healthcare system, 
this study identified a number of key issues hampering change in contemporary pharmacy 
practice (Figure 11). On the basis of these barriers, corresponding areas for action to improve 
practice in community pharmacy practice were proposed (Figure 12). The areas for action 
represent the research team recommendations to promote change from the perspectives of 
pharmacy stakeholders. Our recommendations, however, are broad and require further 
discussion to help refine the priorities and matching strategies to address each of the identified 
areas for action. In addition, stakeholders’ feedback on the extent to which these 
recommendations can be sustainable in everyday practice is needed.  
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Figure 10. Summary of key issues in the practice of Indonesian community pharmacy 
 
 
Figure 11. Areas for action representing research team recommendation 
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Community pharmacy in Indonesia: regulation, education and practice 
It is important to understand the context of community pharmacy in Indonesia to 
interpret the findings of this study. Therefore, this section provides an overview of the regulation, 
educational system and practice of community pharmacy in Indonesia. 
Community pharmacy is one of the most highly-regulated sectors in Indonesia. Regulation 
is complex and is an amalgam of legislation and policy frameworks ranging from the national to 
the local level, advocated by a myriad of actors including the Ministry of Health (representing 
government), National Agency of food and drug control (BPOM), community pharmacy 
organisations and pharmacists’ association (IAI). The first and currently the highest order of 
legislation governing pharmacy practice in Indonesia is the Pharmacy Practice Act 2009 
(Government of Indonesia, 2009). The Act, which can be considered the main policy framework 
which underpins practice in community pharmacy, defines pharmacy practice is under 
responsibility of pharmacist as the sole authorised profession for the operation of a community 
pharmacy.  
In order to become a pharmacist, a high-school graduate must undertake formal 
education for at least five years in a school of pharmacy. The five-year program is divided into 
two education programs: four years for the Bachelor of Pharmacy program (B. Pharm) and one 
year for the Apothecary program (Apothecary) (Tri Murti Andayani and Satibi Satibi, 2016). There 
are 162 schools of pharmacy in Indonesia however only 26 schools are eligible to conduct both 
the B. Pharm and Apothecary programs (BAN-PT, 2017). The remainder, due to their low 
accreditation rating, are only allowed to offer B. Pharm program. While the B.Pharm program is 
designed to provide students with skills and knowledge in basic and theoretical pharmaceutical 
sciences, the apothecary program is focused on developing practical skills and providing 
experiential learning for final year students (Tri Murti Andayani and Satibi Satibi, 2016).  
Interestingly in Indonesia, once a pharmacist receives a license to practice, he or she is 
eligible to work simultaneously in up to three pharmacies (Ministry of Health Indonesia, 2017a). 
While the rationale for allowing pharmacists to work in three pharmacies is neither explicitly 
stated in the regulation nor publicly declared, it is arguably to improve pharmacist accessibility 
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in rural areas where there is a notable shortage of pharmacists. Unfortunately, the regulation is 
not limited to rural areas making it possible for a pharmacist in urban areas to be employed in 
three pharmacies at the same time. A further issue is the potential conflict of interest that is 
created by the fact that personnel in regulatory or supervisory roles are also permitted to practice 
in the community pharmacies which they regulate or supervise.   
There has been increasing competition between pharmacies in Indonesia as there is no 
regulation controlling locations of pharmacies. As a result, maldistribution is evident with urban 
areas oversupplied with pharmacies, while suburban and rural areas experience pharmacy 
shortages (Hermansyah et al., 2012, Yuniar and Herman, 2013). Community pharmacy has been 
underutilised as a healthcare setting in which pharmacists are available to provide professional 
pharmacy services. Generally, patients will go to a pharmacy when they receive prescriptions, 
yet they may not always interact with a pharmacist as it is common that pharmacies operate 
without the physical presence of a pharmacist (Hermansyah et al., 2012). The predominant 
activities in pharmacies have been dispensing prescribed medicines, provision of over the 
counter drugs and sale of other retail goods. Professional services such as drug advice, 
counselling and health education are limited and until recently without direct remuneration.  
The overview highlighted a gap between education, regulation and practice in the 
Indonesian community pharmacy sector. This gap has presented ongoing challenges for both 
pharmacies and pharmacists reflecting the need for achievable recommendations. Therefore, the 
aim of the study was to systematically identify and prioritise a range of potential 
recommendations to improve practice in Indonesian community pharmacy from the perspective 
of pharmacy stakeholders. 
Methods 
Study design and participants 
We used consensus methods as a means of achieving general agreement around potential 
recommendations for advancing community pharmacy practice in Indonesia. The consensus 
methods including the Nominal Group Technique (NGT) and the Delphi technique have a 
relatively long history of use in health and medicine and have been increasingly adopted in 
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pharmacy practice research (Bradley et al., 2013, McMillan et al., 2014c, Newlands et al., 2018). The 
consensus methods have similar roots with Focus Group Discussion (FGD) in which participants 
are invited to brain-storm ideas and opinion. However, they are somewhat different as they 
involve a structured environment and balanced participation for problem-solving (McMillan et al., 
2016).  
The study used and modified the NGT as developed by Delbecq et. al for identifying 
strategic problems and generating potential and innovative solutions for the problems (Delbecq 
et al., 1975). The technique allows members of the group equal opportunity to express their views, 
vote for their preferences and engage in a group discussion. With this way, domination of 
particular individual(s) during the group discussion and undue influence on the results of the 
discussion may be minimised. Accordingly, the results reflected a balanced consensus achieved 
by the group. This has become the key strength of the technique as compared to FGD (McMillan 
et al., 2016). Furthermore, the NGT can be conducted within a few hours, with less resources and 
may involve lay people such as a wide-range of pharmacy stakeholders who are target 
participants in this study making it a preferable method for this research as compared to the 
Delphi technique (McMillan et al., 2016). 
An NGT involves a small number of participants, usually between six and fifteen 
participants with the group discussing one or two questions (Gastelurrutia et al., 2009, McMillan et 
al., 2015a, Jokanovic et al., 2017). The core process in the NGT generally comprises of four stages: 
silent generation, round robin, clarification and voting (ranking) (Delbecq et al., 1975). However, 
modifications to this process have been common depending on the resources and level of 
consensus wished to be achieved by the research team (Hutchings et al., 2010, Sav et al., 2015, Fakih 
et al., 2016). 
Four nominal group discussions were held in July 2017 during a pre-conference workshop 
of the 17th Asian Conference on Clinical Pharmacy (ACCP, 2017). The ACCP conference is one of 
the foremost and best-known conferences in Indonesia covering issues of clinical pharmacy in 
the hospital and community setting. Information and details about the workshop were advertised 
through the conference website. Interested individuals registered to participate in the workshop 
 203 
and were provided with an information sheet explaining the study and asked to sign a consent 
form prior to attendance.  
Overall, 34 pharmacy stakeholders participated and were assigned to four nominal group 
discussions. The characteristics of the participants are presented in Table 13. The study was 
approved by the Human Research Ethics Committee of the University of Sydney (approval 
number 2014/820). 
Table 13. Characteristics of participants (Indonesian studies 3) 
Characteristic n = 34 
Female 26 
Background: 
 Pharmacy organization representatives 
 Practicing pharmacists 
 Academics and researchers 
 Administrator and regulator 
 
6 
17 
10 
1 
Domiciliary: 
 Java Island (Jakarta, West Java, Central Java, Yogyakarta and East Java) 
 Sumatera Island (North Sumatera, Riau, West Sumatera and South Sumatera) 
 Kalimantan Island (East Kalimantan) 
 Sulawesi Island (Central Sulawesi and South Sulawesi) 
 Papua Island (Papua) 
 
24 
5 
1 
3 
1 
 
Procedures 
The workshop was conducted in two parts. The first part was a 45-minute presentation 
describing the key findings of the researchers’ project which investigated stakeholder 
perspectives on pharmacy practice and practice change in Indonesian community pharmacy. The 
presentation included an overview of the current situation based on the researchers’ findings, 
and challenges to the development of practice in community pharmacy including areas for action 
as proposed by the research team. The second part was the 90-minute NGT discussion (Figure 
13). Participants were invited to join one of four groups according to their interest and assigned 
with one of the following areas of action for discussion: Group 1 (Individual pharmacist 
empowerment) consisted of seven participants, Group 2 (Community pharmacy network 
recognition) had ten participants, Group 3 (Education and curriculum improvement) had eight 
participants and Group 4 (Law and regulation enforcement) had nine participants. In general, 
each group composed of participants with mixed professional background, experiences and 
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location of practice. During the group discussions, the investigator acted as moderator who 
rotated between four groups.  
Stage 1. Introduction
 Investigator explained the procedure for NGT
 Each group selected their facilitator
 Each participant received the  ideas  and  scoring  
form
Stage 2. Silent Generation of Ideas
 Participants were asked the following question: 
 What are the most important and most feasible 
recommendations to improve community 
pharmacy practice based on your area for action? 
 Each participant recorded their ideas in silence on 
the  ideas  form
Stage 3. Round Robin of Ideas, Clarification 
and Discussion
 Facilitator invited one participant to present his/
her ideas
 Facilitator invited other participants who had 
similar ideas for reducing duplication
 Facilitator led brief discussion for clarification and 
recorded agreed ideas
 The process continued with subsequent 
participants
Stage 4. Voting
 Each participant selected top five recommendations 
from their group by providing score from 5 (the 
highest/the most) to 1 (the lowest/the least) in terms 
of importance and time relevance aspect of the 
recommendations on the  scoring  form.
 Facilitator tabulated the results and reported top five 
priorities from their group to investigator.
 Group discussion was concluded
Stage 5. Forum Discussion
 Investigator led forum discussion, reported findings 
from each group and identified similar or overlapping 
ideas.
 Each group was invited to briefly explain their top five 
priorities and mentioned any specific differences of 
their ideas with other groups.
 The priorities of each group were posted on a wall for 
voting
Stage 6. Forum Voting
 Individual participants received five  sticky 
notes , each with score representing level of 
priority (from 5 = the highest to 1 = the least) and 
name of participant.
 Participants voted by putting each  sticky note  
on the selected idea.
 Forum discussion was concluded.
 
Figure 12. The NGT process 
Data Analysis 
Both group discussion and forum discussion were audio-recorded and subsequently 
transcribed verbatim. As the discussions were conducted in Indonesian, the transcripts were back 
translated to English by the lead investigator and reviewed by research team for the quality of 
translation.  
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The lead investigator calculated the total score for each recommendation and created a 
ranked list of priorities from forum voting (stage 6 of the NGT). The priorities are presented in 
Table 14. Recommendations that are relatively similar in nature were pooled together into a 
group of priorities to condense the list with the score was accumulated from each 
recommendation (Table 15). This has reduced the number of recommendations into priority 
recommendations. Accordingly, recommendations that generated the highest score (e.g. 
remuneration for professional pharmacy services) may not reflect the best priority of 
recommendations. Such prioritisation was deemed possible given the degree of interdependence 
between recommendations. The list was then reviewed and subjected to thematic analysis. 
The thematic analysis began with one researcher (AH) independently reviewing the 
transcripts and developing an initial coding framework based on the list of recommendations 
(Table 14). The researcher followed the standard procedure of analysing qualitative data using 
thematic analysis by coding relevant individual statements, collating codes into potential themes, 
refining and allocating remaining data into relevant potential themes (Braun and Clarke, 2006). The 
framework was then discussed within the research team to develop overarching themes and 
subthemes. During this process, priorities that were deemed closely related were grouped 
together and aggregated into a new overarching theme. This process was undertaken several 
times with some revisions required to clarify the research findings. The discussion was also 
important to resolve any discrepancies among researchers and to ensure that all 
recommendations were captured in the final framework. A final consensus thematic list was 
produced reflecting qualitative findings of the study. 
Theoretical framework to aid analysis 
The study analysed the recommendations from the group discussions by adopting a 
cultural theoretical approach to explore the relationship between culture-structure-agency 
(Hays, 1994, Archer, 2005, Dutta, 2011, Moore, 2013). There is increasing interest among 
pharmacy researchers in exploring the “culture” within the community pharmacy sector. Culture, 
however, is an elusive term which may cover inherently complex issues such as the cultural 
competence of pharmacists (O'Connell et al., 2007), the organisational culture of the community 
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pharmacy and pharmacy as a profession (Scahill et al., 2011, Rosenthal et al., 2017), and the 
cultural context in which community pharmacy operates (community context) and/or the 
network of pharmacies is established (country context) (Jacobs et al., 2011, Rosenthal et al., 
2011, Scahill, 2013). The term of “culture” has been conceptualised as the opposite to the 
“structure”. While “culture” has been perceived as flexible and concerns the beliefs, values and 
ideologies, “structure” has been described as a rigid, hierarchical form that constrains nature by 
ruling or regulating a society (Hays, 1994). The operation of both “culture” and “structure” has 
been determined by the role of “agency” which may concern individuals, group of individuals, 
groups of organisations or government.  
By looking at the relationship between culture-structure-agency, this study was able to 
show how pharmacists and community pharmacy locate “power” and produce their own agency 
within the structure of the healthcare system. The culture of practice which is developed during 
the interaction between pharmacists, community pharmacy and the health system structure 
reflects the opportunity for change. This concept provides a framework for analysing the 
recommendations generated from the NGT and sheds light on their applicability in practice, as 
to why these recommendations may or may not be effectively implemented by community 
pharmacies in Indonesia. 
Results 
This section is organised into two parts. The first part comprises the quantitative findings 
of the study, namely the recommendations generated from the NGT, and the second part 
presents the overarching themes emerging from the group discussions reflecting the qualitative 
findings of the study. 
Quantitative findings 
In total, the groups identified twenty recommendations which were believed to be 
important in answering the nominal question (Table 14). These were then condensed into nine 
priority recommendations as explained in the data analysis section (Table 15).  
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Table 14. Recommendations generated from forum voting (stage 6 of the NGT)  
No. Recommendations Score 
1.  Introducing remuneration for professional pharmacy services 63 
2.  Establishing pharmacy quality accreditation 52 
3.  Enforcing mandatory pharmacists’ attendance 43 
4.  Developing role model of good pharmacy practice 36 
5.  Encouraging peers to deliver pharmacy services 33 
6.  Teaching ethics and philosophy of profession for pharmacy students 28 
7.  Revising standard for pharmacy premises, facilities and location 22 
8.  Extending the duration of Apothecary program 19 
9.  Extending the duration of internship program  19 
10.  Providing training for preceptor and conducting periodic follow up for preceptorship 18 
11.  Enforcing the implementation and supervision of regulation 18 
12.  Conducting more periodical pharmacy visits and monitoring by authorities 17 
13.  Broadening public campaign on pharmacists’ roles in drug safety 13 
14.  Setting minimum qualifications for becoming preceptor 12 
15.  Promoting more outreach program involving pharmacy and pharmacists 12 
16.  Collecting evidence of pharmacists’ contribution 12 
17.  Improving delivery and variety of topics in Apothecary program 9 
18.  Building professional image of pharmacists 9 
19.  Developing community pharmacy network 4 
20.  Improving drug supply chain by removing sub-distributors in the distribution of pharmaceuticals 3 
 
Table 15. Priority of recommendations 
Priority of recommendations Sum of the 
score 
Recommendation 1. Encouraging pharmacists to practice responsibly 
Major patterns of dialogue within this recommendation: 
 Enforcing mandatory pharmacists’ attendance (score 43) 
 Promoting the role of peers to encourage pharmacists’ attendance (score 33) 
76 
Recommendation 2. Extending the duration of pharmacy education 
Major patterns of dialogue within this recommendation: 
 Extending the duration of the Apothecary program from one year to two years (score 19) 
 Longer duration for internship from one semester to four semesters (score 19) 
 Teaching ethics and philosophy of profession for pharmacy students (score 28) 
 Improving delivery and variety of topics in Apothecary program (score 9) 
75 
Recommendation 3. Establishing pharmacy quality accreditation 
Major pattern of dialogue within this recommendation: 
 Implementing pharmacy quality assessment (e.g. pharmacy star rating model) (score 52) 
 Revising standards for pharmacy premises, facilities and location (score 22) 
74 
Recommendation 4. Introducing remuneration for professional pharmacy services 
Major patterns of dialogue within this recommendation: 
 Lack of remuneration for pharmacy services (score 63) 
 No additional payment for working overload 
63 
Recommendation 5. Developing the standard model of pharmacy practice 
Major patterns of dialogue within this recommendation: 
 Seeking and disseminating models of good pharmacy practice (score 36) 
 Building networks of care between community pharmacies (score 4) 
52 
 208 
Priority of recommendations Sum of the 
score 
 Collecting evidence of pharmacists’ contribution (score 12) 
Recommendation 7. Reforming and strengthening policies and regulations 
Major patterns of dialogue within this recommendation: 
 Enforcing the implementation and supervision of regulation (score 18) 
 Conducting more periodical pharmacy visits and monitoring by authorities (score 17) 
 Improving drug supply chain by removing function of sub-distributors in the distribution of 
pharmaceuticals (score 3) 
38 
Recommendation 6. Improving the quality of preceptorship 
Major patterns of dialogue within this recommendation: 
 Training for preceptors and periodic follow up for preceptorship (score 18) 
 Setting minimum qualifications for becoming a preceptor (score 12) 
30 
Recommendation 8. Involving in public campaign and outreach program 
Major patterns of dialogue within this recommendation: 
 Broadening public campaign on pharmacists’ roles in drug safety (score 13) 
 Promoting more outreach programs involving pharmacy and pharmacists (score 12) 
25 
Recommendation 9. Building the nation-wide professional image of pharmacists 
Major patterns of dialogue within this recommendation: 
 Branding through social media and participating in government-initiated campaign 
program (score 9) 
9 
 
Qualitative findings 
Using thematic analysis, the priorities were grouped into four overarching themes which 
can be considered important areas for implementing change in the community pharmacy sector: 
(1) improving professional pharmacy practice, (2) reforming pharmacy education, (3) enforcing 
policy and regulation and (4) enhancing public recognition of pharmacists. 
First theme: Improving professional pharmacy practice 
In general, participants recognised the professional roles of community pharmacists and 
the potential contribution of community pharmacy as a vehicle for improving community health. 
However, many participants were deeply concerned about pharmacists’ common absence from 
the pharmacy in direct contravention of the regulation. In addition, the current regulation which 
allows pharmacists to work simultaneously in up to three pharmacies was a common topic in 
each group discussion with several participants raising concerns about the negative impact of 
this regulation which also fosters pharmacists’ absence at pharmacies. One participant described 
her experience: 
 209 
“We have to be strict in ensuring pharmacists’ presence. IAI should withdraw the license if turns out pharmacists are 
not present…but in reality, it is challenging because some members (of IAI) perceive it as ruining pharmacists’ wealth. 
We had issue in [name of a city in East Java] with the word “wealth”. There was a pregnant pharmacist who already 
had one child who applied for practicing in three pharmacies as regulated by the new regulation. She was obviously 
unable to attend these pharmacies and therefore we did not grant recommendation for her to practice. But she cried 
desperately and said that it is for her family’s wealth and we could do nothing except give her recommendation”  
(Female) 
Further, some participants raised the notion that provision of professional pharmacy 
services is extremely difficult to apply in the current setting as pharmacy is predominantly 
focused on medicine selling. One participant proposed to change the identity and layout of 
pharmacy as a means to disseminate professional practice 
“If the lay-out of pharmacy is like what we see today, then no wonder retailing is dominant. We need to change the 
physical lay-out, pharmacist is at the front and medicines at the back. Pharmacy (currently) displays medicines at the 
front of the shop. With this change, people will look for pharmacists and might not proceed if there is no pharmacist 
(at the front) and pharmacists will start to think about service” (Male) 
Corresponding to this notion, other participants argued the need to revisit the standard 
for pharmacy premises and location as many pharmacies are adjacent to each other and without 
careful consideration of safety and quality aspects. One participant argued that changing 
pharmacy premises is more feasible than any efforts to improve pharmacy practice 
“What I see now is there are many pharmacies opened without considering the location particularly after location 
rules (500 m distance between pharmacies) were lifted. Pharmacies are like merchant stores, like small kiosks. They 
might not have cooling fridge to store insulin. In [name of a city in East Java], they just put medicines on the display 
shelf exposed to the sun which I guarantee does not meet the requirements to store medicines. Some pharmacies 
installed TV for convenience reasons but close to the pharmacy rooftop which may trigger fire as heat meets the 
electricity and they even don’t have a fire extinguisher. It is actually easier to change pharmacy by improving the 
premises rather than other efforts” (Female) 
Pharmacy accreditation was also perceived as a crucial instrument to improve pharmacy 
practice. In fact, all participants agreed with the notion that pharmacy must be accredited to 
ensure the sustainability of good pharmacy practice delivered by the pharmacists and pharmacy. 
One participant appreciated the initiative conducted by IAI and Health Department to assess 
pharmacy quality in Yogyakarta. 
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“The Ministry of Health has what is called an accreditation board and I had experience of working as volunteer for 
that board. A community pharmacy can request accreditation by the board. Alternatively, pharmacy can adopt the 
approach in Yogyakarta where IAI and Health Department apply a rating model to pharmacy. It might be pleasant 
to see a pharmacy get five stars for service excellence” (Female) 
While there was no disagreement that professional services must be conducted by 
pharmacists, the majority of participants highlighted the lack of remuneration for delivering such 
services. This triggered recommendations for setting remuneration for pharmacists providing 
professional services.    
“Remuneration is crucial as pharmacists have a clear job description. I am often overloaded with work but receive no 
additional payment. I do health education and health promotion but they are free, then how am I supposed to deliver 
medication management and follow up to patients (if these are also free)?” (Female) 
With respect to remuneration, some participants were aware that payers will not pay 
pharmacy for nothing. Therefore, they argued that pharmacy needs to develop a strategy to 
collect evidence of the contribution of pharmacy to community health which is currently lacking 
as pharmacies have limited capacity for documentation. 
“Collecting evidence is important to show the benefits of pharmacy services because there are some good 
pharmacies. If these pharmacies can document their advice, their patients’ education, clinical outcomes or whatever 
they do that improves patient’s life then there is potential for recognition. However, the majority (of pharmacists) 
have not conducted (proper) practice so there is no such documentation” (Female) 
Second theme: reforming pharmacy education 
Reforming pharmacy education received much attention from participants as they viewed 
it as fundamental to improving the practice of pharmacy. There was agreement for extending the 
current five-year program to a six-year program. The justification for this extension is based on 
the fact that development of clinical knowledge and practical skills are lacking within the current 
pharmacy curriculum. However, there was mixed response from the participants regarding the 
format of the proposed education. Several participants proposed the extension of the apothecary 
program from a one-year course to two years. Others wished that the extension of the 
apothecary program places emphasis on a longer duration for internships which is currently 
conducted in one semester (6 month) to four semesters (two years). 
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One participant who was highly supportive of extending the apothecary program outlined 
her plan for curriculum reform as follows: 
“When I took the apothecary degree, I only did it for 2 semesters. One semester for theory and one semester 
internship which was also not fully practice based…I propose two years program with first 6 months for theory and 
18 months for internship, divided into 6 months general internship to understand the whole pharmacy healthcare 
system by rotating at industry and clinic – whether in community or hospital, and 12 months focused internship for 
example students assigned to ward placement for practical experience” (Female) 
Several other participants, who preferred an extended internship posited that pharmacy 
students would have a richer learning experience in developing practical and decision-making 
skills. Consequently, theoretical courses should be provided in the Bachelor program prior to 
undertaking the apothecary degree. One participant expressed this recommendation by adding 
the need to develop a national curriculum as she observed only a few universities have such a 
program. 
“Students must undertake intensive 2 years internship so they become really competent after graduation. This means 
4 years of Bachelor program and another 2 years for internship. In addition, there should be national syllabi for 
internship so it is not only graduates from [name of several A accredited school of pharmacies] who are excellent. 
Others can be excellent too” (Female) 
Extension of the apothecary program would however require many more high-quality 
preceptors with qualifications. Few such preceptors are currently available within the apothecary 
curriculum of the majority of pharmacy schools. In addition, one participant proposed the idea 
that a preceptor could have the authority to direct interns to undertake a competency exam. 
“There must be a minimum qualification for becoming a preceptor, for example they have practice experience at 
least 5 years, their practice is focused on service delivery, they must be knowledgeable and can assist interns because 
not every practitioner is a good mentor…I suggest the preceptor can issue recommendation for interns to undertake 
a competency exam” (Female) 
Other participants identified the need to maintain preceptorship quality and therefore he 
suggested issuing guidelines for preceptorship and requirements for preceptors to attend 
workshops in preceptorship to improve their role in assisting students. 
“There should be guidelines in preceptorship and preceptors must attend workshops to enhance their role” (Male) 
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Apart from the focus on reform of education through improvement of the apothecary 
program, there was a recommendation to provide better understanding of ethics and philosophy 
of the profession for pharmacy students. One participant who initially raised this concern argued 
that the absence of pharmacists is a form of malpractice and negligence which compromises 
patient safety. Therefore, it is fundamental that students must understand the ethics and 
philosophy of their profession. 
“When pharmacists are not present, they do not conduct professional and ethical roles as well as deliberately letting 
patients be at risk …pharmacists are not aware of this issue and therefore, they are taking it lightly to be 
absent…what they always demand is remuneration but there is a more philosophical problem, they have violated 
their oath of practice. I suggest we educate the altruistic side first that when you are not present, you have harmed 
others, you harm your profession” (Male) 
Third theme: enforcing policy and regulation 
Participants identified that enforcement of policy and regulation is crucial to ensure good 
pharmacy practice. The discussion about policy and regulation actually occurred across all four 
discussion groups, primarily relating to pharmacists’ absence, however no new policy 
frameworks or regulations were proposed by participants to improve the current situation. The 
fact that policy related recommendation sits in the seventh place in the priority table reflects that 
policy improvement was not considered as a top priority recommendation. There seemed to be 
a general satisfaction with the range of policies and regulations enacted in the Indonesian 
community pharmacy sector, and most of the discussion was about the poor implementation of 
the regulation in practice. One participant noted the need for more monitoring and site visits by 
authorities (e.g. BPOM) to minimise pharmacists’ absence. However, she also blamed the 
authorities for justifying the irresponsible practice given that some staff of BPOM are also 
working in such pharmacies. 
“Of a hundred pharmacies in [name of a city in Central Sulawesi], only four have full time pharmacists in 
charge…there should be a penalty for that but unfortunately BPOM only audits every three years. In fact, it is difficult 
because there are BPOM staff working at those pharmacies” (Female) 
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However, in contrast, another participant commented that the head of BPOM has issued 
a directive prohibiting its staff from an association with a community pharmacy.  
“There was a directive from the head of BPOM which prohibits BPOM staff from being involved in community 
pharmacy operation either as a pharmacist practitioner or owner. It is effective as in Palembang (a city in Sumatera), 
BPOM staff are no longer affiliated to community pharmacy” (Female) 
These two contradictory arguments highlight that the execution of the policy varies at the 
practice level and/or between regions indicating the complexity and challenges for regulation 
enforcement across Indonesia. The problem might be amplified as other institutions such as the 
police also have the authority to investigate medicines supply at a pharmacy. One participant 
who holds a prominent position in a pharmacy organization said that police audit is not necessary 
as it is a form of intervention to the profession. However, he emphasized that to some extent the 
audit may be effective in encouraging pharmacists to return to the dispensary. 
“Many pharmacists complained that they were often visited by undercover police. While I consider it as a form of 
intervention to the profession, I guess there is “hidden benefit” that many pharmacies were investigated and forcedly 
closed by the police. I protested (to Police) but to be honest those (pharmacies) were without pharmacists. I actually 
did not expect police to come but with this way pharmacists are concerned and start to be present during pharmacy 
hours” (Male) 
Rather than focusing on the role of authorities to enforce the regulation, some of the 
participants highlighted the role of peer groups to endorse pharmacists’ presence. This effort 
might be more encouraging for pharmacists.  
“Pharmacist’s presence must be at the top priority. There are many policies mandating pharmacists to be present. 
Regulation requires pharmacists to be present (at pharmacy). Ethical profession requires pharmacists to be 
present…we (peer group) must enforce that absence is not appropriate and it is a disgrace to the profession”  (Male) 
Fourth theme: enhancing public recognition of pharmacists 
Overall, participants agreed that pharmacists must create a better image to improve their 
role recognition among the public. Part of this recommendation is a suggestion for pharmacists 
to use a dedicated social media account to interact with the public. However, the participant who 
raised this idea was aware that pharmacists must develop their own original branding which can 
be easily and instantly noticed by the public 
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“I think pharmacy should have a social media account to educate people but not pharmacists as individuals. It can 
be a team of care collaborating with other (health professionals). What is more important is that pharmacists develop 
their own branding and be confident with the branding. A public image where people will say “Oh this is the 
pharmacist. Ask them about medicine” (Female) 
One participant recommended community pharmacists be actively involved in public 
campaigns and outreach programs on medicine use as these programs were often conducted by 
other professions 
“Pharmacists need to conduct more outreach programs, more campaigns on medicine use. It is often doctors who 
take such initiatives. We need to be confident to say “I am a pharmacist and this (medicine) is my expertise” (Female) 
The Ministry of Health actually has promoted a national campaign, aimed to raise 
community awareness about the appropriate and safe use of medicine, which involves 
community pharmacists as the main facilitator (Gema Cermat). Similarly, IAI has also introduced 
Dagusibu which emphasises self-management of medicines by patients under the supervision of 
pharmacists. However, the majority of participants argued that, despite the importance of these 
existing programs, their effectiveness is limited due to frequent absence of pharmacists in the 
pharmacy. 
“When people get sick they seek the best doctor but not with the pharmacists. They go to whatever pharmacy. We 
need to educate people so they look for the best pharmacists. Dagusibu, Gema Cermat are the campaigns for such 
purposes but it is shameful that pharmacists are not there (at pharmacy)” (Female) 
Discussion 
This study aims to identify and prioritise potential recommendations for advancing 
community pharmacy practice in Indonesia. In this paper, we identified nine potential 
recommendations which were subsequently clustered into four overarching themes: improving 
professional practice, education, policy and enhancing public recognition of pharmacists. These 
themes form the basis of the discussion of this study.  
The four themes provide a direction that there is a need for careful consideration on how 
the key recommendations may be effectively implemented within the context of the community 
pharmacy sector. To assess the applicability of the recommendations in practice a culture-
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structure-agency framework was applied. Within this framework, we began our analysis by 
interrogating the health system (structure), and incorporating the cultural contexts surrounding 
the everyday practice of pharmacists and the role of community pharmacy and how these two 
groups found their agency to negotiate and change the structure (culture). 
The findings of this study demonstrate that the structure in terms of the regulatory and 
policy framework has provided a legal basis for community pharmacy and pharmacists in 
Indonesia to participate within the healthcare sector. This is very important considering 
pharmacy practice is in the state of infancy in many other developing countries. The fact that 
there are policy instruments and regulations in place have presented opportunities to promote 
changes in community pharmacy. However, these findings also highlighted that the top down 
structure has not been effectively enforced leading to limitations in practice, one of which is the 
common absence of pharmacists. 
Although there is a common perception that community pharmacy is known as a place to 
obtain medicines, it was found that the dialectical element is missing from the relationship 
between pharmacists and consumers. As a dialectical space, a prescription and community 
pharmacy enable pharmacists to engage in conversation with consumers and exchange 
information about medicines and health-related conditions before making informed decisions 
regarding treatment options (Weiss and Sutton, 2009, Hattingh et al., 2015). The absence of 
pharmacists in the community pharmacy creates a space which allows non-pharmacists to 
undertake the roles of pharmacists. As this situation becomes more prevalent with no immediate 
solution provided by the profession and the government, communities begin to establish a new 
culture of viewing and interacting with pharmacists. The public perceives less need to interact 
with pharmacists as their primary care needs in obtaining medicines have been fulfilled by other 
agents. As a consequence, pharmacists start to “disappear” from public recognition. In the long 
term, this may lead to a reduction in the authority of pharmacists in community pharmacy. 
The interplay between structure and agency as described earlier suggests that the process 
for advocating change is particularly dependent on the role of agency to convey the 
transformation. The discussion below provides an alternative entry to understand how 
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pharmacists locate their agency and negotiate the structure in everyday roles as both community 
health advisor and educator as well as health professional. We would further explore how this 
may be achieved in relation to the four themes that emerged from the NGT. 
Breaking down the solutions 
The first theme relates to the nature of pharmacy as a setting for professional practice. 
The recommendations to physically and socially upgrade community pharmacy to accommodate 
a forward-pharmacist approach appears feasible as it opens up opportunities for interaction with 
pharmacy clients. This  aligns with the findings of Rapport et.al that improving the community 
pharmacy workspace will enhance “a professional sense of self and meet the demands of the 
public” (Rapport et al., 2009). Furthermore, the recommendation to revise the standard for 
premises and facilities and quality accreditation for pharmacy appears to be crucial in order to 
maintain professional practice. The development of standards, guidelines and accreditation has 
been highlighted as an attempt to reduce the variation in the qualification of pharmacists and 
distribution of pharmacies across the country while at the same time promoting “best practice” 
as both pharmacists and pharmacies have the essential values to optimal patient care (Albanese 
et al., 2010).  
The second theme emerging from the discussions relates to the nature of pharmacists as 
health professionals. Reforming education is perhaps the most fundamental way to change the 
culture of a profession. In some developing countries, pharmacy education comprises six years 
including two years for skills advancement through practice placements (Jamshed et al., 2007, 
Kheir et al., 2008). While the recommendation to create six years of pharmacy education is 
common in other developing countries, there are some issues with respect to the Indonesian 
context. Firstly, extension of the course duration will have an impact on cost both for the schools 
and more importantly for students. Secondly, the extension will demand longer internships which 
is problematic as there are relatively few suitable role models who practice at a high professional 
standard. Existing “good” pharmacies will be overtaxed with too many students and this may 
further downgrade the quality of preceptorship. Thirdly, a longer course duration for the 
apothecary program will increase the current bottleneck of graduates at the end of the B. Pharm 
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program given only a few universities are eligible to conduct the apothecary program. Despite 
the different country context and practice setting, pharmacy education stakeholders in Indonesia 
can learn from their neighbouring country, Thailand, by exploring how they transformed a 5-year 
Bachelor of Science in Pharmacy program into a 6-year PharmD (Doctor of Pharmacy) program 
in 1999 (Chanakit et al., 2014). The transformation was initiated by collaboration under a US-Thai 
consortium within which Thai pharmacy educators and practitioners were prepared to develop 
the first Thai PharmD program. This suggests that a significant transition in pharmacy education 
in Indonesia requires cooperation between stakeholders within and beyond the country level. 
The third theme relates to the strong need to secure a new culture as proposed in the 
first and second themes. On the one hand, it is essential that professional practice be audited to 
ensure the quality and safety of services delivered to communities. This approach is common in 
many sectors including community pharmacy. On the other hand, this may signify an 
enforcement approach which requires firm and consistent effort by authorities. This is a 
problematic issue in Indonesia given the people charged with enforcing regulations are 
practitioners themselves. Previous research demonstrated that good governance that addresses 
transparency and ensures the framework for action is one step closer towards achieving good 
pharmacy practice (Kohler et al., 2014, Pastakia et al., 2018). Therefore, separating the role 
between authorities and practitioners, and thus removing a significant conflict of interest, is 
indeed necessary in Indonesia for creating control and good governance in the pharmacy sector.  
The fourth theme concentrates on the need to broaden the impact of the new culture. 
Participation in public campaigns and outreach programs as suggested in the group discussion 
offers a pathway to introduce this identity. In addition, the association of pharmacists (IAI) has 
mandated that its members wear a pharmacy coat and pharmacist’s badge during practice as 
well as display pharmacists’ names and working hours at the pharmacy (Ikatan Apoteker 
Indonesia, 2014e). This can be considered an effort to introduce pharmacists’ identity to public. 
In so doing, pharmacists must be present at the pharmacy. Therefore, this approach implies that 
stronger image branding may not necessarily contribute to public recognition unless the 
pertinent issues as mentioned in the prior themes have been addressed.  
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The way forward 
Good community pharmacy practice cannot be provided without pharmacists (Azhar and 
Ibrahim, 2018). Indonesian pharmacists should start embracing and actively playing their role as a 
provider of pharmacy services. Strategic attempts including broadening participation of 
pharmacy within JKN must be initiated. Alongside this work, there is a need to build evidence-
based information and research showing the potential contribution of pharmacists to health. 
Ibrahim et. al. noted that developing countries have not invested in research, thus leading to a 
lack of evidence (Ibrahim et al., 2016). The initial steps might involve cross sectional studies with a 
representative sample of key stakeholders in pharmacy including pharmacists, doctors, and other 
health care professionals, health policy makers and consumers to provide comprehensive and 
detailed knowledge of the current situation and the value of pharmacists’ presence in practice 
(Langer et al., 2004). Such a study has never been conducted in Indonesia. 
Strengths and limitations 
To the best of our knowledge, this is the first study to prioritise recommendations 
provided by pharmacy stakeholders for advancing the practice of community pharmacy in the 
context of a developing country. Although based on a small sample, the problems identified in 
this study are common to many developing countries. This suggests that the recommendations 
might be relevant for implementation in such countries. Nevertheless, the study does have some 
limitations. Firstly, it must be acknowledged that the study participants were self-selected with 
no additional screening concerning practice experience and prerequisite knowledge related to 
particular topic of the group discussion. However, the interest of participants in choosing to 
attend the workshop and join particular group discussions demonstrated intention and 
motivation to improve the current pharmacy situation, a value which is important for 
understanding practice change. Secondly, the fact that only one investigator conducted the NGT 
is another limitation. During the 90 minutes, one researcher had to rotate between groups. There 
is a possibility of researcher bias which may have undervalued some groups and overvalued 
others. While it is necessary to employ two or more investigators for the NGT rather than relying 
on ad-hoc facilitators among participants, the investigator strived to minimise this problem 
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through the help of students’ assistants for tabulation and recording process and providing 
materials about the workshop and the NGT in advance to participants. 
Conclusions 
This study has identified nine priority recommendations with the potential for advancing 
community pharmacy practice in Indonesia. The recommendations target improvement in four 
overarching areas comprising professional practice, education, policy and the professional image 
of pharmacists. While there is much to be done by Indonesian pharmacy stakeholders to improve 
the situation, the framework and discussions in this study offer an alternative for pharmacists 
and community pharmacies to advocate changes within the challenging health system structure. 
Further work is therefore needed to provide evidence of pharmacists’ contribution to healthcare. 
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6.4. Chapter Conclusion 
This chapter highlights the results of three studies conducted in Indonesia. The first two 
studies (chapter 6.1 and chapter 6.2) using in-depth semi structured interviews revealed that 
community pharmacy situation and system in Indonesia have changed particularly after the 
introduction of JKN in 2014. The changes, however, have not always been positive for pharmacy 
given that community pharmacy and pharmacists are still under-utilised and marginalised under 
the JKN. The planes of analysis used in this chapter in fact showed that community pharmacies 
continue to be hampered by structural and fundamental issues which in the main do not relate 
to the policy changes provided by JKN. Having said this, there has been enthusiasm of policy 
makers and pharmacy stakeholders to improve community pharmacy practice given the number 
of approaches introduced within the past ten years. However, the success of these approaches 
has been limited due to poor enforcement, lack of trust for pharmacy authorities and scepticism 
about their impact. Apart from some local initiatives which have tried to improve the situation, 
it is clear that some fundamental and entrenched barriers to practice will need to be overcome 
in order to create a more professional climate for the practice of pharmacy in Indonesia.  
Accordingly, recommendations for advancing practice are importantly and perhaps 
urgently needed. A nominal group discussion involving a wide range pharmacy stakeholder 
identified nine priority recommendations targeting improvement in four overarching areas 
comprising professional practice, education, policy and the professional image of pharmacists. 
The culture-structure-agency framework in the third study (chapter 6.3) presents an alternative 
for pharmacists and community pharmacies to advocate changes within the challenging health 
system structure. This is a massive effort and might require an overhaul of the system. 
Nevertheless, a small step such as providing evidence of pharmacists’ contribution to healthcare 
can be a starting point to improve the system. 
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CHAPTER 7. DISCUSSION AND CONCLUSION 
This chapter highlights the main findings of the studies and discusses their implications 
for practice change and pharmacists’ role development in community pharmacy. Conclusions of 
the studies are presented at the end of the chapter. 
7.1 Discussion 
7.1.1. Answering the research’s aims 
The primary aim of this thesis is to investigate changes in the contemporary practice in 
both Australian and Indonesian community pharmacies, representing the case in developed and 
developing countries, respectively. The objective included exploration of factors influencing 
changes, policy implementation and the role of stakeholders in promoting changes in each 
country, with the goal of providing a framework for future policy development and 
implementation particularly for Indonesian pharmacy sector. 
This study confirmed that the community pharmacy sector in Australia and Indonesia has 
experienced significant changes within the past decades with a number of issues internal and 
external to the pharmacy profession impacting on the nature and performance of traditional 
community pharmacy operating model.  
There are many differences between Australia and Indonesia in how community 
pharmacy is practiced. However, despite the differences in country context and healthcare 
systems, the current pharmacy business model in both countries still largely focuses on 
dispensing activities. This is not surprising as dispensing has been the predominant revenue 
generator for pharmacy over many years (Quilty, 2014, Clarke, 2014). However, this study clearly 
identifies that there is increasing concern from stakeholders in both countries that over-reliance 
on a dispensing business model may constrain the capacity of pharmacy and ability of 
pharmacists to deliver high quality health outcomes and to meet consumer and government 
expectations. In addition, preserving dispensing as the main pharmacy activity may actually 
threaten the viability of community pharmacy as government policies change, leading to a 
reduction in the number of pharmacies (Singleton and Nissen, 2014), pharmacists leaving the 
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profession (Mak et al., 2013) and damage to healthcare delivery in the long term (Clarke, 2014, 
McMillan et al., 2015b). 
This study has noted that practice change has been an ongoing agenda in both countries 
with the main pharmacy organisations – the PSA and the PGA in Australia and the IAI in Indonesia 
– actively advocating and guiding the process of change while at the same time working to protect 
the foundation and the scope of pharmacy practice. The practice change agenda has been 
manifested in a range of legislation and programs and is even more exclusive (and protective) in 
Australia given the implementation of the CPAs and their associated features such as ownership 
restriction and pharmacy location rules. 
Nevertheless, the retail environment, the growing corporatization of pharmacy, the rise 
of supermarket/discount-style pharmacies and the intense competition between pharmacies 
impose another limitation on practice change as pharmacies seek to retain profitability and a 
competitive market edge (Singleton and Nissen, 2014). Despite the rhetoric that pharmacy 
practice is shifting towards patient-oriented care, this thesis suggests strongly that in the 
contemporary situation pharmacy has made little progress towards enshrining such a practice 
model as their primary role.  
Thus, there is a disconnect between the current practice of pharmacy and that being 
envisaged in the practice change related policy objectives and the expectations of pharmacy 
stakeholders. Surprisingly it is common to both Australia and Indonesia, highlighting that both 
developed and developing countries struggle with the agenda of practice change. The lesson to 
be learned here is that, no matter what stage of development a country has reached, challenges 
to future evolution will always remain (Mossialos et al., 2015). 
The tension between professionalism and business continues today with community 
pharmacy attempting to find the balance point between them. Professional roles such as locating 
non-dispensing pharmacists in GP practices or as independent consultants specializing in 
pharmaceutical care are emerging and may offer pathways for moving away from the supply 
model (Freeman et al., 2012, Hazen et al., 2018); these do not yet appear completely viable in 
the current situation which is dominated by the retail and supply model. 
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However, this study provides cause for cautious optimism. The results suggest that there 
remains a case for retention of the supply role, and that this role is not incompatible with the 
practice change agenda. Dispensing is arguably the core of pharmacists’ function and therefore 
it should not be entirely removed from the scope of pharmacy practice. This study therefore 
suggests that dispensing can be conducted in a more professional manner (particularly in 
Indonesia), which allows pharmacists to engage more fully with patients and their care. Whilst 
pharmacy remains as a small business, generating profit is fundamental, but pharmacists must 
be able to expand their revenue sources to ensure sustainability of their business. Practice 
change to incorporate care models offers one way that this may be achieved. The work reported 
in this thesis suggests some key elements of the change process including both aspects to be 
promoted and pitfalls to be avoided. 
7.1.2. Adopting planes of analysis to describe contemporary situation 
Drawing on the planes of analysis framework, this study has demonstrated the 
interrelatedness of factors and influences operating at the micro, meso and macro level of 
practice. Practice change occurs in these three levels simultaneously and interdependently with 
changes at any one level having significant potential to, and actually having had, unintended and 
unpredictable consequences on practice. Thus, understanding one particular level is not 
sufficient. For example, lack of pharmacists’ readiness to change has been cited as a prominent 
barrier in implementing new services (Tootelian et al., 2007, Rosenthal et al., 2010, Rosenthal et 
al., 2016). While it is true that the individual pharmacist’s attributes affect practice change, it 
should not be regarded as the sole barrier (Luetsch, 2016). This is because an individual 
pharmacist works under a system which may or may not be supportive for practice change. The 
value of the approach adopted in this thesis not only lies in its potential to view the practice in a 
holistic manner but also in its ability to focus on critical aspects of the situation while not losing 
sight of the whole. This is quite different to other models where the situation is regarded as a 
complex system and difficult to analyse (Plsek and Greenhalgh, 2001, Jordon et al., 2010, Scahill, 
2012), or as a set of disconnected levels (Dopfer et al., 2004, Kapiriri et al., 2007, Ong et al., 2014). 
To our knowledge, this is the first time such an analysis has been used to explain the interaction 
of the multiple influences on the change process.  
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Emerging from this analysis, it is clear that in both countries the process of change is not 
straightforward and cannot be achieved at once, even in an environment that is “protected” and 
ready for change such as in Australia. Transforming pharmacy into a health hub destination 
(McMillan et al., 2013) may even be unrealistic in developing countries such as Indonesia given 
the limited capacity to resolve fundamental issues such as availability of the pharmacy workforce. 
Therefore, all countries, but especially developing countries, should critically think and be 
reflective about their country contexts, the complexities of practice and challenges before 
adopting successful experiences or stories from other countries. This study confirms that the 
planes of analysis framework offers the potential for reflective thought and transformative 
thinking about the complexities of the system and implications for introducing policies in a 
constantly changing environment such as occurs in the community pharmacy sector. 
It is also the case that there may be valuable lessons for Australian community pharmacy 
from the findings of the Indonesia study. For example, the absence of  location rules in Indonesia 
has led to a maldistribution of pharmacies and intense competition (Nata, 2013, Sukamdi et al., 
2015). In addition, the absence of pharmacist-ownership legislation has resulted in the majority 
of pharmacies in Indonesia being owned by non-pharmacists (Purwanti et al., 2004, Harianto et 
al., 2006, Supardi et al., 2012). This situation may correlate with the poor quality of services and 
commercial operation of pharmacy as non-owner pharmacists in fact control the pharmacy 
(Hermansyah et al., 2012, Dominica et al., 2016). Given the increasing demand to remove location 
rules and pharmacist only ownership particularly as suggested by a number of reviews concerning 
pharmacy competition (Wilkinson, 2000, Harper et al., 2015, Department of Health and 
Pharmacy Guild of Australia, 2017) similar problems may also occur in Australia. 
7.1.3. Analysing practice change development using the PARIHS framework 
The efforts to transform “common practice” ultimately require evidence to forecast the 
desired potential impact of expanding pharmacists’ roles. Therefore, investment in R&D in 
community pharmacy is essential for producing robust evidence supporting the clinical and cost-
effectiveness of new pharmacy services. However, the research reported in this thesis has 
demonstrated that R&D alone is not sufficient to drive change (Hermansyah et al., 2017b).  
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The Australian experiences as highlighted in chapter 5.2 showed that there has been 
some success as a result of R&D investment under the CPAs, but it has not necessarily driven 
practice change as expected. Successfully collecting evidence does not always lead to successful 
and reliable implementation of the research into practice (Hughes et al., 2015). The PARIHS 
framework used in this study guided explanation that while the establishment of robust evidence 
has been a critical reason for implementing evidence-based CPS, the roles of context and 
facilitation cannot be understated. 
The use of evidence in policy making is unquestionably important. However, the context 
in which the research is translated is also crucial. Ultimately, as policies are not developed in a 
vacuum, political commitment (or expediency) is often the main facilitator to drive translation of 
research into practice. Policy makers in Australia have appeared to favour funding of CPS that 
showed evidence of significant potential monetary savings to the healthcare system rather than 
their health benefits. Additionally, translating research needs to take account of the economic 
benefits of CPS to the business of pharmacy including the contribution to the income of individual 
pharmacist(s) and the capacity of pharmacists to deliver the CPS. In contemporary Australia, the 
low income-generating capacity of CPS has proven to be a major reason for its limited uptake 
(Benrimoj et al., 2010, Singleton and Nissen, 2014). 
While Australia has dedicated funding for the R&D program in community pharmacy, this 
is not the case in Indonesia. The fundamental issues in Indonesia are such that R&D in practice 
development is currently a lower priority than regulatory compliance. The process for creating 
the opportunity for practice change is structural and hierarchical with policy-makers and 
pharmacy stakeholders determined to have the policy structure in place before changing 
practice. While this approach might be relevant in the short term, the investment in R&D should 
still be included in the agenda for change particularly in the long term as pre-requisites to the 
introduction of widespread evidence based services. 
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7.1.4. Potential (missed) opportunities in the current practice 
This thesis has presented the process of practice change in Australia and Indonesia. The 
focus is not on comparing both systems but rather on linking features and arrangements of 
practice change in both countries and trying to identify (missed) opportunities within each 
system. 
The findings of the Australian studies demonstrated that the consecutive CPAs in Australia 
have presented an opportunity for community pharmacies to achieve better health outcomes for 
patients and communities through provision of high quality and sustainable pharmacy services 
(Hermansyah et al., 2016a). In addition, the CPAs have been useful in providing certainty for the 
operation of community pharmacy by means of consistency in dispensing income and location 
and ownership rules that in many aspects have preserved “privileges” for community pharmacy. 
In a nutshell, the CPAs have been both a conduit to recognition of an expanded role for 
pharmacists and a strategy to drive practice change. However, the over-reliance on the CPAs – 
particularly the dispensing revenue – in combination with continuous health system and PBS 
reform has threatened the viability of community pharmacy operations. With funding for 
dispensing falling within the last two agreements, community pharmacies are under greater 
pressure to find other sources of income including from provision of CPS. Unfortunately, the 
proportion of income from CPS to date has been relatively small and not sufficient to replace 
potential revenue losses from dispensing. The CPSs have therefore been a double-edged sword 
in that the revenue certainty from dispensing negotiated every five years has also proven to be 
a stumbling block for the development of alternative revenue streams (Quilty, 2014, Singleton 
and Nissen, 2014). 
Indonesia, on the other hand, has introduced various policy initiatives and legislation 
which are not only fundamental in regulating the community pharmacy sector but also reflect 
enthusiasm and commitment from policy makers and pharmacy stakeholders towards 
pharmacists’ role development. However, there has been no evaluation of the effectiveness of 
these regulations in achieving their policy objectives. In addition, the findings of this thesis 
highlighted that some of the initiatives were introduced using a piecemeal approach which 
created collateral damage to the health system. For example, the introduction of JKN which was 
heralded as a “game changer” for community pharmacy sector given the possibility for pharmacy 
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to become involved in primary care networks has in fact created barriers for pharmacy role 
advancement. 
With a myriad of issues including three notable barriers namely poor policy enforcement, 
lack of trust of pharmacy stakeholders and scepticism towards the impact of the policy initiatives 
hampering policy implementation and professional practice of pharmacists, it can be said that 
the regulations in Indonesian pharmacy sector have failed to engage with the practice realm. 
Accordingly and not surprisingly, there have been some local initiatives to drive changes 
reflecting that the top-down approach has been problematic. 
7.1.5. Developing culture-structure-agency approach to advance practice 
This study used the culture-structure-agency approach to deliver a clear message that 
navigating practice change in Indonesia must consider the presence and the interdependence of 
these three aspects. The central assumption of this approach lies in the role of agent(s) to 
introduce a change of culture under the constrained and challenging healthcare structure. In 
doing so, the agent(s) – pharmacists and pharmacy stakeholders – must be proactive, self-
motivated and dedicated about maximizing control over their practice which currently is lacking 
due to poor presence of pharmacists in practice (Dominica et al., 2016, Herman and Susyanty, 
2012). The role of organisational culture, however, is also crucial in helping to facilitate 
engagement by pharmacist and pharmacy stakeholders with the rest of healthcare system once 
the structural change is introduced (Scahill, 2012). The introduction of JKN for example, can be a 
challenging yet promising avenue to reconfigure community pharmacy position, demonstrate 
performance and contribution as the focus of the program has been delivering effective 
healthcare within defined budget cap (Hermansyah et al., 2018b). 
Using culture-structure-agency approach, four recommendations were generated from a 
NGT namely improving professional pharmacy practice, reforming pharmacy education, 
enforcing policy and regulation and enhancing public recognition of pharmacists. While the 
importance of these recommendations is outlined in chapter 6.3, there is a necessity to provide 
conclusive strategies for Indonesia based on the overall findings and comparison with Australian 
studies. 
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Learning from other country experiences (Department of Health, 2008, Canadian 
Pharmacists Association, 2008), there is a need for a shared vision among pharmacy stakeholders 
which conveys commitment to strengthen the profession and align pharmacy practice with 
national health priorities. The proactive participation of all stakeholders is without a doubt a 
prerequisite to deliver a practice change agenda. However, to reach such consensus is also an 
issue. While IAI is currently the main organization advocating changes in the profession, there is 
strong call to bring all pharmacy stakeholders to the table. Thus, a recommendation emerging 
from this research is that the IAI should establish the sense of urgency that change is an 
imperative and preserving status quo is not an option. Reflecting the initiatives by the PSA 
(Pharmaceutical Society of Australia, 2010) and the PGA (Pharmacy Guild of Australia, 2010b), a 
roadmap document to articulate such sense of urgency can be an option for communicating the 
issue within and beyond the profession. Subsequently, a coalition between these stakeholders – 
as the experience of the Australian pharmacy stakeholders’ forum (Pharmacy Stakeholders 
Forum, 2014) – must be established. 
The study findings recognised the importance of national government bodies in 
enhancing pharmacy practice development but concurrent efforts involving local organisations 
and actors also appear to be feasible and realistic in the context of Indonesia. In other words, 
both top down and bottom up approach should be simultaneously established and directed to 
promote sustainable changes in community pharmacy practice. For example, motivating 
pharmacists to change and persuading them to take action is not necessarily the role of 
government or professional organizations. A group of pharmacists working together to sort out 
practice problems can serve as an example to other pharmacists and potentially provide insight 
and guidance for other pharmacists. The role of peers in supporting and mentoring new 
pharmacy graduates to face practice change is also a possible way forward. The success of such 
approach can be scaled up or even replicated to other areas to accelerate the process.  
There has been a lot of discussion among Indonesian pharmacy stakeholders about 
equipping pharmacy graduates with new set of skills focusing on clinical pharmacy (chapters 6.2 
and 6.3). The dialogue however has been rhetoric and commentary with little empiric work 
conducted to change curricula. Furthermore, as Indonesia is also still struggling with the 
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pharmaceutical system and pharmacists’ presence in pharmacy, the movement towards clinical 
pharmacy roles seems have stagnated. The re-professionalisation agenda appears to be poorly 
understood even by pharmacists themselves.  
The above situation reflects a need for a systematic plan in changing pharmacy education 
to ensure that necessary clinical competencies are possessed by graduates. Prior to this, 
stakeholders in pharmacy education must be consistent in adopting and implementing a vision 
of the future of the profession as mentioned earlier.  Schools of pharmacy are indeed in the 
frontline of creating a momentum for change driven by education (Ferreri et al., 2017). An 
important consideration, however, is to carefully design the plan and execute it with a clear 
evaluation strategy given the abundant number of schools of pharmacy in Indonesia and the wide 
gap between these schools in terms of their accreditation level. 
Expanding community pharmacists’ roles and introducing professional pharmacy services 
are difficult – perhaps impossible – under an environment that is tainted by ongoing issues in 
pharmaceutical management and distribution such as shortage of medicines and counterfeit 
drugs and poor enforcement such as illegal supply of medicines and collusion over law 
enforcement (Chapters 6.1 and 6.2). Several papers and reports have confirmed that collusive 
practice in the pharmaceutical sector including in retail pharmacy is evident. Examples include 
directing patients to particular brand name products (Hermawan, 2013), over-servicing patients 
(Sudirman, 2012) and over-charging patients for pharmaceuticals beyond the maximum retailing 
price (Diack et al., 2010). While a solution to this problem might involve an overhaul to the 
system, the findings of this thesis suggest that a thorough evaluation of the effectiveness of 
regulation and consolidation of regulation should be undertaken to improve the access to 
medicines and better enforcement. The fact that pharmaceutical legislation and regulation in 
developing countries is “often inadequate and largely un-enforceable” implies the need for such 
evaluation (Lowe and Montagu, 2009). However, this study acknowledged that part of the reason 
of this problem is perhaps the government has been short-sighted and ill-informed when devising 
strategies for pharmacy. This highlights the need for investment in research and resources to 
better inform the policy making process.  
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The lack of research evidence means contribution of community pharmacists to patient 
care is unknown.  Thus, it is not surprising that policies and regulations have been developed 
without any reliable data to provide a rational basis for the policy direction. The study findings 
emphasize the key role of research in supporting practice change. While pharmacy practice 
research activities in Indonesia are predominantly conducted by academic institutions (Tri Murti 
Andayani and Satibi Satibi, 2016), there is strong reason to expand this scope to include 
community pharmacists in research. Given the scant data around policy effectiveness, 
consideration should be given to making it mandatory or providing incentives for pharmacists to 
participate in “routine research” such as audits or service evaluations to develop an evidence-
based pharmacy practice. Alternatively, research can be directed towards practice development 
by testing new services and innovations in pharmacy. 
Lastly, investing in resources, whether this be workforce, funding or remuneration, time 
and infrastructure, is essential in supporting transformation of pharmacy practice. The increased 
workload, lack of time, lack of pharmacists, inadequate remuneration and limited space for 
patient interaction have often been identified as barriers in realizing the full potential of 
pharmacists (Lounsbery et al., 2009, Berbatis et al., 2007b, Agomo, 2012, Mak et al., 2012, 
McMillan et al., 2015b). However, despite the urgent need to tackle these issues, change takes 
time and is often dependent on the pharmacy-specific context. Identification and prioritisation 
over what can be addressed at the macro, meso and micro level is therefore critical.  
Taking the success of Pharmacy Health Destination Project in Australia as an example 
(Pharmaceutical Society of Australia, 2017), the IAI could provide assistance and coaching to build 
capacity within pharmacies to become service oriented settings while at the same time offering 
a mechanism to ensure that appropriate infrastructure and resources are in place (meso-micro 
level). At the macro level, the profession must actively advocate and lobby the government to 
better utilize pharmacists as untapped resources in primary care. This will open up opportunities 
for broadening pharmacists’ participation under the JKN. More importantly, effective funding 
models for compensating pharmacists, that are not GP-centric as currently occurs under the JKN 
scheme, is likely to increase pharmacy contribution within JKN. The literature has shown that 
introduction of a remuneration scheme based on a payment for service, stimulates pharmacists 
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to change (Houle et al., 2014, Breault et al., 2017). There is a case for a unique pharmacy 
contribution to Indonesian healthcare. However, without significant modification to the health 
system including funding for pharmacy services and governing system, it seems impossible to 
expect a broader and sustainable delivery of high quality pharmacy services. 
7.1.6. Strengths and Limitations 
A key strength of the studies that comprise this thesis lies in the analytical approach taken 
to consider three different levels of influence on practice simultaneously, interdependently and 
comprehensively. This means changes in one level will influence the other levels. While it is 
necessary to focus onto one particular level for deeper analysis, the approach promotes viewing 
the three levels comprehensively as one interdependent system. In addition, a more nuanced 
understanding of the contemporary situation offers an insight on how to influence the process 
of change in community pharmacy. This study used the contemporary situation to represent the 
starting point from which any change begins. With this approach, pharmacy leaders and policy 
makers can develop future potential ways of stimulating practice change.   
The use of relevant theoretical frameworks incorporated in the discussion of the findings 
facilitated an in-depth analysis of the current state of practice of pharmacy and the influences 
affecting its stage of development in each country. In this thesis, several theoretical frameworks 
were used including planes of analysis (chapter 5.1 and 6.1), the PARIHS framework (chapter 5.2) 
and culture-structure-agency approach (chapter 6.3). As far as can be determined, this is the first 
study that has applied these frameworks in the context of practice change in community 
pharmacy. 
This thesis gathered a broad range of views of key stakeholders in healthcare and 
pharmacy system in each country reflecting rich experiences regarding changes in community 
pharmacy across different actors in the respective health systems. Another strength is that 
conducting research in the Indonesian community pharmacy sector has helped to fill a gap 
concerning pharmacy development in Indonesia. This is undoubtedly a significant contribution 
for pharmacy research and practice in Indonesia particularly because this study provides 
evidence regarding the experiences of community pharmacies and pharmacists facing the 
changing climate in Indonesian healthcare and pharmacy system. 
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However, there are a number of limitations that need to be acknowledged. 
First, a systematic review was conducted pertaining to pharmacy services and emerging 
public health initiatives in five developing Southeast Asian countries. Given the dearth of such 
reviews in the context of developing countries, the review presented in this paper addressed this 
gap by reporting the evidence base of pharmacy role expansion in the public health sector. A 
systematic review of published literature can be a useful reference to help set and inform the 
background of a research before it is initiated. In addition, a systematic review is also an 
important tool for policy makers to support rational decision making. However, the evidence 
base of a systematic review strongly depends on the quality of the studies included in the review. 
By limiting the search to articles published only in English, the review may have not covered other 
important papers and reports published in other languages. In addition, opting for five particular 
countries may not entirely reflect community pharmacy practice within the region. 
Second, the use of a qualitative research method in this study also involves some 
limitations. With a wide-range of key stakeholders from both countries participating in the 
studies, the use of interviews was essential to portray the complexity and dynamic of practice 
change in both countries. While the method was not intended to be generalizable, the decision 
to include “particular” stakeholders through purposive sampling is an inherent limitation of the 
method. In addition, the study was unable to capture the perspectives of participants who 
declined to participate such as discount pharmacies in Australia and GP Farmasi in Indonesia 
despite their significant role in influencing practice in community pharmacy. Likewise, a nominal 
group discussion is a useful and effective method to elicit information and prioritise actions or 
recommendations from participating individuals. However, one of the limitations as highlighted 
in chapter 6.3 is that the participants in the group discussion might not represent the overall 
stakeholders and groups in the community pharmacy sector. Coupled with the diverse 
experiences and backgrounds of the participants, the group discussion may not explore the 
complete picture of pharmacy practice and accordingly the recommendations generated from 
the discussion may not tackle some specific issues in the community pharmacy sector for 
example pharmacy workforce allocation and distribution. 
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Third and finally, given the evolving state of community pharmacy practice, it is important 
to consider the contemporary situation prior to applying the findings and the recommendations 
provided by a number of published papers in this thesis. The studies have emphasized data 
collection based on the contemporary situation which may change in the future. Therefore, to 
the extent possible, consideration of other factors such as context, culture and contemporary 
practice must be acknowledged when navigating future changes using references from this study. 
7.1.7. Implications for future research 
There are several areas of future research that emerge from the research presented in 
this thesis. While Australia already has national data about community pharmacists’ value, roles 
and scope of practice (Roughead et al., 2002, Berbatis et al., 2003), there is a paucity of such data 
in Indonesia. Therefore, the first area for future research is to collect national data regarding 
pharmacists’ activities, workplace structure and function in Indonesian community pharmacies. 
This research would be best designed as quantitative research in the form of a national survey 
recruiting pharmacists working in both community pharmacies and Puskesmas. The availability 
of such information is crucial to map and to provide baseline data about pharmacists’ roles, 
characteristics and positions in everyday practice. 
The second area of future research which is relevant to both countries is to collect 
evidence of pharmacists’ contributions to providing professional pharmacy services in terms of 
Economic, Clinical and Humanistic Outcomes (ECHO). While there has been research examining 
the impact of HMRs in relation to ECHO, other professional services such as Medscheck and 
Clinical Interventions have not been supported by robust evidence about their contribution to 
patients’ quality of life – apart from economic benefits obtained by the pharmacy for delivering 
the services (Paola, 2017). In addition, funding for Medscheck and Clinical Interventions was 
extended under the 6th CPA with funding for HMRs remaining capped and unclear as a result of 
a review to the MBS item (Department of Health, 2017). It is therefore important to extend 
research into these services aiming not only to estimate cost-effectiveness but also to explore 
continuity of care and conjunction between the existing services to enable pharmacists to 
provide continuing support to patients. The pharmacy remuneration and regulation review in its 
interim report has recommended an expanded HMR program which for example can be a 
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pathway for resolving health issues for high-risk patients initially identified by Medscheck at the 
pharmacy (Department of Health and Pharmacy Guild of Australia, 2017). While pharmacists in 
Indonesia have been limited in their provision of expanded services as compared to their 
colleagues in Australia, future research can be directed to observe and quantify the potential 
value of pharmacists being present in community pharmacies. This would include designing an 
action research or case study that explores the quality of patients’ lives and the availability of 
pharmacy resources in a practice setting that employs full-time pharmacists. 
More research could also be conducted to seek the possibility of alternative practice 
models that focus on the delivery of professional services yet offer certainty for viability under 
the changing climate in the community pharmacy sector. Specific to Indonesia, such research can 
be targeted to investigate community pharmacies which already provide a high standard of 
pharmacy practice as a means of fostering role models in practice. The concept resembles the 
experience of the Health Destination Pharmacy Trial program in Australia where support and 
assistance were provided for pharmacies to enable them to advance practice (Pharmaceutical 
Society of Australia, 2017). The application in Indonesia, however, would initially aim to enable 
pharmacies to consistently achieve a minimum standard of good pharmacy practice as defined 
by the legislation (Ministry of Health Indonesia, 2016e) and which is currently not fulfilled by the 
majority of pharmacies in Indonesia. 
Finally, there is a need for continuous evaluation and review of the community pharmacy 
sector. Although Australia has experience with a number of reviews concerning the practice of 
community pharmacy (Australian National Audit Office, 2015, Harper et al., 2015, Department of 
Health and Pharmacy Guild of Australia, 2017), there has been no national scale review 
evaluating pharmacy integration within primary care practice and the extent to which pharmacy 
acts as link between GPs and hospitals. Likewise, Indonesia is lacking evaluation of a number of 
aspects such as the effectiveness of policy implementation and evaluation of the roles of 
community pharmacy. 
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7.2. Conclusion 
For generations, we have heard that “pharmacy is at the crossroads” and “pharmacy is 
changing” but the critical question is what does this mean for the practice of community 
pharmacy? In reality, we have seen that the progress of change has been slow with limited 
provision of professional services beyond the dispensary. Unfortunately, this is true in the 
contemporary practice of community pharmacy in both developed and developing countries.  
This is the first body of research that explores and contrasts practice change in community 
pharmacy in both developed and developing countries. The studies demonstrated that practice 
change is driven by a myriad of factors that are both internal and external to the community 
pharmacy sector and that it is only likely to be successful and sustainable if policies take account 
of these various influences 
There are a number of conclusions generated from this study. Firstly, the contemporary 
situation in community pharmacy is complex and dynamic with multiple factors influencing 
changes interrelatedly, and simultaneously operating at micro (individual pharmacist), meso 
(community pharmacy) and macro (network of community pharmacy within healthcare system) 
levels of practice. Secondly, the R&D programs funded under the CPAs have had a positive impact 
on Australian community pharmacy. However, when it comes to implementation of new CPS, 
there are problems concerning the evidence, context and facilitation. Thirdly, both Australia and 
Indonesia have introduced several key policy initiatives to support practice change with 
pharmacy stakeholders playing active roles in advocating such changes. However, what remains 
a challenge is that the income of pharmacists and pharmacies is still highly reliant on dispensing 
which represents a missed opportunity for patient care. Fourthly, a number of recommendations 
have been proposed but their implementation is challenging and to some extent may require an 
overhaul of the current system. 
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This is not the first call for community pharmacy and pharmacists to change. However, 
this thesis provides frameworks and approaches to comprehensively understand the situation in 
community pharmacy. While the situations in Australia and Indonesia – representing developed 
and developing countries, respectively – are unique in terms of practice change, these tools can 
be used to obtain insight on what is occurring and what is needed to initiate the transformation 
in other countries.  
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